

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images,
Please do not report the images to the
Image Problem Mailbox.

THIS PAGE BLANK (USPTO)

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C12N 15/12, 5/10, C07K 14/47, A01K 67/027, G01N 33/50, C12Q 1/68	A1	(11) International Publication Number: WO 00/09686 (43) International Publication Date: 24 February 2000 (24.02.00)
(21) International Application Number: PCT/GB99/02658 (22) International Filing Date: 12 August 1999 (12.08.99) (30) Priority Data: 9817566.4 12 August 1998 (12.08.98) GB 9910522.3 6 May 1999 (06.05.99) GB (71) Applicant (for all designated States except US): MEDICAL RESEARCH COUNCIL [GB/GB]; 20 Park Crescent, London WIN 4AL (GB). (72) Inventors; and (75) Inventors/Applicants (for US only): ROBINSON, Iain; Clive, Andrew, Franklin [GB/GB]; National Institute for Medical Research, The Ridgeway, Mill Hill, London NW7 1AA (GB). STOYE, Jonathan, Paul [GB/GB]; National Institute for Medical Research, The Ridgeway, Mill Hill, London NW7 1AA (GB). FLAVELL, David [GB/GB]; Centre for Cardiovascular Genetics, The Rayne Institute, London WC1E 6JJ (GB). WELLS, Sara, Elizabeth [GB/GB]; Department of Medicine, University of Bristol, Bristol BS2 8HW (GB). LE TISSIER, Paul [GB/GB]; National Institute for Medical Research, The Ridgeway, Mill Hill, London NW1AA (GB).		(74) Agents: MASCHIO, Antonio et al.; D Young & Co., 21 New Fetter Lane, London EC4A 1DA (GB). (81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: GENE (57) Abstract <p>The invention describes a previously unknown gene, termed <i>5'OT-EST</i>, which is responsible for inducing an obesity and/or infertility phenotype in transgenic animals, and transgenic animals comprising mutants of <i>5'OT-EST</i> which are useful for assaying compounds for the treatment of obesity and/or infertility.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

Gene

The present invention relates to a gene which is involved in the control of obesity and fertility. In particular, the gene disclosed herein is involved in late-onset obesity in males, which is coupled with infertility. Moreover, the invention relates to animal models for late-onset obesity.

Obesity, which differs from being overweight by being characterised by an increase in the proportion of body fat present as opposed to a mere increase in body weight, is one of the major contributors to chronic disease development. Mortality in overweight males (5–15% overweight) increases to 125%, but rises up to 500% in obese males. Laboratory and epidemiological studies have also shown that mortality amongst obese males aged between 25 and 34 can increase up to twelve times. This increase in mortality is caused by the multitude of health risks associated with obesity, including cardiovascular disease, hypertension, diabetes, sleep apnoea (the abnormal ceasing of breathing during sleep), hernias, flat feet, arthritis, osteoarthritis, some cancers, varicose veins, gout, respiratory problems, gall bladder disease and liver disease. The more serious complaints include:

- Cardiovascular Disease – Obesity is an important factor in cardiovascular disease in both increasing blood cholesterol and blood pressure, and has been shown to increase the risk of disease by up to three times. Obesity also increases the work of the heart – cardiac volume, stroke volume and blood volume must all increase to cope with the increased weight. The detrimental effects of obesity on cardiovascular disease are reversible with weight loss.
- Diabetes – Excess weight also increases the chance of acquiring diabetes mellitus by threefold and increases the risk of dying from diabetes by up to eight times. The mechanism by which an increase in body fat increases the risk of diabetes is largely unknown. However, it is postulated that a slight increase in circulating serum glucose or L-leucine may increase the basal levels of insulin. This rise in insulin is then associated with resistance to insulin, caused both by decreased intracellular effects of insulin and a reduction in insulin receptors in the cell. Obesity has also been proven to

alter pancreatic function and in susceptible individuals this may lead to the development of diabetes mellitus .

- 5 • Cancer - cancer has also shown a significant association with obesity, but the mechanisms are not understood. One proposed explanation is that obesity alters hormone levels and this could influence cancer development. In males, obesity is associated with a greater risk of developing prostate and colorectal cancers.
- 10 • Gall bladder Disease – obese males show a four times increase in the risk of developing gall bladder disease.
- 15 • Endocrine Function – this is also modified by elevated fat levels. The Beta cells in the islets of Langerhans are enlarged in obese people and glucose intolerance is also frequently inhibited.
- 20 • Reproductive System – obesity in males also impairs the functioning of the reproductive system.
- Growth Hormone – obesity impairs the release of growth hormone from the pituitary gland. This problem is of particular importance in obese children whose growth may be impaired. It is fully reversible if weight is lost.

Numerous genes, gene products and their receptors have been characterised in rodent models of obesity which bear mutations associated with different forms of obesity (Bray & York, 1979; Comuzzie & Allison, 1998). Most such spontaneous mutations are recessive, and include mutations affecting leptin and its receptors in such models as ob/ob and db/db mice, Zucker fa/fa rats, Koletsky (f) rats, OLETF rats, corpulent (cp) rats and their substrains or derivatives (Zhang *et al.*, 1994; Tartaglia *et al.*, 1995; Iida *et al.*, 1996; Takaya *et al.*, 1996; Chen *et al.*, 1996; Jamal *et al.* 1997; Kahle *et al.*, 1997; Lee *et al.*, 30 1997; Moon & Friedman, 1997; Takiguchi *et al.*, 1998). These phenotypes are thought to result from a disruption in leptin or its receptors or in CCK-A receptors, and affect the control of food intake or energy expenditure or metabolism, and disrupt the gonadotrophic

axis in females.

There are numerous other candidate genes putatively involved in obesity, some of which have been recently been summarised by Comuzzie & Allison (1998; Table 1). These include tubby (tub), agouti, Nhl2, MCH, CRH, hypocretins or orexins, CART peptides, melanocortin-4 ligands, uncoupling proteins (UCP1-3), carboxypeptidase E, NPY, their related transcripts or homologues or their receptors (Coleman *et al.*, 1990; Miller *et al.*, 1993; Good *et al.*, 1997; Klebig *et al.*, 1995; Naggert *et al.*, 1995; Ollman *et al.*, 1995; Kleyn *et al.*, 1996; Richard, 1996; Qu *et al.*, 1996; Fan *et al.*, 1997; Huszar *et al.*, 1997; North *et al.*, 1997; Ohki-Hamazaki *et al.*, 1997; Graham *et al.*, 1997; Boss *et al.*, 1997; Vidal-Puig *et al.*, 1997; Millet *et al.*, 1997; Cool *et al.*, 1997; Kristensen *et al.*, 1998; De Lecea *et al.*, 1998; Sakurai *et al.*, 1998). These models exhibit some degree of sexual dimorphism, a slight delay in onset of obesity or a dominant pattern of inheritance, though none show all of these in combination. It is generally believed that obesity is due to the complex interaction of a number of different factors.

The study of obesity and its effects on health requires suitable animal models which can faithfully replicate the condition as seen in humans. None of the available models combines all of the symptoms of obesity. In particular, the symptoms of male pattern obesity, which include late onset, sterility and a concentration of fat around the abdomen, are not displayed by currently available models. There is therefore a need for an improved model for obesity, which displays more of the characteristics of obesity observed in human patients.

Transgenesis is a well established technique for the introduction of DNA sequences into the mammalian genome, and has been used to insert endocrine genes in several species, predominantly in mice (Palmiter *et al.*, 1982; Bucchini *et al.*, 1986; McGrane *et al.*, 1988; Ho *et al.*, 1995), but also in other species (Hammer *et al.*, 1985; Pursel *et al.*, 1989), including rats (Mullins *et al.*, 1990; Zeng *et al.*, 1994; Chareau *et al.*, 1996; Flavell *et al.*, 1996). The methods are well described (Hogan *et al.*, 1986; Chareau *et al.*, 1996) and usually involve the microinjection of cloned DNA fragments into the male pro-nuclei of eggs isolated from superovulated females. Such eggs are transferred into the oviduct of

pseudopregnant females (obtained by mating with vasectomized males) and carried to term. DNA extracted from tail clippings obtained from the progeny may be examined for the presence of specific transgene DNA. Depending on the integrity and stability of the DNA sequence, the number of integration sites and their location in the host genome, transgenes may become stably integrated in the host genome and transmitted to subsequent progeny.

If promoter and enhancer sequences are present in the transgene, the transgene may show high levels of expression in the host animals and the products may induce an endocrine phenotype that would be expected from the hormone product. For example, overexpression of human growth hormone (hGH) using a variety of heterologous non-specific promoters induces variable degrees of growth stimulation in transgenic animals (Palmiter *et al.*, 1982, 1983; Morello *et al.*, 1986; Pursel *et al.*, 1989; Shanahan *et al.*, 1989; Stewart *et al.*, 1992; Short *et al.*, 1992). However, transgene expression levels often differ between different transgenic lines made with the same insert, and the tissue specificity may vary, being highly dependent on the size of the DNA insert, the number of copies of the insert, its integrity and its integration site(s) in host DNA (Lacy *et al.*, 1983; Al-Shawi *et al.*, 1990; Huber *et al.*, 1994). Unexpected phenotypes may result, either as pathological consequences of inappropriate amounts of transgene product or its production in ectopic sites, and examples of this for hGH transgenes include glomerulosclerosis or female infertility in mice or rats (Bartke *et al.*, 1988; Brem *et al.*, 1989; Quaife *et al.*, 1989; Ninomiya *et al.*, 1994). Intentionally directed expression of a transgene to an ectopic site may also have a significant influence on the nature of the phenotype produced (Ornitz *et al.*, 1985; Baker *et al.*, 1992). This is well exemplified using hGH transgenes, since instead of an overgrowth phenotype, hGH can produce an opposite, dwarf phenotype in transgenic mice or rats when driven by a promoter that targets it to the central nervous system to induce negative feedback effects on the endogenous GH system (Hollingshead *et al.*, 1989; Banerjee *et al.*, 1994; Szabo *et al.*, 1995; Flavell *et al.*, 1996).

30

Other examples of endocrine transgenes include those targeting the genes for oxytocin (OT) and vasopressin (AVP) (Russo *et al.*, 1988; Habener *et al.*, 1989; Grant *et al.*,

1993a,b; Ang *et al.*, 1991, 1994; Murphy & Ho, 1995). These genes are expressed mainly in magnocellular neurones of the supraoptic (SON) and paraventricular (PVN) nuclei of the hypothalamus (Vandesande *et al.*, 1975; Young, 1992; Gainer & Wray, 1994). The expression of these hormonal peptides appears to be mutually exclusive, coexpression in the same neurone occurring only rarely (Kiyama *et al.*, 1990). A construct consisting of sequences 0.6 kb 5', 1.8 kb 3' and the entire structural gene of bovine OT directed expression to the oxytocinergic cells of the SON and the PVN, but also to the lung and Sertoli cells of the testis in transgenic mice (Ho *et al.*, 1995). The hypothalamic expression was also physiologically regulated with an increase in the abundance of the transgene transcript occurring during dehydration. The Sertoli cells are a site of peripheral expression of the endogenous OT gene in cattle but not in mice or rats. In these transgenic mice, the testicular transcripts are translated and processed (Ang *et al.*, 1994), suggesting that this construct contained regulatory elements capable of recapitulate the bovine expression pattern of OT in the mouse testis (Ang *et al.* 1991). Foo *et al.* (1994) have identified a testis-specific promoter in the rat AVP gene.

The AVP and OT genes are highly homologous in structure, and are transcribed in opposite orientations from positions closely linked in the genome within a single locus (Sausville *et al.*, 1985; Young, 1992). It is therefore possible that elements in the flanking sequence of the OT gene normally interact with those present in the nearby homologous AVP gene to regulate their mutually exclusive expression (Young *et al.*, 1990; Young, 1992). To test this theory, mice were generated bearing 1.25 kb of 5', 0.2 kb of 3' and the structural gene for bovine AVP fused, in same the same orientation as the endogenous genes, to the bovine OT transgene already described to show hypothalamic expression (Ho *et al.*, 1995). The resulting mice expressed the bovine OT transgene in the testis and lung, but lacked hypothalamic expression of this transgene and did not express the bovine AVP transgene. A further bovine OT transgene, including 3 kb of 5' sequence, the structural gene and 2.5 kb of downstream sequence was used in an attempt to overcome this repression, but no animals were generated, and it was argued that the region between 0.6 kb and 3 kb 5' of the bovine OT gene conferred a toxic effect in embryonic development which is usually repressed (Ho *et al.*, 1995). Transgenic rats have also been generated bearing fragments of the rat AVP gene with reporter genes inserted

into the third exon of the AVP gene. Transgenes containing 1.5 kb and 3kb of 5', 0.2kb of 3' and the rat AVP gene with a β -galactosidase reporter gene in the third exon also conferred expression to the testis. This was attributed to the presence of a cryptic testicular promoter within the reporter gene (Zeng *et al.*, 1994a). Clearly however, the use of small fragments of DNA containing OT or AVP sequences gives rise to unpredictable patterns of transgene expression.

One theory is that this variation may be overcome if sufficiently large DNA constructs are used, containing regions of DNA known as locus control regions (LCRs) that can direct tissue specific, position independent, copy number dependent, physiologically appropriate, expression of the transgene in the host (Grosveld *et al.*, 1987; Bonifer *et al.*, 1990; Huber *et al.*, 1994; Fujiwara *et al.*, 1997). Again this may be exemplified with hGH transgenes. An LCR region for the hGH gene has been defined by Jones *et al.* (1995). When a cosmid containing this sequence was used to generate several lines of transgenic mice, hGH was expressed in the pituitary gland in an appropriately regulated fashion, and the mice showed no overgrowth phenotype or other pathological consequences of overproduction of hGH.

Summary of the invention

A line of transgenic rats has been generated using a cosmid of rat DNA containing the genes for oxytocin (OT) and vasopressin (AVP), into which reporter genes were inserted, namely hGH (Roskam *et al.*, 1979) in the AVP gene and bovine OT mostly replacing the rat OT gene. To attempt to include LCR regions for this gene locus in our transgene constructs, larger DNA fragments containing both OT and AVP genes and larger amounts of flanking sequences were used, which were isolated from a rat cosmid library. One line of such rats, bearing at least 4 copies of this cosmid as a concatamer integrant, exhibits an unexpected and novel late onset obesity and infertility dominant phenotype that would not be predicted from the known DNA sequences present in this cosmid. This phenotype is clearly distinguishable from other obesity/infertility syndromes so far described.

Analysis of the cosmid sequences used in the transgene constructs reveals the presence of a previously unknown gene, which is responsible for the observed obesity phenotype.

Accordingly, in the first aspect of the present invention there is provided a 5'OT-EST polypeptide having a sequence selected from the group comprising the sequences set forth in any one of SEQ. ID. Nos. 2, 4 or 6, and sequences substantially homologous to any one of the polypeptides set forth in SEQ. ID. Nos. 2, 4 or 6.

In a second aspect, the invention provides a mutant of a 5'OT-EST polypeptide according to the first aspect of the invention which is capable, *in vivo*, of modulating the obesity of an animal expressing it.

In a third aspect, the present invention provides a nucleic acid encoding a 5'OT-EST polypeptide or mutant 5'OT-EST polypeptide according to the first aspect of the invention. Advantageously, the nucleic acid has a sequence selected from the group consisting of any one of SEQ. ID. Nos. 1, 3, 5 or 7; sequences which are hybridisable under stringent conditions with an oligonucleotide comprising 20 contiguous bases from any one of SEQ. ID. Nos. 1, 3, 5 or 7; sequences substantially homologous to any one of SEQ. ID. Nos. 1, 3, 5 or 7; and sequences complementary thereto. Stringent hybridisation conditions are preferably as defined below.

In a fourth aspect, the invention provides diagnostic reagents for the detection of mutations, polymorphisms or other changes in 5'OT-EST which may predispose an individual to obesity. For example, the invention provides probes useful for amplifying 5'OT-EST nucleic acids.

In a fifth aspect, the invention provides a transgenic non-human animal expressing, as a result of transgene expression, a 5'OT-EST polypeptide or mutant 5'OT-EST polypeptide according to the invention. Transgenic animals according to this aspect of the invention are models for obesity in humans, and may be used for research into therapies and treatments which may be used to alleviate obesity.

Brief Description of the Drawings

Figure 1 shows a partial restriction map of the rat AVP/OT locus, from cosmid cVO1, cVO2 and cVO3. Restriction sites for the enzymes listed are shown as a vertical marks.

- 5 The known sequence of the rat AVP and OT genes is indicated by single dashed lines, and the sequence determined and disclosed herein of the rat 5'OT-EST gene is indicated by the double dashed line. Scale is approximate.

- 10 Figure 2 is a diagrammatic representation of the subcloning steps leading to the insertion of the hGH reporter gene into the 5' untranslated region of the rat vasopressin gene. The final subclone shows the Cla 1 to Xho 1 fragment which was inserted into the construct used to make transgenic lines.

- 15 Figure 3 is a diagrammatic representation of the subcloning steps required for the production of the rat-bovine hybrid gene which was inserted into the final construct. For simplicity, this is shown in reversed orientation compared to its orientation in the construct.

- 20 Figure 4 shows the extent of the rat AVP/OT locus present in the cosmid cVO1, 2 and 3. These clones span a total of 44kb, including 8kb 5' of rAVP and 24kb 5' of rOT. The structure of the final cosmid construct CVO14 is illustrated and some restriction sites indicated.

- 25 Figure 5 shows a point mutation in the cVO14 construct in a conserved region 5' to the OT gene. A conserved G residue is substituted with an A residue in the construct.

Figure 6 is an alignment of the sequences of 5'OT-EST from rat, human and mouse sources.

- 30 Figure 7 is a comparison of the body weights of transgenic and non-transgenic rats.

Figure 8 is a comparison of the body weights of transgenic and non-transgenic male and female rats.

Figure 9 is a comparison of the measurements (in mm) of the pelvis (b) and of the body length (a) of 20 and 52 week male transgenic and non-transgenic rats (mean \pm sem, ***= $p < 0.001$, $n=6-7$ per group).

Figure 10 illustrates the increased body weight/body length ratio of transgenic rats compared with non-transgenic rats.

10

Figure 11 shows the weights of the peri-renal and testicular fat pads in JP17 male transgenic and non-transgenic animals at different ages. (*= $p < 0.05$; **= $p < 0.01$, $n=6-7$ per group).

15 Figure 12 shows the levels of plasma insulin, glucose, cholesterol, triglycerides, leptin and corticosterone in terminal blood samples from transgenic and non-transgenic rats. Values shown are mean of each group \pm SEM ($n=6$ for transgenic groups; $n=4$ for non-transgenic groups) (* Significantly different ($p < 0.05$) from sex matched non transgenic group).

20

Figure 13 shows the changes in body weight, leptin levels and food intake associated with young (100 day old) rats fed on normal fat (4%) or high fat (30%) diets. Results are shown for SLOB, non-transgenic and dwarf rats, fed either 4% fat diet (clear bars) or a 30% fat diet (stippled bars) over a 27-day period (* = $p < 0.05$; ** = $p < 0.01$; *** = $p < 0.001$, high vs. low fat diet: ## = $p < 0.01$; ### = $p < 0.001$, SLOB vs. non-transgenic rats).

25

Figure 14 shows the changes in body weight associated with ovariectomy in transgenic rats and non-transgenic littermates. ■ - ovariectomised SLOB rat; □ - ovariectomised wild-type rat; • - sham ovariectomised SLOB rat; o - sham ovariectomised wild-type rat.

30

Detailed Description of the Invention

Definitions

5 As referred to herein, "5'OT-EST" is the polypeptide represented in SEQ. ID. Nos. 2, 4 or 6 (rat, human and mouse respectively). Preferably, it is the human sequence. However, the term also covers alternative peptides homologous to 5'OT-EST, such as polypeptides derived from other species, including other mammalian species.

10 "Mutants" of 5'OT-EST include polypeptides which differ only in minor, insignificant ways from wild-type 5'OT-EST, for example polypeptides having conservative amino acid replacements or additions or deletions. Preferred, however, are mutants which are able to confer, on animals expressing them, an obese phenotype as defined herein. An example of such a mutant is the 5'OT-EST - xdel polypeptide set forth in SEQ. ID. No. 8.

15 Further mutants may be obtained as described herein, and defined according to their functional effects in transgenic animals or host cells.

"Substantially homologous", whether applied to polypeptide or nucleotide sequences, is as defined herein with reference to homology screening. It may be interpreted as referring

20 either to sequence alignment and direct comparison, or to homology as defined by BLAST homology searching as defined herein.

A "transgenic animal" is an animal whose genome has been functionally altered by genetic manipulation. In the context of the present invention, this includes animals

25 bearing and expressing a 5'OT-EST or mutant 5'OT-EST transgene, animals from which 5'OT-EST sequences have been deleted or in which they have been modified, and animals which are transiently transformed to express a (mutant) 5'OT-EST transgene such as by transformation with viral sequences.

30 "Transformation" refers to the functional insertion of a gene by nucleic acid transfer, or the functional deletion of a gene, in a cell or organism. The term thus includes transfection, transduction and any other techniques useful for transferring nucleic acids

into cells or organisms. Cells transformed according to the invention express a novel genotype as a result of the transformation.

For the avoidance of doubt, unless otherwise required by the specific context, reference
5 herein to an entity in the singular includes the plural thereof. Thus, the expressions "a gene" and "one or more genes" are equivalent.

Moreover, unless otherwise required by context, references to 5'OT-EST (*5'OT-EST*) preferably include mutants of 5'OT-EST (*5'OT-EST*).

10

A "cosmid" is a bacteriophage-based vector as commonly known in the art.

References herein to "obesity" and obese animals are preferably references to the SLOB phenotype observed in SLOB rats according to the invention, characterised in being *inter*
15 *alia* male-specific, late onset, with fat deposition concentrated in the abdominal area and associated with sterility.

Description of Preferred Embodiments

20 A cosmid (cVO14) of rat DNA containing the rat vasopressin (AVP) and rat oxytocin (OT) genes (Ivell & Richter, 1984) was constructed, and DNA reporter sequences inserted therein using standard methods (Sambrook *et al.*, 1989) as outlined in Examples 1 & 2 below. Microinjection of the cVO14 DNA insert into fertilised rat eggs and their transfer into pseudopregnant recipients resulted in production of viable offspring. Unexpectedly,
25 the male founder rat with 4-5 copies of cVO14 (JP17) showed a dominant phenotype of severe late-onset visceral obesity. This form of obesity shows (i) a very late onset, (ii) a highly selective visceral distribution of fat developing on a normal rodent diet, without hyperphagia, (iii) an effect greatly preponderant in males, (iv) a predisposition to excessive dietary-fat induced obesity at an early age, before the phenotype becomes
30 apparent on a normal diet, and (v) a dominant pattern of inheritance. Moreover, male transgenics show severe infertility in males, whilst females are fertile. Rats bearing this transgene have been termed **SLOB** rats (for Severe Late-onset **OB**esity). The symptoms

of obesity observed in SLOB rats all occur in several forms of human obesity, including that associated with human syndrome-X (Reaven *et al.*, 1988) for which a late-onset increase in abdominally distributed fat, affecting males much more severely than females (Gray *et al.* 1997) may be mimicked in the SLOB rat. Obvious causes, such as leptin
5 deficiency or insulin resistance or overt Type 1 or 2 diabetes may be excluded.

Although the SLOB phenotype is preponderant in males, it may be markedly exacerbated in females by ovariectomy.

10 Mapping and analysis of cosmid DNA used to generate cVO14, revealed a putative gene, 5' of the OT locus. A fragment of this DNA was subcloned and sequenced. Analysis of this region of rat DNA enabled us to determine the location, orientation, partial exon structure and predicted protein product of a novel gene lying 5' of the OT gene in rat DNA. Further sequencing and analysis elucidated the structure of this gene, and provided
15 additional sequence information for the cosmid DNA surrounding the known sequence of the OT and AVP genes. The novel rat gene is termed herein *5'OT-EST*, which encodes the *5'OT-EST* polypeptide. The genomic sequence of *5'OT-EST* is given in SEQ. ID. No. 16.

20 A search of DNA and protein databases revealed no significant match to any known gene, but recognised partial matches to DNA sequences homologous to *5'OT-EST* in expressed sequence tag (EST) databases from rat, mouse and human DNA sources. These represent partial products of the rat gene, and of genes homologous to this novel rat gene, in mouse and human DNA. The predicted structures of four exons, termed w, x, y, z, and predicted
25 protein sequences are highly conserved between these species. A partial match was noted to a human genomic DNA sequence alluded to, but not disclosed in White *et al.* PNAS 95:305-309 (1998), but deposited by them in Genbank (Accession no:AF036329) as a putative genomic fragment containing the human GnRH-II gene. The relationship between human *5'OT-EST* and human *GnRH-II* as described by White *et al.* is confirmed
30 by the present work; however, there does not appear to be any such relationship in rats or mice. Homologous rat *GnRH-II* sequences cannot be recognised by sequence analysis in cVO14, which contains more than 10kb of rat DNA flanking *5'OT-EST*. Neither can any

homologous mouse *GnRH-II* sequence be identified by hybridisation or PCR studies in multiple mouse genomic clones which contain 5'OT-EST and at least 50kb of flanking DNA. Thus, it appears highly unlikely that the *GnRH-II* sequence corresponds functionally with 5'OT-EST.

5

In rats, 5'OT-EST lies about 10kb downstream of the 3' exon of the protein tyrosine phosphatase receptor alpha (*Ptptra*) gene, and the intervening 10kb show no homology with *GnRH-II*. Additionally, mouse BAC clones containing 5'OT-EST show no homology to *GnRH-II*. Thus, *GnRH-II* sequences are not adjacent to 5'OT-EST in rats or
10 mice, and neither *GnRH-II* nor *Ptptra* is present in the cosmid used to generate SLOB rats. Complete sequencing of the cosmid reveals no other novel genes.

Based on physical linkage to *Ptptra*, *Avp* and *Oxt*, 5'OT-EST maps to the distal region of mouse chromosome 2, 7.32 cM from the centromere. *Ptptra* has itself been implicated in
15 the control of insulin sensitivity, and both 5'OT-EST and *Ptptra* lie within 0.21 cM of *mg*, another gene implicated in the suppression of obesity. In mouse, all three genes map to the same region as the mouse obesity locus *Mob5* (Encyclopaedia of the Mouse genome VII: Mouse Chromosome 2; (1998) Peters *et al.*, Mamm. genome 8 Spec No:S27-49). It is likely therefore that 5'OT-EST contributes to the trait observed at this locus in mice.

20

Accordingly, the present invention provides 5'OT-EST polypeptide. 5'OT-EST according to the present invention may be mouse, rat or human 5'OT-EST, as well as variants of 5'OT-EST derivable from other species or by natural or artificial mutation of a 5'OT-EST gene.

25

The variant provided by the present invention includes splice variants encoded by mRNA generated by alternative splicing of a primary transcript, amino acid mutants, glycosylation variants and other covalent derivatives of 5'OT-EST which retain the physiological and/or physical properties thereof. Exemplary derivatives include
30 molecules wherein 5'OT-EST is covalently modified by substitution, chemical, enzymatic, or other appropriate means with a moiety other than a naturally occurring amino acid. Such a moiety may be a detectable moiety such as an enzyme or a

radioisotope. Further included are naturally occurring variants of 5'OT-EST found within a particular species, preferably a mammal. Such a variant may be encoded by a related gene of the same gene family, by an allelic variant of a particular gene, or represent an alternative splicing variant of 5'OT-EST.

5

Variants which retain common structural features can be fragments of 5'OT-EST. Fragments of 5'OT-EST comprise smaller polypeptides derived from therefrom. Preferably, smaller polypeptides derived from 5'OT-EST according to the invention define a single feature which is characteristic of 5'OT-EST as described in the present application.

10

Derivatives of 5'OT-EST also comprise mutants thereof, which may contain amino acid deletions, additions or substitutions. Thus, conservative amino acid substitutions may be made substantially without altering the nature of 5'OT-EST. Deletions and substitutions may moreover be made to the fragments of 5'OT-EST comprised by the invention.

15

Mutants of 5'OT-EST according to the present invention may possess properties different from those of naturally occurring 5'OT-EST. In particular, 5'OT-EST mutants may modulate the expression of native 5'OT-EST.

20

5'OT-EST mutants may be produced from a nucleic acid encoding 5'OT-EST which has been subjected to in vitro mutagenesis resulting e.g. in an addition, exchange and/or deletion of one or more amino acids. For example, substitutional, deletional or insertional variants of 5'OT-EST can be prepared by recombinant methods and screened for immuno-crossreactivity with the native forms of 5'OT-EST.

25

Preferably, 5'OT-EST according to the present invention has the sequence of SEQ. ID. No. 2 (rat), SEQ. ID. No. 4 (human) or SEQ. ID. No. 6 (mouse). Mutants possessing desired properties may be generated from these sequences, or isolated from natural sources, by a variety of techniques which assess the biological function of the 5'OT-

30

EST mutant. For example, nucleic acids encoding 5'OT-EST mutants may be used to generate transgenic animals and these animals assessed for indications of an obesity phenotype.

5 For example, the effects of mutant transgenes may be assessed by carcass analysis, measurement of growth, body weight, body fat distribution, as well as other measures of analytes in body fluids or tissues relevant to obesity in transgenic animals (Mathe, 1995; Shillabeer, 1992). These include, but are not limited to, cholesterol, triglycerides, fatty acids, lipoproteins, and other dietary constituents or metabolites, as well as metabolic
10 hormones, such as leptin, insulin, glucagon, catecholamines or glucocorticoids. Other relevant parameters include cardiovascular measures (Reaven, 1988, Gray & Yudkin, 1997). These may include measures of systolic or diastolic blood pressure, cardiac output, or vascular resistance, together with morphological changes to organ systems known to be affected by cardiovascular or obesity disorders, such as heart, major or minor
15 blood vessels, their muscle or endothelial layers, and their elasticity or fragility. See for example McNamee *et al.* (1994).

Similarly, parameters related to the infertility phenotype that may be measured, include, but are not limited to, testicular weight, volume, development, spermatogenesis, sperm
20 number, motility or ability to fertilise oocytes. They may also include measures of testicular fluid production and constituents, as well as products of other accessory organs including seminal vesicles or prostate, as well as hormones, receptors, and proteins important in male sexual function, such as testosterone, LH, FSH, inhibin or activin. Other responses that may be affected include energy expenditure, physical activity,
25 ingestive behaviour, excretory behaviour, or reproductive behaviour, or the organs, hormones or receptors commonly recognised to be associated with these physiological systems, their metabolism or morphological structure.

5'OT-EST as disclosed herein is a polypeptide composed of four exons, termed w, x, y
30 and z (see SEQ. ID. No. 16). Advantageously, mutants of 5'OT-EST are mutated in, or preferably lack all or part of, the sequences encoded by one or more exons of 5'-OT-EST. Preferably, mutants of 5'OT-EST lack, or are mutated in, all or part of the sequences

encoded by exons x, y and z of 5'-OT-EST.

Preferably, the sequences encoded by exons x, y and z are deleted and those encoded by exon w partially deleted. Most preferably, the mutant is 5'OT-EST - xdel as described
5 herein, for example in SEQ. ID. No. 8.

The fragments, mutants and other derivatives of 5'OT-EST preferably retain substantial homology with 5'OT-EST. As used herein, "homology" means that the two entities share sufficient characteristics for the skilled person to determine that they are similar
10 in origin and function. Preferably, homology is used to refer to sequence identity. Thus, the derivatives of 5'OT-EST preferably retain substantial sequence identity with 5'OT-EST.

"Substantial homology", where homology indicates sequence identity, means more than
15 40% sequence identity, preferably more than 45% sequence identity and most preferably a sequence identity of 50% or more, as judged by direct best-fit sequence alignment and comparison.

Sequence homology (or identity) may moreover be determined using any suitable
20 homology algorithm, using for example default parameters. Advantageously, the BLAST algorithm is employed, with parameters set to default values. The BLAST algorithm is described in detail at http://www.ncbi.nih.gov/BLAST/blast_help.html, which is incorporated herein by reference. The search parameters are defined as follows, and are advantageously set to the defined default parameters.

25

Advantageously, "substantial homology" when assessed by BLAST equates to sequences which match with an EXPECT value of at least about 7, preferably at least about 9 and most preferably 10 or more. The default threshold for EXPECT in BLAST searching is usually 10.

30

BLAST (Basic Local Alignment Search Tool) is the heuristic search algorithm employed by the programs blastp, blastn, blastx, tblastn, and tblastx; these programs

ascribe significance to their findings using the statistical methods of Karlin and Altschul (see http://www.ncbi.nih.gov/BLAST/blast_help.html) with a few enhancements. The BLAST programs were tailored for sequence similarity searching, for example to identify homologues to a query sequence. The programs are not generally useful for motif-style searching. For a discussion of basic issues in similarity searching of sequence databases, see Altschul *et al.* (1994).

The five BLAST programs available at <http://www.ncbi.nlm.nih.gov> perform the following tasks:

10

blastp compares an amino acid query sequence against a protein sequence database;

blastn compares a nucleotide query sequence against a nucleotide sequence database;

15 **blastx** compares the six-frame conceptual translation products of a nucleotide query sequence (both strands) against a protein sequence database;

tblastn compares a protein query sequence against a nucleotide sequence database dynamically translated in all six reading frames (both strands).

20

tblastx compares the six-frame translations of a nucleotide query sequence against the six-frame translations of a nucleotide sequence database.

BLAST uses the following search parameters:

25

HISTOGRAM Display a histogram of scores for each search; default is yes. (See parameter H in the BLAST Manual).

30

DESCRIPTIONS Restricts the number of short descriptions of matching sequences reported to the number specified; default limit is 100 descriptions. (See parameter V in the manual page). See also **EXPECT** and **CUTOFF**.

ALIGNMENTS Restricts database sequences to the number specified for which high-scoring segment pairs (HSPs) are reported; the default limit is 50. If more database sequences than this happen to satisfy the statistical significance threshold for reporting
5 (see EXPECT and CUTOFF below), only the matches ascribed the greatest statistical significance are reported. (See parameter B in the BLAST Manual).

EXPECT The statistical significance threshold for reporting matches against database sequences; the default value is 10, such that 10 matches are expected to be found
10 merely by chance, according to the stochastic model of Karlin and Altschul (1990). If the statistical significance ascribed to a match is greater than the EXPECT threshold, the match will not be reported. Lower EXPECT thresholds are more stringent, leading to fewer chance matches being reported. Fractional values are acceptable. (See parameter E in the BLAST Manual).

15

CUTOFF Cutoff score for reporting high-scoring segment pairs. The default value is calculated from the EXPECT value (see above). HSPs are reported for a database sequence only if the statistical significance ascribed to them is at least as high as would be ascribed to a lone HSP having a score equal to the CUTOFF value. Higher
20 CUTOFF values are more stringent, leading to fewer chance matches being reported. (See parameter S in the BLAST Manual). Typically, significance thresholds can be more intuitively managed using EXPECT.

MATRIX Specify an alternate scoring matrix for BLASTP, BLASTX, TBLASTN and
25 TBLASTX. The default matrix is BLOSUM62 (Henikoff & Henikoff, 1992). The valid alternative choices include: PAM40, PAM120, PAM250 and IDENTITY. No alternate scoring matrices are available for BLASTN; specifying the MATRIX directive in BLASTN requests returns an error response.

STRAND Restrict a TBLASTN search to just the top or bottom strand of the database sequences; or restrict a BLASTN, BLASTX or TBLASTX search to just reading frames on the top or bottom strand of the query sequence.

- 5 FILTER Mask off segments of the query sequence that have low compositional complexity, as determined by the SEG program of Wootton & Federhen (1993) Computers and Chemistry 17:149-163, or segments consisting of short-periodicity internal repeats, as determined by the XNU program of Claverie & States (1993) Computers and Chemistry 17:191-201, or, for BLASTN, by the DUST program of
- 10 Tatusov and Lipman (see <http://www.ncbi.nlm.nih.gov>). Filtering can eliminate statistically significant but biologically uninteresting reports from the blast output (e.g., hits against common acidic-, basic- or proline-rich regions), leaving the more biologically interesting regions of the query sequence available for specific matching against database sequences.

15

Low complexity sequence found by a filter program is substituted using the letter "N" in nucleotide sequence (e.g., "NNNNNNNNNNNNNN") and the letter "X" in protein sequences (e.g., "XXXXXXXXXX").

- 20 Filtering is only applied to the query sequence (or its translation products), not to database sequences. Default filtering is DUST for BLASTN, SEG for other programs.

- It is not unusual for nothing at all to be masked by SEG, XNU, or both, when applied to sequences in SWISS-PROT, so filtering should not be expected to always yield an
- 25 effect. Furthermore, in some cases, sequences are masked in their entirety, indicating that the statistical significance of any matches reported against the unfiltered query sequence should be suspect.

- NCBI-gi Causes NCBI gi identifiers to be shown in the output, in addition to the
- 30 accession and/or locus name.

Most preferably, sequence comparisons are conducted using the simple BLAST search algorithm provided at <http://www.ncbi.nlm.nih.gov/BLAST>.

Conventional BLAST searches of the publically available databases do not reveal any
5 homology of the predicted protein product of *5'OT-EST* to any known protein. However, application of a more sophisticated search algorithm, as described in Taylor *et al.*, 1998, identifies structural similarities to apolipoprotein E (ApoE) in its alpha-helical domains, but without any apparent LDL-receptor domain. Since ApoE is centrally involved in lipid metabolism and transport, a role for *5'OT-EST* in cellular
10 lipid handling is suggested.

Accordingly, the invention provides a method for identifying a candidate compound capable of influencing lipid transport, comprising the steps of:

- 15 a) contacting *5'OT-EST* polypeptide with a candidate compound or compounds and determining which candidate compound or compounds is capable of interacting with *5'OT-EST*;
- b) optionally, testing candidate compounds which interact with *5'OT-EST* in a transgenic animal according to the invention.

20

According to a further aspect of the present invention, there is provided a nucleic acid encoding *5'OT-EST* or a mutant thereof. In addition to being useful for the production of recombinant *5'OT-EST* protein, these nucleic acids are also useful as probes, thus readily enabling those skilled in the art to identify and/or isolate nucleic acid encoding *5'OT-EST*
25 and/or mutant *5'OT-EST*. The nucleic acid may be unlabelled or labelled with a detectable moiety. Furthermore, nucleic acid according to the invention is useful e.g. in a method determining the presence of *5'OT-EST*-specific nucleic acid, said method comprising hybridising the DNA (or RNA) encoding *5'OT-EST* (or its complement) to test sample nucleic acid and determining the presence of *5'OT-EST*. In another aspect, the
30 invention provides a nucleic acid sequence that is complementary to, or hybridises under stringent conditions to, a nucleic acid sequence encoding *5'OT-EST*.

The invention also provides a method for amplifying a nucleic acid test sample comprising priming a nucleic acid polymerase (chain) reaction with nucleic acid corresponding to 5'*OT-EST*, including the untranslated regions (or its complement).

- 5 In still another aspect of the invention, the nucleic acid is DNA and further comprises a replicable vector comprising the nucleic acid encoding 5'*OT-EST* operably linked to control sequences recognised by a host transformed by the vector. Furthermore the invention provides host cells transformed with such a vector and a method of using a nucleic acid encoding 5'*OT-EST* to effect the production of 5'*OT-EST*, comprising
10 expressing 5'*OT-EST* nucleic acid in a culture of the transformed host cells and, if desired, recovering 5'*OT-EST* from the host cell culture.

- Isolated 5'*OT-EST* nucleic acid includes nucleic acid that is free from at least one contaminant nucleic acid with which it is ordinarily associated in the natural source of
15 5'*OT-EST* nucleic acid or in crude nucleic acid preparations, such as DNA libraries and the like. Isolated nucleic acid thus is present in other than in the form or setting in which it is found in nature. However, isolated 5'*OT-EST* encoding nucleic acid includes 5'*OT-EST* nucleic acid in ordinarily 5'*OT-EST*-expressing cells where the nucleic acid is in a chromosomal location different from that of natural cells or is otherwise flanked by a
20 different DNA sequence than that found in nature.

- In accordance with the present invention, there are provided isolated nucleic acids, e.g. DNAs or RNAs, encoding 5'*OT-EST*, particularly mammalian 5'*OT-EST*, e.g. human 5'*OT-EST*, or fragments thereof. In particular, the invention provides a DNA molecule
25 encoding 5'*OT-EST*, or a fragment thereof. By definition, such a DNA comprises a coding single stranded DNA, a double stranded DNA of said coding DNA and complementary DNA thereto, or this complementary (single stranded) DNA itself. An exemplary nucleic acid encoding 5'*OT-EST* is represented in SEQ ID Nos. 1, 3 and/or 5.

- 30 The preferred sequence encoding 5'*OT-EST* is that having substantially the same nucleotide sequence as the coding sequences in SEQ ID Nos. 1, 3 and/or 5, with the nucleic acid having the same sequence as the coding sequence in SEQ ID Nos. 1, 3 and/or

5 being most preferred. As used herein, nucleotide sequences which are substantially the same share at least about 90% identity. However, in the case of splice variants having e.g. an additional exon sequence homology may be lower. Homology is determined as described above.

5

The invention moreover provides nucleic acids encoding 5'OT-EST, comprising the gene *5'OT-EST* or variants thereof as defined herein. The nucleic acids of the invention, whether used as probes or otherwise, are preferably substantially homologous to the sequence of *5'OT-EST* as shown in SEQ ID Nos. 1, 3 and/or 5. The terms "substantially" and "homologous" are used as hereinbefore defined with reference to the 5'OT-EST polypeptide.

10

Preferably, nucleic acids according to the invention are fragments of the *5'OT-EST*-sequence, or derivatives thereof as hereinbefore defined in relation to polypeptides. Fragments of the nucleic acid sequence of a few nucleotides in length, preferably 5 to 150 nucleotides in length, are especially useful as probes.

15

Exemplary nucleic acids can alternatively be characterised as those nucleotide sequences which encode a 5'OT-EST protein, or which correspond to untranslated regions of *5'OT-EST*, and hybridise to the DNA sequences set forth SEQ ID Nos. 2, 4 and/or 6, or a selected fragment of said DNA sequence. Preferred are such sequences encoding 5'OT-EST which hybridise under high-stringency conditions to the sequence of SEQ ID Nos. 1, 3 and/or 5.

20

Stringency of hybridisation refers to conditions under which polynucleic acids hybrids are stable. Such conditions are evident to those of ordinary skill in the field. As known to those of skill in the art, the stability of hybrids is reflected in the melting temperature (T_m) of the hybrid which decreases approximately 1 to 1.5°C with every 1% decrease in sequence homology. In general, the stability of a hybrid is a function of sodium ion concentration and temperature. Typically, the hybridisation reaction is performed under conditions of higher stringency, followed by washes of varying stringency.

30

As used herein, high stringency refers to conditions that permit hybridisation of only those nucleic acid sequences that form stable hybrids in 1 M Na⁺ at 65-68 °C. High stringency conditions can be provided, for example, by hybridisation in an aqueous solution containing 6x SSC, 5x Denhardt's, 1 % SDS (sodium dodecyl sulphate), 0.1 Na⁺ pyrophosphate and 0.1 mg/ml denatured salmon sperm DNA as non specific competitor. Following hybridisation, high stringency washing may be done in several steps, with a final wash (about 30 min) at the hybridisation temperature in 0.2 - 0.1x SSC, 0.1 % SDS.

Moderate stringency refers to conditions equivalent to hybridisation in the above described solution but at about 60-62 °C. In that case the final wash is performed at the hybridisation temperature in 1x SSC, 0.1 % SDS.

Low stringency refers to conditions equivalent to hybridisation in the above described solution at about 50-52 °C. In that case, the final wash is performed at the hybridisation temperature in 2x SSC, 0.1 % SDS.

It is understood that these conditions may be adapted and duplicated using a variety of buffers, e.g. formamide-based buffers, and temperatures. Denhardt's solution and SSC are well known to those of skill in the art as are other suitable hybridisation buffers (see, e.g. Sambrook, *et al.*, eds. (1989) *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, New York or Ausubel, *et al.*, eds. (1990) *Current Protocols in Molecular Biology*, John Wiley & Sons, Inc.). Optimal hybridisation conditions have to be determined empirically, as the length and the GC content of the probe also play a role.

Advantageously, the invention moreover provides nucleic acid sequence which are capable of hybridising, under stringent conditions, to a fragment of SEQ. ID. Nos. 1, 3, 5 or 7. Preferably, the fragment is between 15 and 50 bases in length. Advantageously, it is about 25 bases in length, preferably about 20 bases in length. For differentiating between mutant and wild type 5'OT-EST by PCR reactions, 20mers are the preferred size, whilst for use as probes in, for example, Southern hybridisation, the use of 40mers is preferred. Riboprobes may be designed to be substantially any length, up to and including the entire length of the largest specific cDNA sequence.

Specifically included, moreover, are sequences complementary to the foregoing sequences.

5 Given the guidance provided herein, the nucleic acids of the invention are obtainable according to methods well known in the art. For example, a DNA of the invention is obtainable by chemical synthesis, using polymerase chain reaction (PCR) or by screening a genomic library or a suitable cDNA library prepared from a source believed to possess *5'OT-EST* and to express it at a detectable level.

10

Chemical methods for synthesis of a nucleic acid of interest are known in the art and include triester, phosphite, phosphoramidite and H-phosphonate methods, PCR and other autoprimer methods as well as oligonucleotide synthesis on solid supports. These methods may be used if the entire nucleic acid sequence of the nucleic acid is known, or the
15 sequence of the nucleic acid complementary to the coding strand is available. Alternatively, if the target amino acid sequence is known, one may infer potential nucleic acid sequences using known and preferred coding residues for each amino acid residue.

An alternative means to isolate the gene encoding *5'OT-EST* is to use PCR technology as
20 described e.g. in section 14 of Sambrook *et al.*, 1989. This method requires the use of oligonucleotide probes that will hybridise to *5'OT-EST* nucleic acid. Strategies for selection of oligonucleotides are described below.

Libraries are screened with probes or analytical tools designed to identify the gene of
25 interest or the protein encoded by it. For cDNA expression libraries suitable means include monoclonal or polyclonal antibodies that recognise and specifically bind to *5'OT-EST*; oligonucleotides of about 20 to 80 bases in length that encode known or suspected *5'OT-EST* cDNA from the same or different species; and/or complementary or homologous cDNAs or fragments thereof that encode the same or a hybridising gene.
30 Appropriate probes for screening genomic DNA libraries include, but are not limited to oligonucleotides, cDNAs or fragments thereof that encode the same or hybridising DNA; and/or homologous genomic DNAs or fragments thereof.

A nucleic acid encoding 5'OT-EST may be isolated by screening suitable cDNA or genomic libraries under suitable hybridisation conditions with a probe, i.e. a nucleic acid disclosed herein including oligonucleotides derivable from the sequences set forth in SEQ ID Nos. 1, 3 and/or 5. Suitable libraries are commercially available or can be prepared e.g. from cell lines, tissue samples, and the like.

As used herein, a probe is e.g. a single-stranded DNA or RNA that has a sequence of nucleotides that includes between 10 and 50, preferably between 15 and 30 and most preferably at least about 20 contiguous bases that are the same as (or the complement of) an equivalent or greater number of contiguous bases set forth in SEQ ID Nos. 1, 3 and/or 5. The nucleic acid sequences selected as probes should be of sufficient length and sufficiently unambiguous so that false positive results are minimised. The nucleotide sequences are usually based on conserved or highly homologous nucleotide sequences or regions of 5'OT-EST. The nucleic acids used as probes may be degenerate at one or more positions. The use of degenerate oligonucleotides may be of particular importance where a library is screened from a species in which preferential codon usage in that species is not known.

Preferred regions from which to construct probes include 5' and/or 3' coding sequences, sequences predicted to encode ligand binding sites, and the like. For example, either the full-length cDNA clone disclosed herein or fragments thereof can be used as probes. Preferably, nucleic acid probes of the invention are labelled with suitable label means for ready detection upon hybridisation. For example, a suitable label means is a radiolabel. The preferred method of labelling a DNA fragment is by incorporating α - ^{32}P dATP with the Klenow fragment of DNA polymerase in a random priming reaction, as is well known in the art. Oligonucleotides are usually end-labelled with γ - ^{32}P -labelled ATP and polynucleotide kinase. However, other methods (e.g. non-radioactive) may also be used to label the fragment or oligonucleotide, including e.g. enzyme labelling, fluorescent labelling with suitable fluorophores and biotinylation.

Probes for cloning and amplifying *5'OT-EST*, especially human *5'OT-EST*, may be deduced from the sequence thereof provided herein. Preferred probes may be selected from the following:

5	1U	GGACAGCCCCGAAGGACTACAGGT	SEQ. ID. No. 18
	1L	CGAAGAAGTCCGCAGGGTCC	SEQ. ID. No. 19
	2U	AAGACCCGCCACGACCCG	SEQ. ID. No. 20
	2L	GAATCAGCACCTCTCCGCC	SEQ. ID. No. 21
10			
	3U	TGCGGAGTTCTTCGTGCTGATGGAG	SEQ. ID. No. 22
	3L	GGTGCTCGGCGGCGTCCTTC	SEQ. ID. No. 23
	4U	GAGTGGCGGAGAGGGTGCTGA	SEQ. ID. No. 24
15	4L	GGCCGAGGCTGAGCGGGG	SEQ. ID. No. 25
	5U	CTGAAGGACGCCGCCGAGCA	SEQ. ID. No. 26
	5L	CTCCAACGCCTGCCGCTGC	SEQ. ID. No. 27
20	6U	GCAGGAGGAGCGGGAGCAGGA	SEQ. ID. No. 28
	6L	TCCAGTGCCCCGCAAGCCG	SEQ. ID. No. 29

Probes according to the invention are suitable for use as diagnostic reagents to amplify *5'OT-EST* and thereby enable the analysis of the nucleic acid for the presence of mutations, polymorphisms or other changes which could render an individual susceptible to obesity.

After screening the library, e.g. with a portion of DNA including substantially the entire *5'OT-EST*-encoding sequence or a suitable oligonucleotide based on a portion of said DNA, positive clones are identified by detecting a hybridisation signal; the identified clones are characterised by restriction enzyme mapping and/or DNA sequence analysis,

and then examined, e.g. by comparison with the sequences set forth herein, to ascertain whether they include DNA encoding a complete 5'OT-EST (i.e., if they include translation initiation and termination codons). If the selected clones are incomplete, they may be used to rescreen the same or a different library to obtain overlapping clones. If the library is genomic, then the overlapping clones may include exons and introns. If the library is a cDNA library, then the overlapping clones will include an open reading frame. In both instances, complete clones may be identified by comparison with the DNAs and deduced amino acid sequences provided herein.

10 In order to detect any abnormality of endogenous 5'OT-EST, genetic screening may be carried out using the nucleotide sequences of the invention as hybridisation probes or as PCR primers, using which genomic nucleic acid may be amplified, and subsequently sequenced. Also, based on the nucleic acid sequences provided herein antisense-type therapeutic agents may be designed.

15 It is envisaged that the nucleic acid of the invention can be readily modified by nucleotide substitution, nucleotide deletion, nucleotide insertion or inversion of a nucleotide stretch, and any combination thereof. Such mutants can be used e.g. to produce a 5'OT-EST mutant that has an amino acid sequence differing from the 5'OT-EST sequences as found in nature. Mutagenesis may be predetermined (site-specific) or random. A mutation which is not a silent mutation must not place sequences out of reading frames and preferably will not create complementary regions that could hybridise to produce secondary mRNA structure such as loops or hairpins.

25 The invention accordingly specifically includes nucleic acids encoding mutants of 5'OT-EST, as defined above. Such nucleic acids may be used for all the purposes identified above in relation to wild-type 5'OT-EST nucleic acids. Particularly preferred are nucleic acids encoding 5'OT-EST - *xdel*, which preferably have the sequence
ATGTTGCGGGCTTTGAACCGCCTGGCCGCGCGGCCCGGGGGCCAGCCCCCAACCCTGCTC
30 CTTCTGCCCCGTGCGCGGCCACGGCCCCGCTCATTTCTCGGCTCCTTTTTCTCGCAGGAT
AGC (see SEQ. ID. No. 7), or an equivalent sequence which encodes the same polypeptide having regard to the degeneracy of the nucleic acid code, or a sequence

substantially homologous thereto or complementary thereto. In 5'-OT-EST - *xdel* exon x is deleted, and exons y and z are out of frame and therefore not translated.

For hybridisation probes, it may be desirable to use nucleic acid analogues, in order to
5 improve the stability and binding affinity. A number of modifications have been described that alter the chemistry of the phosphodiester backbone, sugars or heterocyclic bases.

Among useful changes in the backbone chemistry are phosphorothioates;
10 phosphorodithioates, where both of the non-bridging oxygens are substituted with sulphur; phosphoroamidites; alkyl phosphotriesters and boranophosphates. Achiral phosphate derivatives include 3'-O'-5'-S-phosphorothioate, 3'-S-5'-O-phosphorothioate, 3'-CH₂-5'-O-phosphonate and 3'-NH-5'-O-phosphoroamidate. Peptide nucleic acids replace the entire phosphodiester backbone with a peptide linkage.

15 Sugar modifications are also used to enhance stability and affinity. The α -anomer of deoxyribose may be used, where the base is inverted with respect to the natural β -anomer. The 2'-OH of the ribose sugar may be altered to form 2'-O-methyl or 2'-O-allyl sugars, which provides resistance to degradation without comprising affinity.

20 Modification of the heterocyclic bases must maintain proper base pairing. Some useful substitutions include deoxyuridine for deoxythymidine; 5-methyl-2'-deoxycytidine and 5-bromo-2'-deoxycytidine for deoxycytidine. 5-propynyl-2'-deoxyuridine and 5-propynyl-2'-deoxycytidine have been shown to increase affinity and biological
25 activity when substituted for deoxythymidine and deoxycytidine, respectively.

The DNA sequences, particularly nucleic acid analogues as described above, may be used as antisense sequences.

30 In accordance with another embodiment of the present invention, there are provided cells containing the above-described nucleic acids. Such host cells such as prokaryote,

yeast and higher eukaryote cells may be used for replicating DNA and producing 5'OT-EST. Suitable prokaryotes include eubacteria, such as Gram-negative or Gram-positive organisms, such as *E. coli*, e.g. *E. coli* K-12 strains, DH5 α and HB101, or *Bacilli*. Further hosts suitable for 5'OT-EST encoding vectors include eukaryotic microbes such as filamentous fungi or yeast, e.g. *Saccharomyces cerevisiae*. Higher eukaryotic cells include insect and vertebrate cells, particularly mammalian cells, including human cells, or nucleated cells from other multicellular organisms. The propagation of vertebrate cells in culture (tissue culture) is a routine procedure. Examples of useful mammalian host cell lines are epithelial or fibroblastic cell lines such as Chinese hamster ovary (CHO) cells, NIH 3T3 cells, HeLa cells or 293T cells. The host cells referred to in this disclosure comprise cells in *in vitro* culture as well as cells that are within a host animal.

DNA may be stably incorporated into cells or may be transiently expressed using methods known in the art. Stably transfected mammalian cells may be prepared by transfecting cells with an expression vector having a selectable marker gene, and growing the transfected cells under conditions selective for cells expressing the marker gene. To prepare transient transfectants, mammalian cells are transfected with a reporter gene to monitor transfection efficiency.

To produce such stably or transiently transfected cells, the cells should be transfected with a sufficient amount of 5'OT-EST-encoding nucleic acid to form 5'OT-EST. The precise amounts of DNA encoding 5'OT-EST may be empirically determined and optimised for a particular cell and assay.

Host cells are transfected or, preferably, transformed with the above-captioned expression or cloning vectors of this invention and cultured in conventional nutrient media modified as appropriate for inducing promoters, selecting transformants, or amplifying the genes encoding the desired sequences. Heterologous DNA may be introduced into host cells by any method known in the art, such as transfection with a vector encoding a heterologous DNA by the calcium phosphate coprecipitation

technique or by electroporation. Numerous methods of transfection are known to the skilled worker in the field. Successful transfection is generally recognised when any indication of the operation of this vector occurs in the host cell. Transformation is achieved using standard techniques appropriate to the particular host cells used.

5

Incorporation of cloned DNA into a suitable expression vector, transfection of eukaryotic cells with a plasmid vector or a combination of plasmid vectors, each encoding one or more distinct genes or with linear DNA, and selection of transfected cells are well known in the art (see, e.g. Sambrook *et al.* (1989) Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor Laboratory Press).

10

Transfected or transformed cells are cultured using media and culturing methods known in the art, preferably under conditions, whereby 5'OT-EST encoded by the DNA is expressed. The composition of suitable media is known to those in the art, so that they can be readily prepared. Suitable culturing media are also commercially available.

15

The cDNA or genomic DNA encoding native or mutant 5'OT-EST can be incorporated into vectors for further manipulation. As used herein, vector (or plasmid) refers to discrete elements that are used to introduce heterologous DNA into cells for either expression or replication thereof. Selection and use of such vehicles are well within the skill of the artisan. Many vectors are available, and selection of appropriate vector will depend on the intended use of the vector, i.e. whether it is to be used for DNA amplification or for DNA expression, the size of the DNA to be inserted into the vector, and the host cell to be transformed with the vector. Each vector contains various components depending on its function (amplification of DNA or expression of DNA) and the host cell for which it is compatible. The vector components generally include, but are not limited to, one or more of the following: an origin of replication, one or more marker genes, an enhancer element, a promoter, a transcription termination sequence and optionally a signal sequence.

20

25

30

Both expression and cloning vectors generally contain nucleic acid sequence that enable the vector to replicate in one or more selected host cells. Typically in cloning vectors, this sequence is one that enables the vector to replicate independently of the host chromosomal DNA, and includes origins of replication or autonomously replicating sequences. Such sequences are well known for a variety of bacteria, yeast and viruses. The origin of replication from the plasmid pBR322 is suitable for most Gram-negative bacteria, the 2 μ plasmid origin is suitable for yeast, and various viral origins (e.g. SV 40, polyoma, adenovirus) are useful for cloning vectors in mammalian cells. Generally, the origin of replication component is not needed for mammalian expression vectors unless these are used in mammalian cells competent for high level DNA replication, such as COS cells.

Most expression vectors are shuttle vectors, i.e. they are capable of replication in at least one class of organisms but can be transfected into another class of organisms for expression. For example, a vector is cloned in *E. coli* and then the same vector is transfected into yeast or mammalian cells even though it is not capable of replicating independently of the host cell chromosome. DNA may also be replicated by insertion into the host genome. However, the recovery of genomic DNA encoding 5'OT-EST is more complex than that of exogenously replicated vector because restriction enzyme digestion is required to excise 5'OT-EST DNA. DNA can be amplified by PCR and be directly transfected into the host cells without any replication component.

Advantageously, an expression and cloning vector may contain a selection gene also referred to as selectable marker. This gene encodes a protein necessary for the survival or growth of transformed host cells grown in a selective culture medium. Host cells not transformed with the vector containing the selection gene will not survive in the culture medium. Typical selection genes encode proteins that confer resistance to antibiotics and other toxins, e.g. ampicillin, neomycin, methotrexate or tetracycline, complement auxotrophic deficiencies, or supply critical nutrients not available from complex media.

As to a selective gene marker appropriate for yeast, any marker gene can be used which facilitates the selection for transformants due to the phenotypic expression of the marker gene. Suitable markers for yeast are, for example, those conferring resistance to antibiotics G418, hygromycin or bleomycin, or provide for prototrophy in an auxotrophic yeast mutant, for example the URA3, LEU2, LYS2, TRP1, or HIS3 gene.

Since the replication of vectors is conveniently done in *E. coli*, an *E. coli* genetic marker and an *E. coli* origin of replication are advantageously included. These can be obtained from *E. coli* plasmids, such as pBR322, Bluescript® vector or a pUC plasmid, e.g. pUC18 or pUC19, which contain both *E. coli* replication origin and *E. coli* genetic marker conferring resistance to antibiotics, such as ampicillin.

Suitable selectable markers for mammalian cells are those that enable the identification of cells competent to take up 5'OT-EST nucleic acid, such as dihydrofolate reductase (DHFR, methotrexate resistance), thymidine kinase, or genes conferring resistance to G418 or hygromycin. The mammalian cell transformants are placed under selection pressure which only those transformants which have taken up and are expressing the marker are uniquely adapted to survive. In the case of a DHFR or glutamine synthase (GS) marker, selection pressure can be imposed by culturing the transformants under conditions in which the pressure is progressively increased, thereby leading to amplification (at its chromosomal integration site) of both the selection gene and the linked DNA that encodes 5'OT-EST. Amplification is the process by which genes in greater demand for the production of a protein critical for growth, together with closely associated genes which may encode a desired protein, are reiterated in tandem within the chromosomes of recombinant cells. Increased quantities of desired protein are usually synthesised from thus amplified DNA.

Expression and cloning vectors usually contain a promoter that is recognised by the host organism and is operably linked to 5'OT-EST nucleic acid. Such a promoter may be inducible or constitutive. The promoters are operably linked to DNA encoding 5'OT-EST by removing the promoter from the source DNA by restriction enzyme

digestion and inserting the isolated promoter sequence into the vector. Both the native 5'OT-EST promoter sequence and many heterologous promoters may be used to direct amplification and/or expression of 5'OT-EST DNA. The term "operably linked" refers to a juxtaposition wherein the components described are in a relationship permitting them to function in their intended manner. A control sequence "operably linked" to a coding sequence is ligated in such a way that expression of the coding sequence is achieved under conditions compatible with the control sequences.

Promoters suitable for use with prokaryotic hosts include, for example, the β -lactamase and lactose promoter systems, alkaline phosphatase, the tryptophan (trp) promoter system and hybrid promoters such as the tac promoter. Their nucleotide sequences have been published, thereby enabling the skilled worker operably to ligate them to DNA encoding 5'OT-EST, using linkers or adaptors to supply any required restriction sites. Promoters for use in bacterial systems will also generally contain a Shine-Delgarno sequence operably linked to the DNA encoding 5'OT-EST.

Preferred expression vectors are bacterial expression vectors which comprise a promoter of a bacteriophage such as phagex or T7 which is capable of functioning in the bacteria. In one of the most widely used expression systems, the nucleic acid encoding the fusion protein may be transcribed from the vector by T7 RNA polymerase (Studier *et al.*, Methods in Enzymol. 185; 60-89, 1990). In the *E. coli* BL21(DE3) host strain, used in conjunction with pET vectors, the T7 RNA polymerase is produced from the λ -lysogen DE3 in the host bacterium, and its expression is under the control of the IPTG inducible lac UV5 promoter. This system has been employed successfully for over-production of many proteins. Alternatively the polymerase gene may be introduced on a lambda phage by infection with an int- phage such as the CE6 phage which is commercially available (Novagen, Madison, USA). other vectors include vectors containing the lambda PL promoter such as PLEX (Invitrogen, NL) , vectors containing the trc promoters such as pTrcHisXpressTm (Invitrogen) or pTrc99 (Pharmacia Biotech, SE) , or vectors containing the tac promoter such as pKK223-3 (Pharmacia Biotech) or PMAL (new England Biolabs, MA, USA).

Moreover, the *5'OT-EST* gene according to the invention preferably includes a secretion sequence in order to facilitate secretion of the polypeptide from bacterial hosts, such that it will be produced as a soluble native peptide rather than in an inclusion body. The peptide may be recovered from the bacterial periplasmic space, or
5 the culture medium, as appropriate.

Suitable promoting sequences for use with yeast hosts may be regulated or constitutive and are preferably derived from a highly expressed yeast gene, especially a
10 *Saccharomyces cerevisiae* gene. Thus, the promoter of the *TRP1* gene, the *ADHI* or *ADHII* gene, the acid phosphatase (*PH05*) gene, a promoter of the yeast mating pheromone genes coding for the α - or α -factor or a promoter derived from a gene encoding a glycolytic enzyme such as the promoter of the enolase, glyceraldehyde-3-phosphate dehydrogenase (*GAP*), 3-phospho glycerate kinase (*PGK*), hexokinase,
15 pyruvate decarboxylase, phosphofructokinase, glucose-6-phosphate isomerase, 3-phosphoglycerate mutase, pyruvate kinase, triose phosphate isomerase, phosphoglucose isomerase or glucokinase genes, the *S. cerevisiae* *GAL 4* gene, the *S. pombe* *nmt 1* gene or a promoter from the TATA binding protein (*TBP*) gene can be used. Furthermore, it is possible to use hybrid promoters comprising upstream activation
20 sequences (*UAS*) of one yeast gene and downstream promoter elements including a functional TATA box of another yeast gene, for example a hybrid promoter including the *UAS(s)* of the yeast *PH05* gene and downstream promoter elements including a functional TATA box of the yeast *GAP* gene (*PH05-GAP* hybrid promoter). A suitable constitutive *PH05* promoter is e.g. a shortened acid phosphatase *PH05* promoter
25 devoid of the upstream regulatory elements (*UAS*) such as the *PH05* (-173) promoter element starting at nucleotide -173 and ending at nucleotide -9 of the *PH05* gene.

5'OT-EST gene transcription from vectors in mammalian hosts may be controlled by promoters derived from the genomes of viruses such as polyoma virus, adenovirus,
30 fowlpox virus, bovine papilloma virus, avian sarcoma virus, cytomegalovirus (*CMV*), a retrovirus and Simian Virus 40 (*SV40*), from heterologous mammalian promoters such

as the actin promoter or a very strong promoter, e.g. a ribosomal protein promoter, and from the promoter normally associated with *5'OT-EST* sequence, provided such promoters are compatible with the host cell systems.

- 5 Transcription of a DNA encoding *5'OT-EST* by higher eukaryotes may be increased by inserting an enhancer sequence into the vector. Enhancers are relatively orientation and position independent. Many enhancer sequences are known from mammalian genes (e.g. elastase and globin). However, typically one will employ an enhancer from a eukaryotic cell virus. Examples include the SV40 enhancer on the late side of the
10 replication origin (bp 100-270) and the CMV early promoter enhancer. The enhancer may be spliced into the vector at a position 5' or 3' to *5'OT-EST* DNA; but is preferably located at a site 5' from the promoter.

Advantageously, a eukaryotic expression vector encoding *5'OT-EST* may comprise a
15 locus control region (LCR). LCRs are capable of directing high-level integration site independent expression of transgenes integrated into host cell chromatin, which is of importance especially where the *5'OT-EST* gene is to be expressed in the context of a permanently-transfected eukaryotic cell line in which chromosomal integration of the vector has occurred, in vectors designed for gene therapy applications or in transgenic
20 animals.

Eukaryotic expression vectors will also contain sequences necessary for the termination of transcription and for stabilising the mRNA. Such sequences are commonly available from the 5' and 3' untranslated regions of eukaryotic or viral DNAs or cDNAs. These
25 regions contain nucleotide segments transcribed as polyadenylated fragments in the untranslated portion of the mRNA encoding *5'OT-EST*.

An expression vector includes any vector capable of expressing *5'OT-EST* nucleic acids that are operatively linked with regulatory sequences, such as promoter regions, that
30 are capable of expression of such DNAs. Thus, an expression vector refers to a recombinant DNA or RNA construct, such as a plasmid, a phage, recombinant virus or

other vector, that upon introduction into an appropriate host cell, results in expression of the cloned DNA. Appropriate expression vectors are well known to those with ordinary skill in the art and include those that are replicable in eukaryotic and/or prokaryotic cells and those that remain episomal or those which integrate into the host cell genome. For example, DNAs encoding 5'OT-EST may be inserted into a vector
5 suitable for expression of cDNAs in mammalian cells, e.g. a CMV enhancer-based vector such as pEVRF (Matthias, *et al.*, (1989) NAR 17, 6418).

Particularly useful for practising the present invention are expression vectors that
10 provide for the transient expression of DNA encoding 5'OT-EST in mammalian cells. Transient expression usually involves the use of an expression vector that is able to replicate efficiently in a host cell, such that the host cell accumulates many copies of the expression vector, and, in turn, synthesises high levels of 5'OT-EST. For the purposes of the present invention, transient expression systems are useful e.g. for identifying
15 5'OT-EST mutants, to identify potential phosphorylation sites, or to characterise functional domains of the protein.

Construction of vectors according to the invention employs conventional ligation techniques. Isolated plasmids or DNA fragments are cleaved, tailored, and religated in
20 the form desired to generate the plasmids required. If desired, analysis to confirm correct sequences in the constructed plasmids is performed in a known fashion. Suitable methods for constructing expression vectors, preparing in vitro transcripts, introducing DNA into host cells, and performing analyses for assessing 5'OT-EST expression and function are known to those skilled in the art. Gene presence, amplification and/or
25 expression may be measured in a sample directly, for example, by conventional Southern blotting, Northern blotting to quantitate the transcription of mRNA, dot blotting (DNA or RNA analysis), or in situ hybridisation, using an appropriately labelled probe which may be based on a sequence provided herein. Those skilled in the art will readily envisage how these methods may be modified, if desired.

30

In a further aspect, the present invention provides a transgenic non-human animal which

expresses, as a result of transformation with a transgene, 5'OT-EST or a mutant thereof as defined herein. Preferred animals include mammals, especially rats.

Preferably, the non-human animal is a mammal suitable for use as a test system for therapies and treatments relating to obesity, including human obesity and animal obesity, which is of concern in household animals such as cats and dogs. Thus, the mammal may be a cat or a dog, or other household pet; it is preferably a rodent, such as a mouse or a rat, particularly a rodent adapted for laboratory testing whose genotype and general characteristics are well known.

Any technique may be used to generate transgenic animals according to the invention. Preferably, the technique involves transfer of a transgene comprising 5'OT-EST to the pronucleus of a single-cell embryo, prior to implantation of the embryo into a pseudopregnant foster mother. Such techniques have the advantage that germ-line transgenic animals are readily produced.

Alternatively, transgenic animals may be created by ES cell transfer techniques. In such techniques, ES cells are transformed with the desired transgene and then used to reconstitute an embryo. Animals created by such techniques are normally chimeric for the transgene. However, more accurate positional insertion of the transgene is possible, and selective deletion of endogenous genes by homologous recombination is facilitated (Mansour *et al.*, 1989).

Further techniques include targeted or non-targeted delivery of genes to whole animals, using viral or non-viral vectors. For example, genes may be delivered by recombinant retroviruses or adenovirus vectors, including adeno-assisted virus vectors, which are capable of integrating into the genome of the animal and expressing the delivered gene. Non-viral vectors include liposomal vectors, antibody-targeted DNA-protein complexes and the like.

As used herein, "transgenic" animals include animals from which 5'OT-EST has been deleted, as well as animals to which a 5'OT-EST transgene has been added. Optionally,

the endogenous 5'*OT-EST* may be deleted, and a transgene bearing a heterologous or homologous 5'*OT-EST* gene, which may be wild-type or mutated, inserted into the animal.

5 Preferred vectors for creating transgenic animals include linearised naked DNA from a variety of sources. In a preferred embodiment, transgenes may be derived from linearised cosmid sequences, from which the phage-related sequences have optionally been removed.

10 The 5'*OT-EST* sequences used in a transgene according to the present invention may be inserted separately, or together with further sequences, including reporter genes, further effector genes and the like. Preferably, 5'*OT-EST* is comprised in a nucleic acid fragment which comprises the natural wild-type environment of 5'*OT-EST*, including flanking sequences.

15

5'*OT-EST* is located proximal to the vasopressin (AVP) and oxytocin (OT) genes in the genome, being transcribed in opposite directions from positions closely linked in a single locus. 5'*OT-EST* lies 5' of the OT gene in at the OT/AVP locus. Accordingly, the transgene preferably consists of the OT/AVP locus, including 5'*OT-EST*.

20 Advantageously, one or more of the OT, AVP and 5'*OT-EST* genes may be mutated, for example by insertion of reporter genes, such as the hGH gene.

In a highly preferred aspect, the transgene is cosmid cVO14 as described in Figure 4 herein. The complete sequence of cVO14 is set forth in SEQ. ID. No. 17.

25

Transgenic animals according to the invention may comprise single copies of the transgene, or may comprise multiple integrated copies, which may be present as concatamers. Preferably, transgenic animals according to the invention comprise four or more copies of the transgene.

30

Transgenic animals according to the invention may be employed for a variety of purposes. The characteristics of male specificity, central distribution of adiposity, late onset and

severity, and associated morbidity have parallels in the description of several human forms of central obesity. These include, but are not limited to, the condition known as metabolic syndrome, or Syndrome X, as well as other forms of central obesity which may be most severely expressed in human males, with or without reduced fertility and which are associated with increased morbidity. (For recent reviews of the importance of clinical and health care issues in obesity see Science 1998, vol. 280 pp. 1364-1390). Transgenic animals expressing 5'OT-EST or mutants thereof thus have particular beneficial utility as a novel animal model of late-onset human visceral obesity, preponderant in males.

Moreover, the induction of the SLOB phenotype in juvenile rats as a result of dietary fat increases suggests that transgenic animals expressing 5'OT-EST are a model for juvenile obesity in mammals, predominantly male mammals, which is induced by the consumption of a high-fat diet.

Furthermore, the onset of obesity in ovariectomised SLOB female rats suggests the model may be suitable to investigate post-menopausal obesity in female mammals.

For instance, one recognised value of animals bearing 5'OT-EST or mutant constructs is to use such animals and their nontransgenic littermates as animal experimental models for studying obesity or male infertility and their related conditions. Using the information disclosed herein, it is possible to identify transgenic animals before they become obese or sexually mature, and to use them as a model for studying the factors that affect the development of obesity or male infertility in any animal classified as a mammal, including humans, domestic, and farm animals, and zoo, sports, or pet animals, such as but not limited to sheep pigs, cows, horses, dogs, cats, etc.

In particular, rodent models of obesity or infertility are of value in testing the ability of pharmaceutical preparations of novel agents, to be beneficial in delaying or preventing the occurrence, development, course, severity, progression, or exacerbation of obesity or infertility (Mathe, 1995; Fan *et al.*, 1997). Animals bearing 5'OT-EST or mutant constructs are particularly useful in testing agents in this regard, since the phenotype is predictable and non-transgenic littermates are ideal controls.

In addition to screening for unknown compounds, animals bearing 5'OT-EST or mutants thereof may be particularly useful in studies employing administration of natural or recombinant proteins, peptides or other agents or their derivatives already known or suspected to be involved in some forms of obesity or male infertility (e.g. growth hormones, or reproductive hormones, their homologues, analogues, antagonists, inhibitors or secretagogues, or leptin, its homologues, analogues and antagonists) or other natural or pharmacological agents already known to be active and/or of therapeutic value in these conditions (e.g. insulin, thiazolidinones, catecholamines, gonadal steroids) or agents already known to affect their actions, distribution, catabolism or elimination).

Typically in such studies, compounds may be administered to animals bearing 5'OT-EST or mutants thereof and their non-transgenic littermates by oral, parenteral (e.g., intramuscular, intraperitoneal, intravenous, or subcutaneous injection or infusion, or implant), nasal, pulmonary, rectal, sublingual, or topical routes of administration, and can be formulated in dosage forms appropriate for each route of administration, e.g. in soluble form, suspension, or other suitable pharmaceutical formulations.

For example, the effects of such compounds on the obese phenotype may be assessed by carcass analysis, measurement of growth, body weight, body fat distribution, as well as other measures of analytes in body fluids or tissues relevant to obesity (Mathe, 1995; Shillabeer, 1992). These include, but are not limited to, cholesterol, triglycerides, fatty acids, lipoproteins, and other dietary constituents or metabolites, as well as metabolic hormones, such as leptin, insulin, glucagon, catecholamines or glucocorticoids. Other relevant parameters include cardiovascular measures (Reaven, 1988, Gray & Yudkin, 1997). These may include measures of systolic or diastolic blood pressure, cardiac output, or vascular resistance, together with morphological changes to organ systems known to be affected by cardiovascular or obesity disorders, such as heart, major or minor blood vessels, their muscle or endothelial layers, and their elasticity or fragility. See for example McNamee *et al.* (1994).

Similarly, parameters related to the infertility phenotype that may be measured, include,

but are not limited to, testicular weight, volume, development, spermatogenesis, sperm number, motility or ability to fertilise oocytes. They may also include measures of testicular fluid production and constituents, as well as products of other accessory organs including seminal vesicles or prostate, as well as hormones, receptors, and proteins important in male sexual function, such as testosterone, LH, FSH, inhibin or activin. Other responses that may be affected include energy expenditure, physical activity, ingestive behaviour, excretory behaviour, or reproductive behaviour, or the organs, hormones or receptors commonly recognised to be associated with these physiological systems, their metabolism or morphological structure.

10

Compounds identified as effective in such screening or analysis based on the use of animals bearing *5'OT-EST* or mutants thereof are particularly useful in treatment of late-onset visceral obesity, or male infertility, in particular where they occur in combination, and disorders related to these conditions with a view to delaying or preventing the occurrence, development, course, severity or progression of the phenotype, avoiding its exacerbation, and preferably promoting its amelioration or cure in animals of commercial importance, or more preferably in humans.

In another embodiment, converse but also therapeutically valuable compounds may be developed based on screening or analysis as above in animals bearing *5'OT-EST* or mutants thereof but which are intended to *promote* the occurrence, development, or progression of *increased* fat deposition or increased calorie intake or decreased energy consumption. Such disorders in humans include, but are not limited to, wasting, or anorexia, or cachexia, associated with prolonged illness, or malabsorptive states or catabolic states associated with other diseases, such as, but not limited to, inflammatory conditions, Crohns disease, or AIDS wasting, or burns, or cancer, or bone disease.

Similarly, therapeutically valuable approaches may be developed based on screening or analysis as above in animals bearing *5'OT-EST* or mutants thereof but which *reduce* the degree of male fertility in those conditions in which it might be beneficial. For example, this may be beneficial in the control of populations in animals of commercial or environmental importance, or to develop novel forms of contraception which may be

effective in human males. Such approaches specifically include, but are not limited to, the possibility of blocking 5'OT-EST or mutants thereof function by administering 5'OT-EST mutant products or by immunisation against 5'OT-EST to generate neutralising antibodies that interfere with the normal functioning of this gene product in the testis, or hypothalamus or adrenal gland or gastrointestinal tract, or other organ system in which 5'OT-EST is expressed or upon which its products act.

The development and late-onset of obesity in transgenic animals may be particularly useful in studying the chronic effects of novel food additives or formulations designed to prevent or exacerbate the deposition of fat in animals of commercial importance, of destined for use in human food products or dietary aids. Such compounds may be administered as above and their effects on the development, course, severity, progression, exacerbation, amelioration or cure of the obesity phenotype assessed as described above. Additives or formulations shown to reduce the development of visceral obesity in this model may have utility in human food products or dietary aids or find beneficial medicinal use in reducing fat accretion or retention.

In another embodiment, transgenic animals, such as mice bearing 5'OT-EST or mutants thereof or in which 5'OT-EST has been disrupted, may be usefully intercrossed with other animal strains with defined mutations, or with undefined genetic backgrounds associated with propensity for the development of obesity or infertility. Comparison of the resulting progeny with or without the 5'OT-EST transgene will provide additional information on the alterations in occurrence, development, course, severity, progression, exacerbation, amelioration or cure of the obesity phenotype when expressed in these other genetic backgrounds, and analysed as described above. Such intercrossing may then be envisaged to enhance the utility of the resulting progeny exhibiting the obesity phenotype.

Examples of this use include (without being limited to) interbreeding with Zucker fa/fa rats (Iida *et al.*, 1996), corpulent (cp) rats (Kahle *et al.*, 1997), OLETF rats (Takiguchi *et al.*, 1998), ZDF rats, tfm rats, spontaneously hypertensive or salt-sensitive rats (Michaelis *et al.*, 1995) or other dwarf rats such as dw/dw (Charlton *et al.*, 1988) or dr/dr rats (Takeuchi *et al.*, 1991). An example of the utility of this approach is given by

(Michaelis *et al.*, 1995). Examples of mouse lines that may be usefully interbred with mice carrying transgenes or deletions affecting 5'OT-EST include, but are not limited to, ob/ob, db/db, tfm/tfm or hpg/hpg mice. A related example includes intercrossing mice carrying transgenes or deletions affecting 5'OT-EST with other strains of mice in which genes already known to be involved in obesity or male fertility have been deleted by homologous recombination or introduced by transgenesis (singly or in combination). Examples of these are already known to include (but are not limited to) leptin, tubby and related genes, NPY, insulin, GLP-1, IGF-1, IGF-II, MCH, CRH, POMC, CCK, orexins or hypocretins, CART peptides, agouti protein, as well as the genes or alternate products structurally related to or homologous with, the above peptides. This example is also intended to include mice with disruptions in or extra copies of normal or mutated forms of, genes for the specific receptors of the peptides listed above (for example NPY receptors, such as subtype 5), or bombesin-receptor 3, IRS-1 or 2, uncoupling proteins such as UCP1-3, carboxypeptidase E, or PPARs or adrenergic receptor subtype 3 or TNF alpha or, all of which have been implicated in obesity.

Similarly, the fertility disruption in transgenic animals according to the invention may also be studied to advantage by crossing these animals or other animals in which 5'OT-EST has been disrupted onto genetic backgrounds in which genes for gonadal or adrenal steroid biosynthesis or metabolism or gonadal steroid receptors and other reproductive hormones or their receptors or hypothalamic or pituitary hormones thought to affect male fertility (such as gonadotrophins, activins, inhibins, PRL, GnRH or transcription factors such as DAX1 or SF1, or other known gene products affecting male gonadal development, such as MIS, AMH, SCF) have been disrupted. Comparison of the resulting progeny with or without the 5'OT-EST or mutant transgene may shed light on the alterations in occurrence, development, course, severity, progression, exacerbation, amelioration or cure of the infertility phenotype when expressed in these other genetic backgrounds. Such intercrossed lines, for example with those genetic strains as outlined above, and in which the obesity phenotype is present in full or in a modified form, may also be additionally useful for screening applications.

Conversely, the transfer of the obese phenotype onto these genetic backgrounds may also

alter the occurrence, development, course, severity, progression, exacerbation, amelioration or cure of the specific phenotypes expressed in the strain with which animals bearing *5'OT-EST* or mutants thereof are bred. Such intercrossed lines, for example with those genetic strains as outlined above, and in which the obesity phenotype is present in full or in a modified form, may also be useful for screening applications.

Animals bearing *5'OT-EST* or mutants thereof may be used to study the transfer of other gene products other than by breeding, e.g. by administration of suitable vectors containing constructs expressing proteins of interest, or by transgenesis. Such examples include, but are not limited to, constructs containing the gene products or analogues of other genes already thought to be active in obesity or male infertility, whose effects may be advantageously studied in transgenic animals according to the invention due to the predictable development of their phenotype. Such genes and their products include those mentioned in above in relation to alternative obese strains. Such derived animals in which the obesity phenotype is present in full or in a modified form, may also be useful for the various applications outlined above.

Animals bearing *5'OT-EST* or mutants thereof and exhibiting a specific late-onset visceral obesity may prove of particular value when used in a similar way to screen for the beneficial effects of reducing or eliminating other gene products by their silencing or elimination as described above using transgenesis, or homologous recombination, or by adenoviral delivery of antisense nucleotides. Examination of any alterations in the occurrence, development, course, severity, or progression of the obesity phenotype in these genetic backgrounds would be of utility in identifying the role, if any, of such disrupted genes in the expression of the obesity phenotype. Such animals in which the obesity phenotype is present in full or in a modified form, may also be useful for the applications outlined above.

In another embodiment, animals bearing *5'OT-EST* or mutants thereof or material derived from them and/or their nontransgenic littermates may prove useful in experiments designed to identify obesity -related or male-fertility-related differences in gene expression, RNA transcripts, proteins, or other biochemical measures, such as, but not

limited to lipids, peptides, carbohydrates, amino acids or compounds or precursors or metabolites thereof, or their distribution, in whole animals, or in samples of biological fluids taken from animals bearing *5'OT-EST* or mutants thereof. These may include, but are not limited to: serum, plasma, lymph fluid, synovial fluid, follicular fluid, seminal fluid, amniotic fluid, milk, whole blood, urine, cerebrospinal fluid, saliva, sputum, tears, perspiration, mucus, tissue culture medium, tissue extracts, and cellular extracts.

Similar analyses may be advantageously performed in samples of any tissue from animals bearing *5'OT-EST* or mutants thereof or their non-transgenic littermates, or tissue derived from animals interbred with SLOB rats or other animals bearing *5'OT-EST* or mutants thereof. Such tissues are preferably (but not limited to) endocrine tissues, such as pancreas, adrenals, or pituitary gland, adipose tissues from different locations, preferably but not limited to, inguinal, omental, perirenal, subcutaneous, mammary, periorbital or other regions, thermogenic fat, brown or white adipose tissue in other locations, areas of the CNS though to be involved in obesity, preferably but not limited to the hypothalamus, and other tissues, preferably, but not restricted to liver, gastrointestinal tract, gonads, heart, musculoskeletal system, immune system, kidney, connective tissue including skin, epithelial or endothelial tissues.

Specifically included are cells or tissues removed from animals bearing *5'OT-EST* or mutants thereof, or animals interbred with them, and maintained thereafter *ex vivo*, e.g. in tissue culture, or by transplantation in animals bearing *5'OT-EST* or mutants thereof or other hosts, with or without immune suppression, provided the particular utility is enhanced by the presence of the obesity gene or phenotype.

The invention thus provides the use of a tissue derived from a transgenic animal according to any one of claims 17 to 24 in a screen to identify a genetic cause of obesity, comprising the steps of:

- a) isolating one or more gene products from tissue derived from a transgenic animal according to any one of claims 17 to 24; and
- b) determining whether the expression of a gene product is correlated with obesity.

Tissues derived from SLOB rats, including in particular fat pad tissue, may for example be used for differential screening in order to determine differences in gene expression between obese and non-obese animals. The gene products analysed may be nucleic acid or protein gene products. For example, mRNA may be isolated from the tissue and screened to identify differentially expressed transcripts. In particular, gene products which may be involved in cellular lipid transport may be identified by such means.

The development of obesity or male infertility itself in animals bearing 5'*OT-EST* or mutants thereof is predicted to induce secondary changes in other obesity or fertility - related parameters and regulators. These include, but are not limited to, blood pressure, pituitary hormones, sperm development, maturation, and/or motility, lipid mobilising enzymes or receptors, or agents controlling these. The latter include, but are not limited to leptin and its receptors, melanocortin, NPY, catecholamines, adrenal or gonadal or pituitary hormones, gut hormones such as insulin and glucagon, growth hormone and other growth factors such as members of the GH and IGF-1 families, their binding proteins and receptors. They may also include drugs of several classes that have been thought useful in obesity. Examples of such classes include agents affecting the serotonin system or the fat cell free fatty acid uptake or release or metabolism or lipase activity or hepatic lipid uptake, or insulin sensitisers. This example may also include morphological alterations in any tissue or cells of the cardiovascular system, including but not limited to, the heart and major blood vessels, other blood vessels carrying either arterial or venous blood, and any or all cells comprising these tissues.

Transgenic animals according to the invention appear to present with obesity without obvious diabetes or hypercortisolism. They may thus prove particularly beneficial in studying the developmental changes in these secondary parameters induced by other means, in the development of diabetes, or hypertension or cardiovascular disease or hypercortisolism (Russell *et al.*, 1993), all which are known to be associated with obesity in humans (Reaven, 1988). Examples of such means includes (but is not limited to) variation in dietary components or quantity, or treatment with diabetogenic agents, such as GH or cortisol. Examples of such agents affecting cardiac output or peripheral resistance or blood pressure include angiotensin-converting enzyme inhibitors or cardiac

glycosides, or beta adrenergic receptor 3 agonists or antagonists.

Morphological changes may also be seen in adipose tissues or cells, or the other tissues in the body containing fat, such as the liver and related cells, or the skeleton, or in other
5 organs or tissues in the gonadal system, relating to the effects on male fertility. Differences in these measures detected specifically in animals bearing *5'OT-EST* or mutants thereof and their alteration by elimination, blockade, endogenous stimulation, or exogenous administration of anti-obesity or other agents affective in obesity or male infertility or related disorders would provide novel approaches to evaluate improve and
10 perfect existing or novel therapeutic approaches to obesity or male infertility in other animals of commercial importance, and more preferably, in humans. An obvious example is the ready source of adipocyte cells and products from specific fat depots that are differentially increased in transgenic animals according to the invention. Responses to agents affecting fat cell metabolism or fat storage or lipogenesis or lipolysis or lipid-
15 lowering agents, may be studied with particular advantage to discern effects on visceral or peripheral fat tissues. and to seek differential effects on fat from different depots in the animals.

The information disclosed herein will enable those skilled in the art to produce protein or
20 peptide fragments corresponding in sequence to *5'OT-EST* or mutants thereof, as described above. Such proteins or peptides (or simple analogues thereof), when administered to rats or other animals, or more preferably humans, would be expected to affect the development of obesity and fertility in males, and serve as the basis for the development of similar compounds, based on the homologous human sequences, useful in
25 the treatment of these conditions in humans.

This also includes simple analogues that incorporate alterations known to improve the in vivo stability or delay the clearance, elimination or metabolism of proteins or peptides such as those derived from *5'OT-EST* or mutants thereof. Such alterations are obvious to
30 those skilled in the art, and examples include amidation or acetylation of C or N-termini of peptides, or replacement of methionine residues with norleucine residues to avoid oxidation. This example also includes formulations or modifications of proteins known

to be effect for the same purposes, e.g. by PEGylation to prolong the half-life of peptides or proteins, or formulations of proteins with inert carriers (such as mannitol or lactose) or buffers or salts, that provide stable solutions suitable for in vivo administration of the active agents to animals or to humans.

5

In another embodiment, the information disclosed herein will enable those skilled in the art to design nucleotide probes for, or develop polyclonal or monoclonal antibodies against, the DNA, RNA or protein sequences corresponding to the whole or parts of the *5'OT-EST* gene in other animals of commercial importance, or more preferably, humans.

10

These are of value in diagnostic tests to screen for mutations in this gene in animal or human populations subject to variations in obesity or fertility. They may also be used to monitor the development, progression, amelioration or cure of obesity or infertility as may be reflected in changes in the activity of this gene or its products. Such predictive tests are recognised to have beneficial value when applied to the human population (Whitaker *et al.*, 1997)

15

Examples of such probes or peptides or proteins used to develop antibodies include those predicted from the wild-type and mutated sequences in the rat *5'OT-EST* gene and mutants thereof, as well as their derivatives as described above, as well as those that may be inferred from homologous genes in human and mouse, either as intact sequences or formed in whole or in part as fusion sequences with other proteins to facilitate production or purification by standard methods known to those skilled in the art. For this purpose, products of the *5'OT-EST* gene may also be reacted with, produced as fusion products with, or mixed with, other proteins or adjuvants known to enhance the immune response.

20

25

Also included are modifications to the nucleotide sequences, already known to those skilled in the arts to confer useful chemical properties on the products, for example by incorporating modified nucleotides to render them more stable, or to incorporate nucleotides tagged with functional groups such as biotin or digoxigenin, or incorporation of fluorescent or radioisotopically labelled derivatives, in order to render the products themselves more readily detectable.

30

In a further embodiment, the information disclosed herein will enable those skilled in the

art to isolate factors which interact directly with 5'OT EST or mutants thereof. For example, two-hybrid screens provide a means for isolating genes for proteins which interact with 5'OT EST or mutant proteins, their fragments or derivatives. Similarly, co-precipitation studies using antibodies directed against 5'OT EST or mutants thereof, produced as outlined herein, might allow identification of such interacting factors. Such factors, when administered to rats or other animals, or more preferably humans, would be expected to affect the development of obesity and/or male infertility in a similar fashion to that seen in transgenic animals, and would therefore be predicted to have similar uses. The use of transgenic animals or materials derived from them, or from the information disclosed herein, has particular utility in providing a specific means of isolating such factors that interact directly with the novel gene products disclosed herein, as well as in screening their biological activities in vivo.

The invention is described further, for the purpose of illustration only, in the following examples.

MATERIALS AND METHODS

Bacterial cultures.

All media are made with double distilled water and autoclaved prior to use. Liquid cultures of bacteria are incubated with shaking at 37 °C in either LB broth or terrific broth. Bacterial colonies are grown on agar plates made with either LB broth or terrific broth with 15g/l bacto-agar. These media are supplemented with combinations of 20µg/ml or 50µg/ml ampicillin, 20µg/ml tetracycline and 0.2% glucose. Bacterial clones are stored at - 80 °C after the addition of 15% glycerol.

Purification of nucleic acids.

Aqueous solutions containing DNA are purified by vortex mixing with an equal volume of phenol:chloroform:isoamyl alcohol (25:24:1). The emulsion is then centrifuged at 12,000 rpm for 5 minutes in a microfuge at room temperature. DNA is precipitated by adding 3M sodium acetate (pH 5.2) to a final concentration of 300mM and two volumes

of absolute ethanol. The samples are frozen before centrifugation, the supernatant removed and the pellet resuspended in 10mM Tris.HCl pH 8, 1mM EDTA (TE buffer).

DNA preparation from bacteria stocks.

5 The alkaline lysis method of DNA isolation may be used (Birnboim and Doly, 1979; Sambrook *et al.*, 1989) to prepare plasmid DNA from small volumes of bacterial cultures, typically 10ml. For large scale preparation of plasmid and cosmid DNA, DNA may also be prepared from 1 L overnight cultures by the alkaline lysis method. DNA is dissolved in 100mM Tris.HCl pH 8, 1mM EDTA and further purified on a caesium chloride gradient which is centrifuged at 55,000rpm overnight (Sambrook *et al.*, 1989).

Preparation of genomic DNA from animal tissue.

Rat tail biopsies, up to 1 cm, are taken from 10-14 day old rats and placed in 50mM Tris.HCl pH8, 100mM EDTA, 100mM NaCl ('tail mix'). Genomic DNA is prepared following a standard procedure (Hogan *et al.* 1986) involving incubation with proteinase K, RNase A, phenol extraction and precipitation with isopropanol. Genomic DNA from other tissue such as liver may be prepared by the same method, though this requires additional homogenisation in a larger volume (typically 5ml) of tail mix using a Kinematica Polytron PT 3000 homogeniser prior to the preparation of DNA from a smaller aliquot of homogenate.

Restriction digestion of DNA.

25 Restriction enzyme digestion is performed using standard procedures in accordance with manufacturers instructions. Enzymes are sourced from Boehringer Mannheim, Cambio, or New England Biolabs. Plasmid DNA is incubated for up to 4 hours whilst genomic DNA digests may be incubated overnight.

Subcloning DNA fragments into plasmid vectors.

Blunting of DNA fragments with a 3' overhang

After digestion of DNA with a restriction enzyme which leaves a 3' overhang, the overhang may be removed by incubation with T4 DNA polymerase to create a blunt end for ligation with other blunt-ended DNA fragments. The digests are phenol-extracted,

ethanol-precipitated with the addition of 10µg tRNA, and resuspended in TE. MgCl₂ and deoxynucleotide triphosphates (dNTPs) are added to final concentrations of 10mM and 0.1mM respectively prior to the addition of 2 units of T4 DNA polymerase (New England Biolabs). The reaction is incubated for 15 minutes at 12 °C. The polymerase is inactivated at 75 °C for 10 minutes before purification.

Blunting a DNA fragment by refilling the 5' overhang.

DNA fragments with 5' overhangs may be blunted by filling in the single stranded ends. This may be done using the Klenow fragment of E. coli DNA polymerase I (New England Biolabs). The DNA is digested with an appropriate restriction enzyme, phenol extracted, ethanol precipitated with the addition of 1µg of tRNA and resuspended in TE. 10x Klenow buffer (0.5M Tris.HCl, pH7.6, 0.1M MgCl₂) and dNTPs to a final concentration of 1x and 0.2mM respectively are added with 10 units of Klenow fragment. The reaction is incubated at 37 °C for 30 minutes prior to purification of the DNA.

15

Vector dephosphorylation.

Calf alkaline phosphatase (CAP) may be used to remove 5' phosphate groups from digested vectors to prevent self-ligation during subcloning. Plasmid and cosmid vectors, linearised with restriction enzymes, are incubated with 2 units of CAP (Boehringer) in 50mM Tris.HCl, pH 8.5, 50 mM EDTA, for 30 minutes prior to purification.

20

Inserting linkers into DNA fragments.

Digested plasmid DNA may be blunted if necessary, phenol-extracted, ethanol-precipitated with the addition of 1µg of tRNA and resuspended in TE. 0.5-1µg of phosphorylated linkers are ligated to linearised, blunt-ended plasmid DNA. Ligations are performed in a final concentration of 1x ligase buffer (50mM Tris.HCl (pH 7.5), 10mM MgCl₂, 10mM dithiothreitol, 1mM ATP, 25µg/ml bovine serum albumin (BSA), 0.5mM spermidine-HCl with the addition of 400units of T4 DNA ligase (New England Biolabs). The reactions are incubated at room temperature overnight. The enzyme is then inactivated at 65 °C for 15 minutes. The linkered fragments are digested with an excess amount of the appropriate restriction enzyme and the DNA purified prior to further subcloning procedures.

30

Electrophoresis of DNA fragments

DNA fragments may be electrophoresed in gels of varying percentages of agarose in 90mM Tris-borate, 2mM EDTA, pH 8.0 (TBE buffer) containing 0.5ng/ml ethidium bromide. The DNA bands are visualised on an ultraviolet transilluminator and photographed. Size markers may be Lambda DNA digested with Bst EII, pUC19 DNA digested with Msp I, or a commercially available 1kb ladder (Gibco-BRL).

Purification of DNA fragments.

Digested, blunted, dephosphorylated or linkered DNA fragments are electrophoresed in low melting-point agarose. Gel bands are excised, melted at 65 °C for 5 minutes, and extracted twice with phenol/0.3M NaOAc. Following a phenol extraction and ethanol precipitation with the addition of 1µg tRNA, the DNA is recovered by centrifugation and resuspended in TE. Alternatively, DNA fragments may be purified from agarose using the Prep-A-Gene DNA Purification System (Bio-Rad Laboratories) according to manufacturers instructions.

Purification of larger cosmid-containing fragments.

Large vectors are digested and treated with 50 units of CAP for in excess of 3 hours. EDTA and SDS are added to final concentrations of 5mM and 0.5% respectively. The phosphatase is denatured for 1 hour at 65 °C and the solution is phenol-extracted, ethanol precipitated with the addition of 1µg tRNA, and the DNA recovered is resuspended in TE.

Ligation of DNA fragments into phosphatased vectors.

After purification, DNA fragments and vectors are mixed at equimolar ratios at an approximate concentration of up to 80ng/ml, whilst DNA for recircularisation is used at a concentration of 20ng/ml. Ligation may be done in a volume of 5µl with 200 units of T4 DNA ligase (New England Biolabs) in ligase buffer. Two control reactions are performed simultaneously omitting the insert alone, or omitting both insert and ligase. Ligations are incubated overnight at 16 °C.

Preparation of competent cells.

	psi-broth	5g/l bacto-yeast extract, 20g/l bacto-tryptone, 5g/l MgSO ₄ , adjusted to pH 7.6 with NaOH.
5	TFbI	30mM KAc, 100mM KCl, 10mM CaCl ₂ , 50mM MnCl ₂ , 15% glycerol (v/v), adjusted pH 5.8 with acetic acid and filter sterilised.
10	TFbII	10mM PIPES, 74mM CaCl ₂ , 10mM KCl, 15% glycerol (v/v), adjusted to pH 6.5 with acetic acid and filter sterilised.

- Competent cells yielding a transformation frequency $>5 \times 10^8$ transformed colonies per μg of supercoiled plasmid DNA may be prepared by a method modified from Hanahan *et al.* (1983). Bacteria of the strain DH10B (Grant *et al.*, 1990) are plated on an agar plate and grown overnight at 37 °C. 10ml of psi-broth is then inoculated with 4 colonies from this plate. The bacteria are then shaken at 37 °C until OD550=0.3.
- 5 ml of this broth is then diluted into 100 ml psi-broth and shaken until OD550=0.28. The flask is then placed on ice, the bacteria are centrifuged at 4 °C for 15 minutes at 2,000 rpm. The supernatant is removed and the pellet allowed to dry briefly before being resuspended in 20ml TFbI. This suspension is left on ice for 5 minutes and then centrifuged at 2,000 rpm for 10 minutes at 4 °C. The supernatant is then removed and the pellet resuspended in 3 ml TFbII and placed on ice for 15 minutes. Aliquots are then frozen on dry ice and stored at -80 °C. The competence of the cells may be tested by transforming plasmid DNA of known concentrations.

Transformation of competent cells.

- Competent cells are thawed on ice before 50 μl of cells is added to each ligation. These tubes are then incubated on ice for 30 minutes. The cells are then subjected to heatshock at 42 °C for 90 seconds before being placed on ice for 2 minutes. 0.4ml of LB

broth is added and the culture is shaken at 37°C for 1 hour. Cells are then incubated overnight at 37 °C on agar plates containing the appropriate antibiotic. Single colonies are picked with a flamed wire loop and used to inoculate 10ml of media for minipreparation of plasmid DNA.

5

Packaging of Cosmid DNA into bacteriophage particles.

Cosmid constructs may be packaged into bacteriophage particles using Gigapack II packaging extracts (Stratagene) and *E. coli* strain DH10B is infected in accordance with manufacturer's instructions.

10

Southern blotting.

DNA (10µg of genomic DNA or 0.5 µg of plasmid DNA) is digested with appropriate restriction enzymes and electrophoresed on agarose gels with marker DNA of known size. After photography, gels are treated as described by Sambrook *et al.* (1989) and the DNA transferred from the gels onto nitro-cellulose filters by the capillary transfer method (Southern, 1975; Sambrook *et al.*, 1989) and these are then baked for 2 hours.

15

Radiolabelling of DNA fragments for Southern blots.

DNA probes are obtained by gel purifying appropriate fragments from restriction digests of subcloned DNA. The DNA is denatured by being incubated for 3 minutes in a boiling water bath. The resulting single-stranded DNA fragments are radiolabelled with α -³²PdCTP, e.g. by the random primer labelling kit, Prime-It II supplied from Stratagene, in accordance with manufacturer's instructions. The labelling reaction is halted by the addition of TES buffer to a final concentration of 10mM Tris.HCl (pH 7.5), 10mM EDTA, 0.1% SDS. Radiolabelled DNA probes are separated from unincorporated nucleotides by eluting through a column containing Sephadex G-50.

20

25

Hybridisation of Southern blots.

30

100X Denhardts solution

2% BSA, 2% Ficoll 400, 2%

Polyvinyl Pyrrolidone.

1M sodium phosphate buffer (pH6.6)

352 ml 1M Na₂HPO₄, 648ml 1M NaH₂PO₄.

Prehybridisation mix

0.1mg/ml tRNA, 5x SSC

50mM Na Phosphate buffer (pH 6.6)

5

10x Denhardts solution, 1% SDS.

Hybridisation mix

Prehybridisation mix with the above
described radiolabelled DNA probe.

- 10 Filters from Southern blotting are gently shaken at 65 °C in prehybridisation mix for a minimum of 2 hours. This solution is then replaced with hybridisation mix and incubated overnight. The filters are washed in varying concentrations of SSC with 0.1% SDS for varying amounts of time dependent on the DNA probe being used. Filters are then dried and placed between two intensifying screens at -70 °C with Kodak "Xomat-AR" film.

15

Screening a rat cosmid library

- Duplicate filters from a Wistar rat cosmid library containing genomic DNA inserts in the pWE15 cosmid vector (Wahl *et al.* 1987) are prehybridised and hybridised with probes for the rat OT and AVP genes. Following overnight hybridisation, filters are washed with
- 20 3x SSC/0.1% SDS for 20 minutes and then SSC/0.1% SDS twice for 20 minutes. Filters are briefly washed in 2x SSC, dried and autoradiographed. Duplicate hybridisation signals are aligned with the master filters and bacteria are picked, placed in media and left to diffuse. The resulting cultures are grown on terrific broth agar with 20µg/ml ampicillin and replica plated. Replica plating of the bacterial culture from the library screening may
- 25 be performed as previously described (Sambrook *et al.*, 1989). Replica filters are prehybridised and hybridised as above. Positively-hybridising colonies are picked from the master filters and grown in larger volumes of ampicillin-supplemented media for miniprep and southern blot analysis of the cosmid DNA.

30 Purification of DNA for microinjection.

50-100µg of DNA is digested with Not I to separate the cVO14 cosmid insert from vector DNA. A salt gradient may be used as described by Dillon *et al.* (1993) to

purify the 44kb fragment. A gradient former is used to pour a gradient ranging in NaCl concentration from 5-25%. The digested DNA is applied to the top of the gradient which is then centrifuged at 5.5 hours at 37,000 rpm. The solution is then removed in 500µl aliquots which are examined by electrophoresis. Fractions containing the fragment to be
5 microinjected are pooled and ethanol precipitated. The pellet is dissolved in microinjection buffer (10mM Tris.HCl, pH 7.5, 0.1mM EDTA). DNA may be purified further using an Elutip column (Schleicher and Schuell) according to manufacturers instructions. cVO14 DNA at a concentration of 1-10ng/µl, typically 2ng/µl, is used to generate transgenic rats.

10

Superovulation, microinjection and embryo transfers.

40 day old prepubertal female Wistar rats are given intraperitoneal injections of 30 IU pregnant mare's serum (Folligon, Intervet Laboratories Ltd) between 9 and 11 o'clock on day -3. The same rats are injected i.p. at midday on day -1 with 22.5 IU human
15 chorionic gonadotrophin (Chorulon, Intervet Laboratories Ltd) and placed in a cage with a stud male of the same strain. On day 1, females are killed and their oviducts removed and placed in M2 media (Hogan *et al.*, 1986). The oviducts are dissected to release the eggs which are subsequently placed in M2 media with 0.5mg/ml hyaluronidase (Sigma) in order to remove the cumulus cells surrounding the eggs. After 5 minutes the eggs are
20 removed from the hyaluronidase solution, washed thoroughly in M2 and placed in the unbuffered M16 (Hogan *et al.*, 1986) in a 37 °C incubator supplemented with 5% CO₂. After 2 hours of incubation the male pronuclei of the eggs are microinjected using standard procedures and equipment (Hogan *et al.*, 1986). Microinjected eggs are incubated overnight at 37 °C.

25

The following day (day 2), eggs which have divided to the two-cell stage are washed in M2 media and transferred into the oviducts of pseudo-pregnant adult Wistar rats which have been mated with vasectomized male rats the previous night. The surgery is performed under halothane anaesthetic, with between 15 and 20 eggs being transferred
30 into each infundibulum. Resulting litters are tail-clipped at 2 weeks of age. The tails are used for DNA preparation as described above and analysed by Southern blotting for animals containing transgenes also as described above

RNA preparation.

RNA may be prepared from rat tissue by the acid guanidium thiocyanate-phenol-chloroform extraction method (Chomczynski *et al.*, 1987). Briefly, tissue is homogenised in 500µl 4M guanidium thiocyanate, 25mM Sodium citrate (pH 7.0), 0.5% (w/v) sodium N-lauroylsarcosine, 100mM 2-mercaptoethanol prior to the addition of 33µl 3M sodium acetate (pH 4.1), 500µl phenol and 100µl chloroform. The mixture is vortexed and placed on ice for 15 minutes before centrifugation at 12,000rpm for 10 minutes at 4 °C. The aqueous fraction is decanted into a fresh tube and precipitated with isopropanol.

10

In vitro transcription.

A plasmid containing a T7 polymerase promoter 5' to the inserted sequence is linearised with a restriction enzyme which cuts at the 3' end of the insert. Transcripts are then obtained of the subcloned fragment using a T7 transcription kit (Boehringer Mannheim) according to the manufacturer's instructions

15

DNA sequencing.

Sequencing of DNA plasmid subclones may be performed manually with the Sequenase version 2.0 sequencing kit (United States Biochemicals) which employs the chain-termination method (Sanger *et al.* 1977), or by automated sequencing using an ABI Prism DNA Sequencing Kit and 377 DNA Sequencer (Perkin Elmer Applied Biosystems) according to manufacturer's instructions.

20

Reverse Transcription of RNA.

RNA may be converted to cDNA using Superscript II reverse transcriptase (GibcoBRL) according to the manufacturer's instructions, in combination with either an oligo dT primer or another specific primer complementary to the RNA sequence of interest.

25

Polymerase Chain Reaction amplification of DNA.

The polymerase chain reaction (PCR) may be used to amplify fragments of DNA using 50µl of a reaction mix which contains 10mM Tris, pH8.3, 20mM KCl, 0.2mM

30

dNTPs, 200nM primers, 50-250ng template DNA, 2.5units Amplitaq DNA polymerase and 1-3mM MgCl₂ (the optimal conditions for each amplification are determined empirically). Conditions vary for each template target, but a typical amplification might be to place the reaction mix in a thermal cycler (MJ Research Inc.), denature for 2 minutes
5 and then subject the reaction to 34 cycles of 94 °C for 1 minute, 58 °C for 1 minute and 72 °C for 1-5 minutes, depending on the length of the expected product.

Cloning of PCR products.

Products generated by PCR may be cloned using a TOPO TA Cloning kit
10 (Invitrogen) according to the manufacturer's instructions.

Nuclease Protection assay.

Riboprobe transcripts incorporating ³²P may be generated by transcribing approximately 250ng of DNA fragment in Transcription Optimised buffer (Promega),
15 500mM ATP, GTP and CTP, 20 units Rnasin RNA inhibitor (Promega), 20mM UTP, 100μCi α-³²P-UTP (Amersham) and 20 units of the appropriate RNA polymerase (Promega) at 37 °C for 90 minutes. After treatment of the reaction with 2 units of DNase I (Promega) at 37 °C for 20 minutes, the reaction is denatured and purified by polyacrylamide electrophoresis, followed by excision of the labelled RNA and elution in
20 350μl of Elution buffer (Ambion) for 2 hours at 37 °C. Nuclease protection may be performed essentially as described by Lee and Costlow (1987) using ³²P-labelled riboprobe with 1-20μg total RNA and the RPAII Ribonuclease Protection Kit (Ambion) according to the manufacturer's instructions.

25 In Situ hybridisation.

Sense and anti-sense riboprobe transcripts may be generated using an SP6/T7 transcription kit (Boehringer) with ³⁵S-UTP (NEN Research Products) according to the manufacturer's instructions. *In situ* hybridisations may be performed as described in Bennett *et al.* (1995). Autoradiographs are analysed densitometrically, from a light box
30 using a video camera linked to a Power Macintosh 7600/132 running the programme NIH Image version 1.61.

Immunocytochemistry

Human growth hormone (hGH) may be localised in pituitary and brain sections using a modified avidin-biotin complex immunocytochemistry technique (Bourne *et al.*, 1984). Tissue is collected and fixed in 4% paraformaldehyde for 24 hours. Tissues may be
 5 stored at 4 °C in 70% ethanol before embedding in paraffin wax and sectioning. Tissue sections (6µm) are dewaxed in Histoclear (National diagnostics) and rehydrated by sequential 20 sec washes of 100%, 70 % and 30 % ethanol followed by a 1 min wash in distilled H₂O. Endogenous peroxidase activity is inhibited by a 30 min incubation in 3% (v/v) hydrogen peroxidase in methanol. Sections are then washed in distilled H₂O for 1
 10 min before being treated with 0.1% (w/v) trypsin (Sigma) for 15 min at 37 °C followed by 0.5% (v/v) Triton X-100 (Sigma) for 15 mins. After two 5 min washes of distilled H₂O and 0.05M Tris buffered saline (pH 7.6), 0.15M NaCl (TBS) the sections are incubated with 20% (v/v) normal rabbit serum (DAKO) with 5% (w/v) BSA for 30 mins in order to reduce non-specific background staining. The sections are then incubated overnight in a
 15 humidity chamber at 4 °C with an antibody specific for hGH, such as sheep anti-hGH primary antibody (1:30,000) (Scottish Antibody Production Unit).

Following two washes in TBS, sections are incubated with biotinylated rabbit anti-goat serum (DAKO, 1:200) for 30 mins. The sections are again washed in TBS and incubated
 20 for 30 mins with avidin complexed to biotinylated horse radish peroxidase (DAKO). Human GH immunoreactivity is then visualised by development using 3,3-Diaminobenzidine tetrachloride/hydrogen peroxide (DAB) (4mg/10ml in 0.05M Tris buffer pH 7.6) containing 3% (v/v) H₂O₂. This reaction is quenched in distilled H₂O prior to counterstaining with Gill's haematoxylin (BDH) and coverslipped for microscopic
 25 examination.

Radioimmunoassays

Tissue samples are homogenised in varying volumes of phosphate buffered saline with either glass homogenisers (for volumes up to 1ml) or a Kinematica Polytron PT 3000
 30 homogeniser (for larger volumes). The same polyclonal sheep anti-hGH antibody (Scottish Antibody Production Unit) may be used to measure hGH in tissue extracts by RIA as described in Fairhall *et al.* (1992) using recombinant hGH as standard. AVP may

be measured by RIA as described in Horn, Robinson & Fink (1985). Rat GH may be measured as in Charton *et al.*, (1988). Bovine neurophysin may be measured by RIA using a specific antiserum that does not recognise rat neurophysins (Gordon Weeks, 1987). Rat leptin and rat insulin may be measured by specific RIAs using kits from Linco Research Inc, following the manufacturer's instructions. Corticosterone may be measured by a double antibody RIA kit obtained from ICN Biomedicals. Cholesterol and triglycerides in blood samples may be measured using kits obtained from Sigma Diagnostics ('Cholesterol 20' and 'Triglycerides, UV'). Plasma glucose values may be measured using a Beckman glucose analyser.

EXAMPLE 1

ISOLATION OF COSMID DNA, CONSTRUCTION OF TRANSGENE COSMIDS AND GENERATION OF TRANSGENIC RATS

Isolation of cosmid DNA

Since the DNA sequences of the rat AVP and OT genes and their orientation and structural relationship to each other in the rat genome are known (Ivell & Richter, 1984a; Mohr *et al.* 1988; Schmitz *et al.*, 1991) the size of restriction fragments which should be detected with cDNA probes for these genes can be predicted. Colonies bearing rat DNA which contained fragments hybridising to these OT and AVP probes in the same areas in duplicate filters from the cosmid screening are aligned with the original bacterial plates. These colonies are picked and grown and DNA prepared from them, digested with Hind III, run on agarose gels, Southern blotted and hybridised to the same OT and AVP probes again. Three positive colonies are chosen for further analysis because their differing restriction fragment patterns indicated that they spanned different regions of the rat AVP/OT locus. From Southern blotting of restriction digests using probes against the first exon of each gene and the vector, they are found to span a total of 44kb, including both genes, the 11kb intergenic region, 8kb of AVP 5' flanking sequence and 24kb of OT 5' flanking sequence. These three overlapping cosmids are designated cVO1, 2 and 3. An overall schematic map of this region, indicating the location and orientation of AVP and OT genes, the location of some important restrictions sites, and areas of sequence known or subsequently determined and disclosed here, is shown in Figure 1

To facilitate further restriction mapping of the 5' flanking sequence of the rat OT gene, 8kb and 14kb Sma I fragments and an 8.5kb Kpn I fragment are subcloned into cloning vectors and subjected to further restriction mapping. Smaller fragments of the OT and AVP genes are also subcloned into pUC 19 derived plasmid vectors and used to remove restriction enzyme sites and to insert the reporter genes into the rat OT and rat AVP loci. Oligonucleotide linkers containing sequences for unique restriction sites are also inserted in the 5' untranslated regions of the two genes to allow for future modifications of this construct.

10

The subcloning strategy used for the AVP locus is outlined in Figure 2. Essentially, the aim is to insert a genomic hGH reporter fragment in a unique cloning site introduced into the 5' untranslated region of rat AVP gene. Swanson *et al.* (1985) had previously shown that hGH reporter transcripts, when fortuitously expressed, may be expressed and translated efficiently in these neuronal cells types. Furthermore, hGH nucleotide sequences can be differentiated from rat GH sequences by specific nucleotide probes (Seeburg *et al.*, 1977; Røksam & Rougeon, 1979) and the protein can be differentiated from rat GH by specific antisera (Appendix 1). An Mlu I linker is initially inserted into a smaller subclone of the rat AVP gene, replacing the Dra III site in the 5' untranslated region. A genomic fragment of the human GH structural gene (Røksam & Rougeon, 1979) is then inserted as an Mlu I-linkered fragment spanning from the 5' untranslated region of the hGH gene to a region 3' of the last exon and containing all 5 exons and 4 introns of hGH. This AVP-hGH fragment is inserted as a 12.2 kb Cla I-Xho I fragment containing 450bp 5' and 8kb 3' of the transgene, with deletion of other Xho I restriction sites.

25

The subcloning strategy used for the OT locus is outlined in Figure 3. In this case the aim is to replace most of the rat OT structural gene with corresponding bovine sequences (Land *et al.*, 1983). The protein produced should function identically, but the bovine sequences would provide a 'silent' reporter since they could be differentiated from rat sequences (Mohr *et al.*, 1988) by specific nucleotide probes, and the protein differentiated from rat neurophysin by specific antisera. Rat neurophysin has previously been used as a

30

transgene reporter in mice (Belenky *et al.*, 1992). Due to the constraints of suitable restriction sites it is necessary to assemble a 5' construct of the hybrid rat/bovine OT gene (containing exon A and most of exon B) and a 3' construct (containing a small fragment of exon B and exon C) separately. These constructs are joined to produce the hybrid gene with the 5' and 3' flanking sequences being added in subsequent steps. A Sal I linker is also inserted immediately 5' to the translational start site of the bovine OT to provide a unique cloning site within the AVP/OT locus for future modification of the construct. The hybrid gene is inserted into the final construct as a 10.5 kb Mun I - Xho I fragment containing 7.8 kb of 5' and 1.7 kb of 3' flanking sequence, after deleting other restriction sites within the cosmid

Assembly of the final construct.

The pWE15 vector is modified to remove the unrequired SV2 neomycin gene. This reduced the vector size from 8.5kb to 4.2 kb and therefore increased the size of the insert that could be subcloned into the-cosmids, which can efficiently package up to 52 kb (Wahl *et al.* 1987). Cla I, Mun I, Sal I and Mlu I restriction sites are also removed from the vector to permit subsequent cloning steps. The pWE15 cosmid vector has Not I sites flanking the insert. Restriction mapping of cVO1 revealed a Not I restriction site 13kb upstream from the rat OT gene (Figure 1) which would also be digested if Not I is used to remove the insert. Therefore, a 4.6kb Aat II-Sca I fragment containing this site is subcloned, the Not I site deleted, and the fragments ligated and replaced into the construct. Digestion of the ligation product with Not I confirmed that this site had been destroyed.

The modified OT and AVP gene fragments are inserted into cVO3, followed by addition of the 5' region present in cVO1 but not in cVO3 using an Aat II fragment. This adds all except 1.1kb of the extreme 5' end of cVO1 and contains a Not I linker at the extreme 5' end.

The final construct, termed cVO14, spans 44kb and includes 8kb 5' of rat AVP, 24kb 5' of rat OT and 11kb of intergenic sequence. The construct has reporter gene hGH sequences inserted into the 5' untranslated region of the rat AVP gene and parts of the

bovine OT gene sequences substituted for equivalent rat OT gene sequences. The final cVO14 construct is illustrated diagrammatically in Figure 4.

5 Generation of transgenic rats bearing the cVO14 construct.

The 44 kb Not I insert is released from cVO14 by Not I digestion, purified on a salt gradient and microinjected into fertilised rat oocytes. These embryos are transferred into pseudopregnant mothers and the offspring are analysed for the presence of the transgenes. Genomic DNA prepared from tail biopsies of these pups is digested with Bgl
10 II, Southern blotted and hybridised with a radiolabelled genomic hGH probe that should identify 2 predicted fragments of 0.9 and 2.1 kB from transgene DNA. This probe does not detect endogenous rat GH sequences. Of 102 pups the hGH transgene is present in the DNA of only 3 pups, termed JP 17, JP 19 and JP 59. JP 19 dies at 11 days of age, and is not analysed further.

15 Other samples of DNA from the two remaining rats is digested with Pst I, Southern blotted and hybridised with a radiolabelled probe that should identify two predicted fragments of 0.9 and 1.6kB from the hybrid rat/bovine transgene sequence, and a single 2.5kB fragment from the endogenous OT gene. Both JP17 and JP59 rats are also found to
20 contain this hybrid gene, as well as the endogenous gene, whilst only the endogenous fragment is visualised in DNA from non-transgenic rats.

DNA from JP 17 and JP 59 rats is also Southern blotted and probed with radiolabelled DNA fragments corresponding to the ends of the cVO14 construct, which confirmed that
25 whole copies of the microinjected fragment are present in both rats. The copy number of the transgenes is estimated by Southern blotting of Hind III fragments and hybridisation with a probe for the rat AVP gene sequences, which recognised a 3.4 kb fragment corresponding to the endogenous rat AVP gene and a 5.2 kb fragment which represents the transgene with its hGH reporter gene insertion. Assuming equal affinity to
30 endogenous or transgene sequences, phosphorimaging these blots suggested that the JP17 rats contained at least 4 copies of cVO14 whereas JP59 rats had a single copy. The copy

number and restriction pattern of the transgenes remained consistent through successive generations of breeding, suggestive of a single site of chromosomal integration.

Further analysis of DNA suggested that the insert contained concatamers of cVO14 in JP17 but not in JP59, and that one concatamer pair contained a truncation which removes a fragment of approximately 1kb between 8kb and 7kb 5' of rat AVP. Restriction mapping and sequence analysis of the cosmid ends enabled us to design PCR primers (PL216 (SEQ. ID. No. 10 and PL210 (SEQ. ID. No. 9)) that uniquely identify DNA from JP17 rats bearing this insert, and distinguishes them both from non-transgenic littermates, and from JP59 rats bearing a single copy of this insert.

Establishing colonies of transgenic rats.

The founder JP17 rat is a male. He sires only single litter of rats at 6 months of age although constantly caged with fertile females. This litter contains both male and female rats bearing the transgene, indicating that the integration has occurred onto an autosomal chromosome. No further litters are sired by male progeny. Litters bred from transgenic JP17 female progeny show an approximate 1:1 ratio of transgenic to non-transgenic rats (46 transgenic versus 54 non-transgenic in the first 100 pups) suggesting that the transgene does not have a detrimental effect on embryonic viability.

The founder of the JP 59 line of rats is female and bred normally (the ratio of transgenic to non-transgenic pups is approximately 1:1 (47 transgenic verses 53 non-transgenic in the first 100 pups). This single copy integrant is also present on an autosomal chromosome since male JP59 rats of this line sire transgenic progeny of both sexes.

EXAMPLE 2

ANALYSIS OF EXPRESSION OF EXPECTED TRANSGENE PRODUCTS

Human growth hormone

The expression of hGH from cVO14 is investigated in both JP59 and JP17 rats. Immunocytochemistry shows expression of hGH protein in hypothalamic magnocellular paraventricular (PVN) and supraoptic nuclei (SON). Human GH immunoreactivity is also

transported via axons passing through the internal zone of the median eminence and present in the axon terminals in the posterior pituitary.

In situ hybridisation confirms strong expression of hGH in the PVN and SON of transgenic rats of both JP59 and JP17 lines. hGH transcripts are also detected in other sites of AVP expression in the CNS in JP 17 transgenic rats, such as the medial amygdaloid nucleus and the habenula (Buijs, 1987; Caffé *et al.*, 1987; Urban *et al.*, 1990). Double *in situ* hybridisation analysis or immunocytochemical analysis confirms that hGH expression is localised in AVP neurones, and not in OT neurones. In independent studies, RT-PCR analysis detects hGH transcripts in hypothalami and pituitaries from both lines, and also detected transcripts in the pancreas and also faintly, in adrenals of JP 17 rats, but not in other tissues tested. These findings are in accordance with previous reports of extrapituitary expression of the endogenous AVP gene in these tissues.

Radioimmunoassay for hGH confirms the presence of significant quantities of hGH in posterior pituitary extracts from both JP59 and JP17 animals, with larger amounts in JP17 line consistent with their higher copy number. Small amounts of hGH immunoreactivity are also found in the pancreas (0.016 ± 0.0075 ng/mg of tissue, $n=3$) of 20 week old JP 17 male rats, though this represents $< 0.1\%$ of the amounts of hGH found in the posterior pituitary extracts of the same rats ($168\text{ng} \pm 16$ ng/mg, $n=5$). Thymus, heart, kidney, fat, liver, ovary, uterus, testis, lung, cortex, cerebellum, spleen and adrenals all had undetectable levels of this protein ($<0.0004\text{ng}$ of hGH/mg of tissue).

If the hGH transgene is correctly expressed, then stimuli for increased AVP synthesis and release should increase hypothalamic expression of the hGH transgene and decrease pituitary stores of hGH. Chronic osmotic stimulation has been shown to regulate the expression of the AVP gene (Lightman *et al.*, 1987; Murphy *et al.*, 1990) and cause a release of AVP from the posterior pituitary (Fitzsimmons *et al.*, 1994). The stimulus of salt-loading has previously been used to detect whether the DNA regulatory regions responsible for physiological regulation of the rat AVP gene are present within microinjected constructs (Zeng *et al.*, 1994b; Waller *et al.*, 1996). Groups of non-transgenic or transgenic JP59 or JP17 male rats given 2% NaCl w/v in their drinking

water for 72 hours both show a marked increase in hGH expression in PVN and SON. Furthermore, posterior pituitary hGH content fall significantly in such salt-loaded animals in parallel with the fall in AVP content. Samples taken from JP17 rats confirm that hGH is secreted, and can be detected in plasma by RIA (1.3 ± 0.09 ng/ml)

5

The effects of transgenic expression of hGH to reduce rat GH by feedback have been documented earlier in other transgenic rats (Flavell *et al.*, 1996). Therefore, rat GH content of the pituitaries of JP 17 rats and non-transgenic littermates are measured by RIA. Rat GH is significantly reduced in both the male and female JP 17 transgenics in
10 comparison to the non-transgenic controls at 23, 77 and 140 days of age. At 140 days, the mean pituitary rat GH content of male JP 17 rats is 34.2% of that of the age-matched non-transgenics. The pituitary rat GH content is less affected in the female JP 17 rats (57.4% of the mean rat GH content of the non-transgenics, $p < 0.02$).

15 The size of the anterior pituitaries also suggests that there is a reduction in their cell number as JP 17 male rats at 140 days have significantly smaller anterior pituitaries than non-transgenic controls (4.6 ± 0.1 mg for JP 17 males versus 8.2 ± 0.5 mg for wild-type rats, $p < 0.002$, $n=6$). The pituitaries of JP 59 males and females do not show a reduction in rat GH content or size ($p > 0.55$).

20

Bovine neurophysin

No bovine OT-NP protein can be detected in posterior pituitary extracts (< 10 pg per pituitary) from JP17 rats, using a specific RIA that distinguishes bovine neurophysin from rat neurophysins (Gordon-Weeks, 1987). An RT-PCR assay for bovine OT-NP
25 transcripts is applied to hypothalamic extracts of adult males or of lactating female rats culled within 24 hours of littering, from both lines. The latter animals are chosen since they should show higher levels of endogenous OT expression (Van Tol *et al.*, 1988). PCR is performed on cDNA generated by reverse transcribing RNA from various tissues of both JP 17 and JP 59 lines (hypothalamus, pituitary, pancreas, ovary, heart, lung,
30 muscle, thymus, cerebellum, uterus, testis, spleen, kidney, adrenals, liver, cortex). Additional reactions with primers for β -actin and hGH are also included. The reactions of the rat/bovine OT primers with the cVO14 construct and in vitro transcribed rat/bovine

OT RNA both yielded the correct size fragment (767bp), but no transcripts from the rat/bovine OT transgene are detected in any tissue. We conclude that the rat/bovine OT portion of the cVO14 construct is not detectably expressed in JP 17 or JP 59 transgenic animals.

5

The lack of expression of the rat/bovine OT transgene may indicate that additional sequences lacking from cVO14 are required to achieve appropriate OT expression in addition to expression from the AVP locus. Other possibilities are that alterations introduced into the OT locus prevent expression. This could be in the coding regions of the hybrid rat/bovine OT cassette. Another possibility is the introduction of the Sal I linker 5' of the OT gene. A further possibility is the presence of a base change in the region immediately 3' of the TATA-box which is discovered upon sequencing this region of cVO14 (Figure 5).

15 **EXAMPLE 3**

DISCOVERY AND ANALYSIS OF 5'OT-EST AND 5'OT-EST-XDEL

cVO14 is noted to contain a CpG island 13kB upstream of OT. Sequencing of 3.3kB of this region of the cosmid reveals a potential novel gene. Comparison with EST sequences in the public databases revealed partial matches to sequences from rat, human and mouse origin. The GenBank accession numbers for such ESTs include: H31114; H31115; AA955566; AA850004; AA104183; AA080247; AA245389; AA242211; AA421310; AA505752; AA421393. Such searches also reveal a partial match to a human genomic sequence GenBank Accession number AF036329. From comparisons with these sequences and the rat genomic DNA sequence disclosed herein, it is predicted that the novel rat gene in cVO14 contains four open reading frames, termed w, x, y, z. This gene is termed 5'OT-EST. The genomic DNA sequence and predicted exon structure is disclosed in SEQ. ID. No. 16. The gene predicts an open reading frame (SEQ. ID. No. 1) and a protein of 200 amino acids, termed 5'OT-EST, whose structure is disclosed in SEQ. ID. No. 2. Comparisons with EST sequences from human and mouse sources and alignment with full length sequences from rat DNA enable the prediction of homologous cDNA and protein sequences in these species and these are disclosed in SEQ. ID. No. 3

and 4 and SEQ. ID. No. 5 and 6 respectively. The protein sequences predicted from these predicted cDNAs are highly homologous, as shown in Figure 6.

5 A Not I restriction site is identified approximately 13kB upstream of OT in cVO3. As described in Appendix 2, this site is deliberately destroyed during the construction and assembly of cVO14 in the pWE15 cosmid vector, as the construct required Not I sites only at the ends of the insert. However, sequence analysis of cVO14 reveals that the Not-1 site lies in 5'*OT-EST*, more precisely, in exon w of 5'*OT-EST*. Furthermore, this sequence analysis reveals that in addition to destroying the Not I site, the procedure used
10 (digestion, filling in and religation) also resulted in an additional unpredicted deletion of 412bp. This deletion includes all of the sequences recognised as exon x as defined herein. The mutated form of this gene, lacking sequences including those for exon x, is therefore termed herein 5'*OT-EST-xdel* for the purposes of this application. Its sequence, and the structures of the predicted exons from this form of the gene are disclosed in SEQ. ID. Nos.
15 7 and 8. The presence of 5'*OT-EST-xdel* in the genome of JP17 and JP59 rats is confirmed by the generation of the predicted shorter product upon amplification of genomic DNA from these animals by PCR with primers PL266 (5'TCATGTTGCGGGCTTTGAAC) and PL271 (5'TCTTTCAGTTGCACCCAAGC) which flank the deletion (see SEQ. ID. Nos. 11 and 12 respectively).

20

The form of 5'*OT-EST* that is incorporated in both JP17 and JP59 in 4 or 1 copies, respectively, is mutated from the wild type sequence. 5'*OT-EST-xdel* would be predicted to give rise to an altered mRNA, which if translated would produce a truncated protein product with an additional novel amino acid sequence. The predicted sequence of this
25 novel product, termed herein 5'*OT-EST-xdel* is disclosed in SEQ. ID. No. 8. Comparison with the aligned predicted protein sequences of 5'*OT-EST* in normal rats and in other species predicts that the protein translated from this RNA would contain an altered exon w, with a novel C-terminal peptide sequence (shown in lower case beginning at the arrow in Figure 6) predicted to arise by translation of DNA sequences normally present as part
30 of an intron in 5'*OT-EST*. Searches in the protein databases in the public domain do not find any significant matches of this mutated protein sequence to known sequences.

To demonstrate that both the endogenous and truncated forms of *5'OT-EST* are transcribed in JP59 and JP17 rats, PCR primers are designed which can distinguish between these gene products. The sequence of these primers is given in SEQ. ID. No. 11, 12 and 13. RT-PCR using these primers confirms the presence of transcripts from the endogenous form of *5'OT-EST* in testicular RNA extracts from JP17, JP59 and wild-type rats, but the presence of a transcript with the 412bp deletion only in such tissue extracts from JP17 and JP59 rats. Sequencing of amplification products generated by PCR with primers PL266 (SEQ. ID. No. 11) and PL273 (SEQ. ID. No. 13) from wild type and JP17 rats confirms this region of the sequence of the endogenous rat transcript as well as the truncated *5'OT-EST-xdel* sequence disclosed in SEQ. ID. No. 8. Extracts of a rat adrenal medullary cell line (PC12 cells) also contain an RNA product of *5'OT-EST* of the expected size.

Identification and sequencing of *5'OT-EST* and *5'OT-EST-xdel* enables the design of probes to carry out *in situ* hybridisation and RNase protection analysis for the products of these genes on normal and JP17 rat tissue extracts. *In situ* hybridisation with probes complementary to exons w or z (more specifically, corresponding to bases 1020-1167 and 2229-2451 of Fig 4.1 respectively) on hypothalamic sections from wild-type or transgenic animals, revealed a highly specific expression in magnocellular SON and PVN. No other specific expression in different brain regions is observed at this level of detection. This is an unexpected finding, which is repeatedly confirmed. *5'OT-EST* is a novel member of the AVP/OT locus and is expressed in the same hypothalamic magnocellular neurones. Similar patterns of expression are seen with both probes and no differences in tissue distribution of hybridisation signal are seen between wild-type or JP17 tissues. Further *in situ* hybridisation analysis on a wide variety of tissues reveals strong expression in the testis consistent in distribution with tubular or Sertoli cell expression. Sparse expression is also seen in other tissues, including lung, spleen, intestinal smooth muscle and adrenal gland.

From the sequence information, it is further possible to design probes for *in situ* hybridisation analysis that distinguish completely between the forms of mRNA produced from *5'OT-EST* and *5'OT-EST-xdel*. More specifically, oligonucleotide probes directed

against transcripts containing exon x would be predicted to detect *5'OT-EST* but not *5'OT-EST -xdel* transcripts, whilst probes directed against the intron sequence in *5'OT-EST* that immediately follows the truncation in *5'OT-EST -xdel* detect transcripts containing this sequence, that code for the truncated product in extracts from rats
5 expressing *5'OT-EST -xdel* transcripts (such as JP17 and JP59 rats) but not from non-transgenic rats. Examples of such probes are given in SEQ. ID. Nos. 14 and 15.

An oligonucleotide probe of the sequence depicted in SEQ. ID. No. 15 (specific for the truncated sequence) is used for in situ hybridization and confirms transgene expression
10 specifically in PVN and SON in JP17 rats, whereas no signal is observed in PVN or SON sections from non-transgenic rats, hybridized at the same time with this probe.

Nuclease protection analysis may also be performed using a riboprobe to exon w as described above. From the sequence we disclose herein, this probe would be predicted to
15 protect 147bp and 94bp bands from transcripts from *5'OT-EST* and *5'OT-EST -xdel* respectively. Using such a probe to analyse testicular RNA extracts confirmed that the full length transcript is present in both transgenic and non-transgenic animals and that the truncated product is present in JP17 and JP59 extracts in a level consistent with the copy number of the cVO14 insertion, that the truncated transcript is indeed absent from non-
20 transgenic testis extracts. The full length product is present in control extracts of PC12 cells.

The gene termed *5'OT-EST -xdel* present in cVO14 in both JP59 and JP17 rats is transcribed in several tissues in JP17 rats, specifically in hypothalamic cells and in
25 testicular cells, and that the sequence of the truncated transcripts if translated, would give rise to a protein product that is severely truncated with respect to the normal gene product and would contain additional novel peptide sequence.

EXAMPLE 4**PHENOTYPIC ANALYSIS OF JP17 TRANSGENIC (SLOB) RATS****Growth measurements**

5 JP 17 transgenic rats of both sexes and non-transgenic littermates are weighed at regular intervals. Male JP 17 rats show a slight but significant reduction in their body weight up to 120 days of age ($p < 0.01$). This juvenile growth retardation is not seen in females of this line or the rats of either sex of the JP 59 line whose body weights are not significantly different to those of the non-transgenic groups ($p > 0.7$). This effect
10 disappears with time. At 140 days, the weight difference between JP 17 and non-transgenic male rats is no longer significant. Some organs of 140 day old rats are dissected and weighed. Heart weights do not differ significantly ($p < 0.14$) but the weights of the kidneys ($0.99 \pm 0.03\text{g}$ in JP 17 rats versus $1.24 \pm 0.05\text{g}$ in non-transgenic rats, $p < 0.001$), liver ($11.11 \pm 0.29\text{g}$ in JP 17 rats versus $14.40 \pm 0.32\text{g}$ in non-transgenic rats,
15 $p < 0.001$) and spleen ($0.66 \pm 0.02\text{g}$ in JP 17 rats versus $0.84 \pm 0.03\text{g}$ in non-transgenic rats, $p < 0.001$) differs in weight ($n=6$ in all groups). Disproportionate growth is well known in transgenic animals expressing hGH (e.g. Shea *et al.*, 1987)

Body weight measurements in ageing JP 17 rats.

20 After about 140 days, the group of JP 17 transgenic male rats gain weight more rapidly than their non-transgenic littermates (Δ weight between 200 and 420 days $356.5 \pm 57.419\text{g}$ for JP 17 males versus 182.50 ± 7.554 for non-transgenic males, $p < 0.03$, $n=5$, Figure 5.1). Female JP 17 transgenic rats show only a slight increase in weight gain when compared to non-transgenic littermates (Δ weight between 280 and 480 days $111.8 \pm 8.2\text{g}$
25 for JP 17 females versus $88 \pm 5.1\text{g}$ for non-transgenic females, $p < 0.04$, $n=6$). This is illustrated in Figure 8, which clearly shows the sexually dimorphic weight gains in these animals. No significant increased weight gain is observed in either sex of transgenic JP 59 rats compared with non-transgenic JP59 rats. At one year, the weights of the kidneys and liver of JP 17 male rats have reached a value that is not significantly different than that of
30 the non-transgenic rats ($n=6$ in both groups) ($p < 0.08$ for kidneys and livers), but the spleens remain lighter ($1.03 \pm 0.04\text{g}$ versus $1.225 \pm 0.05\text{g}$ in wild-type rats, $p < 0.01$).

These organs in transgenic JP 59 rats show no variation from their non-transgenic littermate controls ($p>0.43$).

Body length, width and fat-pad measurements.

5 Measurements of the body lengths (nose-anus) and the width across the pelvic area of anaesthetised male JP17 and non-transgenic rats are taken (Figure 9). At 20 weeks of age male JP 17 transgenic rats are shorter than their littermate non-transgenic controls with an increased width across the pelvic area. At 52 weeks, the difference in nose-anus length is no longer significant but the girth of the transgenic JP17 rats has increased
10 greatly whereas the non-transgenic rats only exhibit a moderate increase in girth. This late-onset increase in the body weight/length ratio is shown in Figure 10.

A comparison of the body proportions of a live SLOB rats and non-transgenic littermates shows a marked increase in abdominal fat. This is also obvious when individual peri-
15 renal fat pads are compared. To evaluate this abdominal distribution of extra fat in SLOB rats, peri-renal and testicular fat pads are dissected and weighed from matched groups of male JP 17 and non-transgenic littermates of 77, 140 and 365 days of age, and the results are shown in Figure 11. The peri-renal fat pads of the transgenic rats are markedly increased in weight at both 140 days and 365 days when their mean weight is almost five
20 times that of the non-transgenic animals. The testicular fat, however, did not show a comparable increase. Although testicular fat pad weights are marginally larger than those of the non-transgenic rats at 140 days ($p<0.05$), no further significant increase occurs during the period of a large accretion in peri-renal fat, and there is no difference in testicular fat pad weights at 365 days between SLOB rats and their non-transgenic
25 littermates, despite their much larger body weight, and evident gross visceral obesity.

In other matched groups of 1 year old SLOB rats and non-transgenic littermates of both sexes, plasma cholesterol, triglycerides, glucose, insulin, leptin and corticosterone are measured in blood samples taken when the animals are killed, and the results are
30 summarised in Figure 12. Plasma triglycerides are modestly but significantly elevated in SLOB males compared to non-transgenic males. There are no differences in plasma triglycerides in females. Cholesterol levels are no different between the groups. Plasma

glucose and insulin values are also in the normal range and did not differ between the groups, suggesting that the obesity is not secondary to diabetes or insulin resistance. Plasma corticosterone is also in the normal range in all groups of rats. Notably however, the plasma leptin levels are elevated significantly in both male and female SLOB rats compared with their non-transgenic littermates, and are almost two-fold higher in SLOB males than in SLOB females. Leptin receptor transcript isoforms are also expressed in normal amounts in the hypothalamus, piriform cortex and choroid plexus. These increases would be expected given their increased body fat, but prompted a study of their food intake.

10

A further group of 5, 11-month old SLOB rats and 5 non-transgenic rats are housed singly in metabolic cages for 14 days, and after a period of acclimatisation to single housing, food intake is measured over the last four days of the experiment. There is no significant difference in food consumption between the two groups (SLOB rats 23.4 ± 1.1 g/day vs. 23.5 ± 1.8 g/day in the non-transgenic males, Mean \pm S.D.).

15

Although the SLOB phenotype, as demonstrated by the forgoing, has a striking late-onset feature, the phenotype is latent at a younger age and can be induced by increasing the levels of fat in the diet. This is demonstrated by observing the phenotypic differences resulting from feeding two groups of 100 day old transgenic and normal littermates either regular rat chow, which has a fat content of 4%, or a high fat diet having a fat content of 30% over a 27 day period.

20

The rats fed a normal diet show no significant difference in weight gain between transgenic and non-transgenic littermates. However, in the case of the rats fed on a 30% fat diet, the transgenic animals gain twice the weight of their non-transgenic littermates (see Figure 13). Controls in dwarf rats show that the obese phenotype is not due to growth hormone deficiency.

25

Plasma leptin levels are measured at sacrifice. These are found to be higher in transgenic animals, and rise in both transgenic and non-transgenic rats fed on a 30% fat diet.

30

Moreover, the increase in dietary fat is associated with a significantly reduced food intake in normal rats, but not in SLOB rats, despite their higher leptin levels.

Induction of obesity in ovariectomised female rats.

5 Four groups of female rats are studied (see Figure 14). Sham-operated transgenic female SLOB rats are lighter than non-transgenic sham-operated female littermates at 100 days, but gain the same amount of weight in the following 11 week period ($\Delta\text{wt } 45.5 \pm 5.3\text{g}$, vs $\Delta\text{wt } 48.4 \pm 3.8\text{g}$). In rats ovariectomised under anaesthesia, both groups show an increase in weight gain; this increase is much higher in SLOB rats than in non-transgenic
10 littermates ($\Delta\text{wt } 128 \pm 7.7\text{g}$ vs $89 \pm 4.3\text{g}$, $P < 0.001$). Some animals from each group are killed 18 weeks post ovariectomy and their supra-renal fat pads dissected and weighed. The fat pad weight is much larger after ovariectomy in SLOB rats (4.67 ± 0.61 vs $1.37 \pm 0.39\text{g}$ in ovariectomised versus sham-ovariectomised SLOB females, $P < 0.01$), than in nontransgenic rats ($2.33 \pm 0.94\text{g}$ vs $1.0 \pm 0.01\text{g}$ in ovariectomised vs sham-
15 ovariectomised nontransgenic littermates).

Fertility of the JP 17 male rats.

Twelve JP 17 and twelve non-transgenic young adult males are each housed with two 12-week old normal females, for several consecutive days. The female rats are
20 examined every morning for evidence of copulation, either in the form of a vaginal plug or sperm in vaginal smears, and are observed for a sufficient amount of time to allow any litters conceived during this time to be born. No litters are sired in this time by JP 17 males, whereas 11 of the 12 females housed with wild-type males produced litters.

25 The immediate cause of infertility in male SLOB rats is unknown. The size and gross anatomy of their testes and seminal vesicles is normal, suggesting unaffected levels of gonadotrophins or androgens. Testicular size, sperm morphology, motility and testosterone levels all appear normal in SLOB rats. Treatment of a SLOB male rat with exogenous androgens did not improve fertility. One cause could be hGH, since infertility
30 is a common problem in GH transgenic animals (Yun *et al.*, 1987, Bartke *et al.*, 1988, Flavell *et al.*, 1996) and male transgenic animals expressing hGH have been reported to have a reduced frequency in the impregnation of females (Bartke *et al.*, 1992). However

female SLOB rats also express equivalent amounts of hGH and are not infertile. Furthermore, we found no evidence for hGH expression or of hGH protein in testes from SLOB rats.

- 5 In contrast, the expression of *5'OT-EST* in normal rats and the high level of a truncated RNA product from *5'OT-EST -xdel* in hypothalamus and in particular, the testis from SLOB male rats, and the lack of expression of either product in ovaries in SLOB females, leads us to conclude that the novel infertility and obesity phenotype more probably results from the presence of multiple copies of *5'OT-EST -xdel* in SLOB rats. A disruption of
10 testicular function by *5'OT-EST -xdel* and consequent infertility is part of, may partly contribute to, or exacerbate the degree of the male-preponderance of, the obesity phenotype of SLOB rats. A testicular disruption is not absolutely required however, since a mild visceral obesity can also be discerned in SLOB females.

15 **Longevity of SLOB male rats.**

- The longevity of JP 17 also appears to differ to that of normal rats. Six male JP 17 rats and six wild-type rats are housed under constant conditions. After two years, all six JP 17 rats have died, five at between 10 and 14 months of age and the sixth at 21 months of age, whereas only a single wild-type rat has died at 13 months. The longevity of JP 17
20 females or JP 59 males or females has not been similarly investigated.

Comparison of phenotype with other rat obesity models

- When comparing the phenotype in SLOB rats with other findings reported in the literature, the closest parallels are lines of transgenic rats expressing hGH driven by a
25 mouse whey acidic protein promoter, (Ninomiya *et al.*, 1994; Ikeda *et al.*, 1994, 1995, 1997). Ikeda *et al.* (1995) described two lines of rats expressing high or low hGH levels in serum. Gigantism is observed in the high hGH-expressing line, but visceral obesity is also observed in the low-expressing line, associated with endogenous GH suppression. No sexual dimorphism is reported, and the obesity is associated with carbohydrate
30 metabolic disorders, hypertriglyceridaemia and insulin resistance. Ikeda *et al.* 1995 specifically concluded that the effect is due to differences in serum hGH levels affecting carbohydrate metabolism. A later study in these rats (Ikeda *et al.* 1997) reported female

infertility and enlarged ovaries which further distinguishes this phenotype from that seen in SLOB rats.

In common with the rats reported by Ikeda *et al.* (1994), SLOB rats also show reduced rat
 5 GH production and secretion. GH deficiency is associated with increased visceral fat in humans, but this can be alleviated by hGH treatment. However, isolated rat GH deficiency is an unlikely cause of obesity in SLOB rats as other lines of severely GH deficient dwarf rats (Charlton *et al.*, 1988) do not develop obesity when housed under identical conditions to SLOB rats. Obesity can be induced in such dwarf rats (as in
 10 normal rats), when placed on high fat diets for prolonged periods though females are more susceptible than males (Clark *et al.*, 1996). A similar pituitary GH suppression is also evident in female SLOB rats but they do not develop the same massive abdominal obesity as males. Pituitary rat GH suppression is also seen in the non-obese JP59 rats of both sexes and in Tgr rats (Flavell *et al.*, 1996) which do not develop obesity.

15 The defects in other genetic models of obesity in the rat have recently clarified; examples of these include the Zucker fa/fa rat, the Koletsky (f) obese rat, the JLA/cp corpulent rat, and the OLETF rat, and their related sub strains (Iida *et al.*, 1996; Wu-peng *et al.*, 1997; Takaya *et al.*, 1996; Lee *et al.*, 1997; Kahle *et al.*, 1997;. None of these show the male
 20 specificity, late onset or pattern of distribution of obesity seen in SLOB rats and they exhibit significant hyperglycaemia and insulin resistance, which again distinguishes them from SLOB rats. Male specificity, infertility, extremely late onset of obesity, a highly selective visceral accumulation of fat, but relatively normal metabolic profile, without insulin resistance, hyperphagia or hyperglycaemia distinguishes the dominant phenotype
 25 in the SLOB rats from all other known models of obesity in the rat, including those with low endogenous rat GH expression or hGH expression from other transgenes.

REFERENCES

- Al-Shawi R Kinnaid, J., Burke, J., Bishop, J.O. 1990 Expression of a foreign gene in a line of transgenic mice is modulated by a chromosomal position effect. *Molecular and Cellular Biology* 10: 1192-1198.
- Altschul *et al.* (1994) *Nature Genetics* 6:119-129.
- Ang H-L., Ivell, R., Walther, N., Nicholson, H., Ungefroren, H., Millar, M., Carter, D., Murphy, D. 1994 Over-expression of oxytocin in the testes of a transgenic mouse model. *Journal of Endocrinology* 140: 53-62.
- Ang H-L, Ungefroren, H., De Bree, F., Foo, N.C., Carter, D., Burbach, J.P., Ivell, R., Murphy, D., 1991 Testicular oxytocin gene expression in seminiferous tubules of cattle and transgenic mice. *Endocrinology* 128: 2110-2117.
- Banerjee SA, Roffler-Tarlov, S., Szabo, M., Frohman, L., Chikaraishi, D.M. 1994 DNA regulatory sequences of the rat tyrosine hydroxylase gene direct correct catecholaminergic cell-type specificity of a human growth hormone reporter in the CNS of transgenic mice causing a dwarf phenotype. *Molecular Brain Research* 24: 89-106.
- Bartke, A., Steger, R.W., Hodges, S.L., Parkening, T.A., Collins, T.J., Yun, J.S., Wagner, T.E. 1988 Infertility in transgenic female mice and human growth hormone expression: evidence for luteal failure. *Journal of Experimental Zoology* 248: 121-124.
- Bartke A., Naar, E.M., Johnson, L., May, M.R., Cecim, M., Yun, J.S., Wagner, T.E. 1992 Effects of expression of human or bovine growth hormone genes on sperm production and male reproductive performance in four lines of transgenic mice. *Journals of Reproduction and Fertility* 95: 109-118.
- Bartke A., Cecim, M., Tang, K., Steger, R.W., Chandrashekar, V., Turyn, D. 1995 Neuroendocrine and reproductive consequences of overexpression of growth hormone in

- transgenic mice. *Proceedings of the Society for Experimental Biology and Medicine* **206**: 345-359.
- 5 Belenky M., Castel, M., Young III, W.S., Gainer, H., Cohen, S. 1992 Ultrastructural immunolocalization of rat oxytocin-neurophysin in transgenic mice expressing the rat oxytocin gene. *Brain Research* **583**: 279-286.
- Bennett PA, Levy, A., Sophokleous, S., Robinson, I.C.A.F., Lightman, S.L. 1995 Hypothalamic GH receptor gene expression in the rat: effects of altered GH status.
- 10 *Journal Endocrinology* **147**: 225-234.
- Birboim HC, Doly, J. 1979 A rapid alkaline extraction procedure for screening recombinant plasmid DNA. *Nucleic Acid Research* **7**: 1513-1523.
- 15 Bonifer C Vidal, M., Grosveld, F., Sippel, A.E. 1990 Tissue-specific and position independent expression of the complete gene domain for chicken lysozyme in transgenic mice. *The European Molecular Biology Organisation Journal* **9**: 2843-2848.
- Boss, O.; Samec, S.; Paoloni-Giacobino, A.; Rossier, C.; Dulloo, A.; Seydoux, J.;
- 20 Muzzin, P.; Giacobino, J.-P. : Uncoupling protein-3: a new member of the mitochondrial carrier family with tissue-specific expression. *FEBS Lett.* **408**: 39-42, 1997.
- Bourne JA 1984 *Handbook of Immunoperoxidase Staining Methods*, DAKO corporation, Santa Barbara, USA.
- 25
- Bray GA York, D.A. 1979 Hypothalamic and genetic obesity in experimental animals: an autonomic and endocrine hypothesis. *Physiological Reviews* **59**: 719-809.
- Brem G Wanke, R., Wolf, E., Buchmuller, T., Muller, M., Brenig, B., Hermanns, W.
- 30 1989 multiple consequences of human growth hormone expression in transgenic mice. *Molecular and Biological Medicine* **6**: 531-547.

- Bucchini D Ripoche, M.-A., Stinnakre, M.-G., P.Desbois., Lores, P., Monthieux, E., Absil, J., Lepesant, J.-A., Pictet, R., Jami, J. 1986 Pancreatic expression of the human insulin gene in transgenic mice. *Proceedings of the National Academy of Science USA* 83: 2511-2515.
- 5 Buijs RM 1987 Vasopressin localization and putative functions in the brain. *In* : Vasopressin principles and properties ; D.M. Gash and G.J. Boer (eds). 91-115.
- 10 Caffé AR van Leeuwen, F.W., Luiten, P.G.M. 1987 Vasopressin cells in the medial amygdala of the rat project to the lateral septum and ventral hippocampus. *The Journal of Comparative Neurology*. 261: 237-252.
- 15 Cecim M Fadden, C., Kerr, J., Steger, R.W., Bartke, A. 1995 Infertility in transgenic mice overexpressing the bovine growth hormone gene: disruption of the neuroendocrine control of prolactin secretion during pregnancy. *Biology of Reproduction* 52: 1187-1192.
- 20 Chandrashekar V Bartke, A., Wagner, T.E. 1991 Interactions of human growth hormone and prolactin on pituitary and Leydig cell function in adult transgenic mice expressing the human growth hormone gene. *Biology of Reproduction* 44: 135-140.
- Charlton HM Clark, R.G., Robinson, I.C.A.F., Porter Goff, A.E., Cox, B.S., Bugnon, C., Bloch, B.A. 1988 Growth hormone-deficient dwarfism in the rat: a new mutation. *Journal of Endocrinology* 119: 51-58.
- 25 Chen, H., O. Charlat, L.A. Tartaglia, E.A. Woolf, X. Weng, S.J. Ellis, N.D. Lakey, J. Culpepper, K.J. Moore, R.E. Breitbart, G.M. Duyk, R.I. Tepper, and J.P. Morgenstern. 1996. Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db/db mice. *Cell*. 84:491-495.
- 30 Chomczynski P Sacchi, N. 1987 Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. *Analytical Biochemistry* 162: 156-9.

- Clark, R. G., Mortensen, D. L., Carlsson, L. M., Carlsson, B., Carmignac, D., and Robinson, I. C. A F. (1996). The obese growth hormone (GH)-deficient dwarf rat: body fat responses to patterned delivery of GH and insulin-like growth factor-I. *Endocrinology* 5 137, 1904-12.
- Coleman DL Eicher, E.M. 1990 Fat (fat) and tubby (tub): Two autosomal recessive mutations causing obesity syndromes in the mouse. *Journal of Hereditary* 81: 424-427.
- 10 Comuzzie, A.G. & Allison, D.B. (1998). The search for human obesity genes. *Science*, 280:1374-1377.
- Cool, D. R.; Normant, E.; Shen, F.; Chen, H.-C.; Pannell, L.; Zhang, Y.; Loh, Y. P. 1997: Carboxypeptidase E is a regulated secretory pathway sorting receptor: genetic obliteration 15 leads to endocrine disorders in Cpe(fat) mice. *Cell* 88: 73-83,
- De Lecea, L.; Kilduff, T. S.; Peyron, C.; Gao, X.-B.; Foye, P.E.; Danielson, P. E.; Fukuhara, C.; Battenberg, E. L. F.; Gautvik, V. T.; Bartlett, F. S., II; Frankel, W. N.; van den Pol, A. N.; Bloom, F. E.; Gautvik, K. M.; Sutcliffe, J. G. 1998 The hypocretins: 20 hypothalamus-specific peptides with neuroexcitatory activity. *Proc. Nat. Acad. Sci.* 95: 322-327.
- Dillon N Grosveld, F. 1993 Gene transcription - a practical approach. IRL Press at Oxford University Press. B.D. Hames and S.J. Higgins (eds): 153-187.
- 25 Fairhall KM Carmignac, D.F., Robinson, I.C.A.F. 1992 Growth hormone (GH) binding protein and GH interactions in vivo in the guinea pig. *Endocrinology* 131: 1963-1969.
- Fan, W., Boston, B. A., Kesterson, R. A., Hruby, V. J., and Cone, R. D. (1997). Role of 30 melanocortineric neurons in feeding and the agouti obesity syndrome. *Nature* 385, 165-8.

- Fitzsimmons MD Roberts, M.M., Robinson, A.G. 1994 Control of the posterior pituitary vasopressin content: Implications for the regulation of the vasopressin gene. *Endocrinology* 134: 1874-1878.
- 5 Flavell DM., Wells, T., Wells, S.E., Carmignac, D.F., Thomas, G.B., Robinson, I.C.A.F. 1996 Dominant dwarfism in transgenic rats by targeting human growth hormone (GH) expression to hypothalamic GH-releasing factor neurons. *The European Molecular Biology Organisation Journal* 15: 3871-3879.
- 10 Foo NC., Funkhouse, J.M., Carter, D., Murphy, D., 1994 A testis specific promoter in the rat vasopressin gene. *Journal of Biological Chemistry* 269: 659-667.
- Fujiwara Y., Miwa, M., Takahashi, R., Hirabayashi, M., Suzuki, T., Ueda, M. 1997 Position-independent and high-level expression of human alpha-lactalbumin in the milk
15 of transgenic rats carrying a 210-kb YAC DNA construct. *Molecular Reproduction and development*. 47: 157-163.
- Gainer H. & Wray, S. 1994 Cellular and molecular biology of oxytocin and vasopressin. In: *The Physiology of Reproduction*, E. Knobil and J.D. Neill (eds): 1099-112
20
- Good DJ., Porter, F.D., Mahon, K.A., Parlow, A.F., Weatphal, H., Kirsch, I.R. 1997 Hypogonadism and obesity in mice with a targeted deletion of the *Nhlh2* gene. *Nature Genetics* 15: 397-401.
- 25 Gordon-Weeks, R 1987 PhD thesis. University of London.
- Graham, M.; Shutter, J. R.; Sarmiento, U.; Sarosi, I.; Stark, K. L. 1997.: Overexpression of *Agtr* leads to obesity in transgenic mice. *Nature Genet.* 17: 273-274,
- 30 Grant SG., Jessee, J., Bloom, F.R., Hanahan, D. 1990 Differential plasmid rescue from transgenic mouse DNAs into *Escherichia coli* methylation-restriction mutants. *Proceedings of the National Academy of Science* 87: 4645-4649.

- Grant FD., Reventos, J., Gordon, J.W., Kawabata, S., Miller, M., Majzoub, J.A. 1993a
Expression of the rat arginine vasopressin gene in transgenic mice. *Molecular
Endocrinology* 7: 659-667.
- 5 Grant FD., Reventos, J., Gordon, J.W., Kawabata, S., Miller, M., Majzoub, J.A. 1993b
Tissue-specific expression and osmotic regulation of a rat vasopressin gene in transgenic
mice. *Annals of the New York Academy of Sciences* 689: 530-533.
- 10 Gray RP & Yudkin, J.S. 1997 Cardiovascular disease in diabetes mellitus. In :
Textbook of diabetes, J. Pickup and G. Williams (eds): pp57.1-57.22.
- Grosveld F., van Assendelft, G.B., Greaves, D.R., Kollias, G. 1987 Position-
independent, high-level expression of human β -globin gene in transgenic mice. *Cell* 51:
15 975-985.
- Habener JF., Cwikel, B.J., Hermann, H., Hammer, R.E., Palmiter, R.D., Brinster, R.L., 1989
Metallothionein-vasopressin fusion gene expression in transgenic mice. *The Journal of
Biological chemistry* 264: 18844-18852.
- 20 Hammer RE., Pursel, V.G., Rexroad, C.E., Wall, R.J., Bolt, D.J., Ebert, K.M., Palmiter,
R.D., Brinster, R.L. 1985 Production of transgenic rabbits, sheep and pigs by
microinjection. *Nature* 315: 680-683.
- 25 Hanahan D. 1983 Studies on transformation of *Escherichia coli* with plasmids. *Journal
of Molecular Biology* 166: 557-569.
- Ho M-Y., Carter, D.A., Ang, H-L., Murphy, D. 1995 Bovine oxytocin transgenes in
mice. *Journal of Biological Chemistry*. 270: 27199-27205.
- 30 Hogan B., Constantini, F., Lacy, E. 1986 Manipulating the mouse embryo. Cold Spring
Harbor Laboratory Press, Cold Spring Harbor, N.Y.

- Hollingshead PG., Martin, L., Pitts, S.L., Stewart, T.A. 1989 A dominant phenocopy of hypopituitarism in transgenic mice resulting from central nervous system synthesis of human growth hormone. *Endocrinology* **125**: 1556-1564.
- 5
Horn AM., Robinson, I.C.A.F., Fink, G. 1985 Oxytocin and vasopressin in rat hypophyseal portal blood: experimental studies in normal and Brattleboro rats. *Journal of Endocrinology* **104**: 211-224.
- 10 Huber MC., Bosch, F.X., Sippel, A.E., Bonifer, C. 1994 Chromosomal position effect in chicken lysozyme gene transgenic mice are correlated with suppression of DNase I hypersensitive site formation. *Nucleic Acid Research* **22**: 4195-4201.
- Huszar, D., Lynch, C. A., Fairchild, H. V., Dunmore, J. H., Fang, Q., Berkemeier, L. R.,
15 Gu, W., Kesterson, R. A., Boston, B. A., Cone, R. D., Smith, F. J., Campfield, L. A., Burn, P., and Lee, F. (1997). Targeted disruption of the melanocortin-4 receptor results in obesity in mice. *Cell* **88**, 131-41.
- Iida M., Murakami, T., Ishida, K., Mizuno, A., Kuwajima, M., Shima, K. 1996
20 Substitution at codon 269 (glutamine-proline) of the leptin receptor (OF-R) cDNA is the only mutation found in the Zucker Fatty (fa/fa) rat. *Biochemical and Biophysical Research Communications* **224**: 597-604.
- Ikeda, A. Chang, K., Matsuyama, M., Nishihara, M. & Takahashi, M. 1995 Disorders in
25 carbohydrate metabolism in two lines of transgenic rats expressing different levels of human growth hormone. *Proceedings of US Endocrine Society Washington* P2-241.
- Ikeda, A., Matsumoto, Y., Chang, K.T., Nakano, T., Matsuyama, S., Yamanouchi, K., Ohta, A., Nishihara, M., Tojo, H., Sasaki, F. & Takahashi, M (1997). Different female
30 reproductive phenotypes determined by human growth hormone (hGH) levels in hGH-transgenic rats. *Biol Reprod.* **56**: 847-851.

- Ikedo, A., Matsuyama, S. Nishihara, M., Tojo, H. & Takahashi, M. 1994. Changes in endogenous growth hormone secretion and onset of puberty in transgenic rats expressing human growth hormone gene. *Endocr J.* **41**: 523-529.
- 5 Ivell R & Richter, D. 1984 Structure and comparison of the oxytocin and vasopressin genes from rat. *Proceedings of the National Academy of Science, USA.* **81**: 2006-2010.
- Jamal, Z., Martin, A., Gomez, M. A., Hales, P., Chang, E., Russell, J. C., and Brindley, D. N. (1997). Phosphatidate phosphohydrolases in liver, heart and adipose tissue of the
- 10 JCR:LA corpulent rat and the lean genotypes: implications for glycerolipid synthesis and signal transduction. *Int J Obes Relat Metab Disord* **16**, 789-99.
- Jones BK., Monks, B.R., Liebhaber, S.A., Cooke, N.E. 1995 The human growth hormone gene is regulated by multicomponent locus control region. *Molecular and*
- 15 *Cellular Biology* **15**: 7010-7021.
- Kahle, E. B., Butz, K. G., Chua, S. C., Kershaw, E. E., Leibel, R. L., Fenger, T. W., Hansen, C. T., and Michaelis, O. E. (1997). The rat corpulent (cp) mutation maps to the same interval on (Pgm1-Glut1) rat chromosome 5 as the fatty (fa) mutation. *Obes Res* **5**,
- 20 142-5.
- Kiyama H & Emson, P.C. 1990 Evidence for the co-expression of oxytocin and vasopressin messenger ribonucleic acids in magnocellular neurosecretory cells: simultaneous demonstration of two neurohypophysin messenger ribonucleic acids by
- 25 hybridization histochemistry. *Journal of Neuroendocrinology* **2**: 257-259.
- Klebig, M. L., Wilkinson, J. E., Geisler, J. G., and Woychik, R. P. (1995). Ectopic expression of the agouti gene in transgenic mice causes obesity, features of type II diabetes, and yellow fur. *Proc Natl Acad Sci U S A* **92**, 4728-32.
- 30 Kleyn, P. W., Fan, W., Kovats, S. G., Lee, J. J., Pulido, J. C., Wu, Y., Berkemeier, L. R., Misumi, D. J., Holmgren, L., Charlat, O., Woolf, E. A., Tayber, O., Brody, T., Shu, P.,

- Hawkins, F., Kennedy, B., Baldini, L., Ebeling, C., Alperin, G. D., Deeds, J., Lakey, N. D., Culpepper, J., Chen, H., Glucksmann, K. M., Moore, K. J., et al (1996). Identification and characterization of the mouse obesity gene *tubby*: a member of a novel gene family. *Cell* **85**, 281-90.
- 5 Kristensen, P.; Judge, M. E.; Thim, L.; Ribel, U.; Christjansen, K. N.; Wulff, B. S.; Clausen, J. T.; Jensen, P. B.; Madsen, O. D.; Vrang, N.; Larsen, P. J.; Hastrup, S. (1998). Hypothalamic CART is a new anorectic peptide regulated by leptin. *Nature* **393**: 72-76
- 10 Lacy E., Roberts, S., Evans, E.P., Burtenshaw, M.D., Costantini, F.D. 1983 A foreign β -globin gene in transgenic mice: Integration at abnormal chromosomal positions and expression in inappropriate tissues. *Cell* **34**: 343-358.
- Land H, Graz,M, Ruppert,S, Schmale,H, Rehbein,M, Richter,D, Schutz,G, 1983
- 15 Deduced amino acid sequence from the bovine oxytocin-neurophysin precursor cDNA. *Nature* **302**: 342-344.
- Lee & Costlow 1987. *Methods in Enzymology* **152**:633-648.
- 20 Lee, G., Li, C., Montez, J., Halaas, J., Darvishzadeh, J., and Friedman, J. M. (1997). Leptin receptor mutations in 129 db3J/db3J mice and NIH *fa^cp/fa^cp* rats. *Mamm Genome* **8**, 445-7.
- Lightman SL & Young III, W.S. 1987 Vasopressin, oxytocin, dynorphin, enkephalin
- 25 and corticotrophin-releasing factor mRNA stimulation in the rat. *Journal of Physiology* **394**: 23-39.
- Mansour *et al.*, (1989) *Nature* **336**, 348-352.
- 30 Mathe, D. (1995). Dyslipidemia and diabetes: animal models. *Diabetes Metab* **21**, 106-11.

- McGrane MM, de Vente, J., Yun, J., Bloom, J., Park, E., Wynshaw-Boris, A., Wagner, T., Rottman, F.M., Hanson, R.W. 1988 Tissue-specific expression and dietary regulation of a chimeric phosphoenolpyruvate carboxykinase/ bovine growth hormone gene in transgenic mice. *Journal of Biological Chemistry* **263**: 11443-11451.
- 5 McNamee, C. J., Kappagoda, C. T., Kunjara, R., and Russell, J. C. (1994). Defective endothelium-dependent relaxation in the JCR:LA-corpulent rat. *Circ Res* **74**, 1126-32.
- 10 Michaelis, O. Velasquez, M. T., Abraham, A. A., Servetnick, D. A., Scholfield, D. J., and Hansen, C. T. (1995). Development and characteristics of a new strain of obese hyperinsulinemic and hyperlipidemic Dahl salt-sensitive rat. The Dahl salt-sensitive/NIH-corpulent rat. *Am J Hypertension*.
- 15 Miller MW., Duhl, D.M., Vrieling, H., Cordes, S.P., Ollmann, M.M., Winkes, B.M., Barsh, G.S. 1993 Cloning of the mouse agouti gene predicts a secreted protein ubiquitously expressed in mice carrying the lethal yellow mutations.. *Genes and Development* **7**: 454-467.
- 20 Millet, L.; Vidal, H.; Andreelli, F.; Larrouy, D.; Riou, J.-P.; Ricquier, D.; Laville, M.; Langin, D. 1997 Increased uncoupling protein-2 and -3 mRNA expression during fasting in obese and lean humans. *J. Clin. Invest.* **100**: 2665-2670.
- 25 Mohr E., Schmitz, E., Richter, D. 1988 A single rat genomic DNA fragment encodes both the oxytocin and vasopressin genes separated by 11 kilobases and orientated in opposite transcriptional directions. *Biochimie* **70**: 649-654.
- Moon, B. C., and Friedman, J. M. (1997). The molecular basis of the obese mutation in ob2J mice. *Genomics* **42**, 152-6.

- Morello D., Moore, G., Salmon, A. M., Yaniv, M., Babinet, C. 1986 Studies on the expression of an H-2K/human growth hormone fusion gene in giant transgenic mice. The European Molecular Biology Organisation Journal 5: 1877-1883.
- 5 Mullins JJ., Peters, J., Ganten, D., 1990 Fulminant hypertension in transgenic rats harbouring the mouse Ren-2 gene. Nature 344: 541-544.
- Murphy D. & Carter, D., 1990 Vasopressin gene expression in the Rodent hypothalamus: Transcriptional and posttranscriptional responses to physiological stimulation. Molecular
10 Endocrinology 1054: 1051-1059.
- Murphy D & Ho, M-Y. 1995 Oxytocin transgenic mice. Advances in Experimental Medicine and Biology 395: 67-78.
- 15 Naggert, J. K.; Fricker, L. D.; Varlamov, O.; Nishina, P. M.; Rouille, Y.; Steiner, D. F.; Carroll, R. J.; Paigen, B. J.; Leiter, E. H. 1995. Hyperproinsulinaemia in obese fat/fat mice associated with a carboxypeptidase E mutation which reduces enzyme activity. Nature Genet. 10: 135-142
- 20 Ninomiya, T., Hirabayashi, M., Sagara, J. & Yuki, A. 1994 Functions of milk protein gene 5' flanking regions on human growth hormone gene. Mol Reprod Dev 37: 276-283.
- North, M. A., Naggert, J. K., Yan, Y., Noben, T. K., and Nishina, P. M. (1997). Molecular characterization of TUB, TULP1, and TULP2, members of the novel tubby gene family
25 and their possible relation to ocular diseases. Proc Natl Acad Sci U S A 94, 3128-33.
- Ohki-Hamazaki, H., Watase, K., Yamamoto, K., Ogura, H., Yamano, M., Yamada, K., Maeno, H., Imaki, J., Kikuyama, S., Wada, E., and Wada, K. (1997). Mice lacking bombesin receptor subtype-3 develop metabolic defects and obesity. Nature 390, 165-169.

- Ollmann, M. M.; Wilson, B. D.; Yang, Y.-K.; Kerns, J. A.; Chen, Y.; Gantz, I.; Barsh, G. S. 1995 Antagonism of central melanocortin receptors in vitro and in vivo by agouti-related protein. *Science* **278**: 135-138, 1997.
- 5 Ornitz DM., Palmiter, R.D., Hammer, R.E., Brinster, R.L., Swift, G.H., MacDonald, R.J. 1985 Specific expression of an elastase-human growth hormone fusion gene in pancreatic acinar cells of transgenic mice. *Nature* **313**: 600-602.
- Palmiter RD., Brinster, R.L., Hammer, R.E., Trumbauer, M.E., Rosenfeld, M.G.,
- 10 Birnberg, N.C., Evans, R.M. 1982 Dramatic growth of mice that develop from eggs microinjected with metallothionein-growth hormone fusion genes. *Nature* **300**: 611-615.
- Palmiter RD., Norstedt, G., Gelinas, R.E., Hammer, R.E., Brinster, R.L. 1983 Metallothionein-human GH fusion genes stimulate growth of mice. *Science* **222**: 809-
- 15 814.
- Pursel VG., Pinkert, C. A., Miller, K. F., Bolt, D. J., Campbell, R. G., Palmiter, R. D., Brinster, R. L., Hammer, R. E. 1989 Genetic engineering of livestock. *Science* **244**: 1281-1287.
- 20 Qu, D.; Ludwig, D. S.; Gammeltoft, S.; Piper, M.; Pelleymounter, M. A.; Cullen, M. J.; Mathes, W. F.; Przypek, J.; Kanarek, R.; Maratos-Flier, E. (1996). A role for melanin-concentrating hormone in the central regulation of feeding behaviour. *Nature* **380**: 243-247.
- 25 Quaife CJ., Mathews, L.S., Pinkert, C.A., Hammer, R.E., Brinster, R.L., Palmiter, R.D. 1989 Histopathology associated with elevated levels of growth hormone and insulin-like growth factor I in transgenic mice. *Endocrinology* **124**: 40-48.
- 30 Reaven, GR. 1988 Role of insulin resistance in human disease. *Diabetes* **37**: 1595-1607.

- Richard, D., Rivest, R., Naimi, N., Timofeeva, E., and Rivest, S. (1996). Expression of corticotropin-releasing factor and its receptors in the brain of lean and obese Zucker rats. *Endocrinology* 137, 4786-95.
- 5 Roskam WG., Rougeon, F. 1979 Molecular cloning and nucleotide sequence of the human growth hormone structural gene. *Nucleic Acid Research* 10: 305-320.
- Russell, J. C., Amy, R. M., Graham, S., Wenzel, L. M., and Dolphin, P. J. (1993). Effect of castration on hyperlipidemic, insulin resistant JCR:LA-corpulent rats. *Atherosclerosis*
10 100, 113-22.
- Russo AF., Crenshaw, E.B, Lira, S.A, Simmons, D.M, Swanson, L.W, Rosenfeld, M.G 1988 Neuronal expression of chimeric genes in transgenic mice. *Neuron* 1: 311-320.
- 15 Sakurai, T.; Amemiya, A.; Ishii, M.; Matsuzaki, I.; Chemelli, R. M.; Tanaka, H.; Williams, S. C.; Richardson, J. A.; Kozlowski, G. P.; Wilson, S.; Arch, J. R. S.; Buckingham, R. E.; Haynes, A. C.; Carr, S. A.; Annan, R. S.; McNulty, D. E.; Liu, W.-S.; Terrett, J. A.; Elshourbagy, N. A.; Bergsma, D. J.; Yanagisawa, M. 1998: Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors
20 that regulate feeding behavior. *Cell* 92: 573-585
- Sambrook J., Fritsch E.F., Maniatis, T. 1989 *Molecular Cloning. A Laboratory Manual*: second edition.
- 25 Sanger F., Nicklen, S., Coulson, A.R. 1977 DNA sequencing with chain-terminating inhibitors. *Proceedings of the National Society of Science. USA* 74: 5463-5467.
- Sausville E, Carney D, Battey J 1985 The human vasopressin gene is linked to the oxytocin gene and is selectively expressed in a cultured lung cancer cell line. *J Biol Chem*
30 260: 10236-10241

- Schmitz E., Mohr, E., Richter, D., 1991 Rat vasopressin and oxytocin genes are linked by a long interspersed repeated DNA element (LINE): Sequence and Transcriptional analysis of LINE. *DNA and Cell Biology* 10: 81-91.
- 5 Seeburg PH., Shine, J., Martial, J.A., Baxter, J.D., Goodman, H.M. 1977 Nucleotide sequence and amplification in bacteria of structural gene for rat growth hormone. *Nature* 270: 486-494.
- Shanahan CM., Rigby, N.W., Murray, J.D., Marshall, J.T., Townrow, C.A., Nancarrow, C.D., Ward, K.A. 1989 Regulation of expression of a sheep metallothionein 1a-Sheep growth hormone fusion gene in transgenic mice. *Molecular and Cellular Biology* 9: 5473-5479.
- 10 Shea BT., Hammer, R.E., Brinster, R.L. 1987 Growth allometry of the organs in giant transgenic mice. *Endocrinology* 121: 1924-1930.
- 15 Shillabeer, G., Hornford, J., Forden, J. M., Wong, N. C., Russell, J. C., and Lau, D. C. (1992). Fatty acid synthase and adipin mRNA levels in obese and lean JCR:LA-cp rats: effect of diet. *J Lipid Res* 33, 31-9.
- 20 Short MK., Clouthier, D.E., Schaefer, I.M., Hammer, R.E., Magnuson, M.A., Beale, E.G. 1992 Tissue-specific, developmental, hormonal and dietary regulation of rat phosphoenolpyruvate carboxykinase-human growth hormone fusion genes in transgenic mice. *Molecular and Cellular Biology* 12: 1007-1020.
- 25 Southern EM. 1975 Detection of specific sequences among DNA fragments separated by gel electrophoresis. *Journal of Molecular Biology* 98: 503-509.
- Stewart TA., Clift, S., Pitts-Meek, S., Martin, L., Terrell, T.G., Liggitt, D., Oakley, H. 30 1992 An evaluation of the functions of the 22-kilodalton (kDa), the 20 kDa, and the N-terminal polypeptide forms of human growth hormone using transgenic mice. *Endocrinology* 130: 405-414.

- Swanson LW., Simmons, D.M., Arriza, J., Hammer, R., Brinster, R., Rosenfeld, M.G., Evans, R.M. 1985 Novel developmental specificity in the nervous system of transgenic animals expressing growth hormone fusion genes. *Nature* **317**: 363-366.
- 5 Szabo M., Butz, M.R., Banerjee, S.A., Chikaraishi, D.M., Frohman, L.A. 1995 Autofeedback suppression of growth hormone (GH) secretion in transgenic mice expressing a human GH reporter targeted by tyrosine hydroxylase 5'-flanking sequences to the hypothalamus. *Endocrinology* **136**: 4044-4048.
- 10 Takaya K., Ogawa, Y., Isse, N., Okazaki, T., Satoh, Masuzaki, H., Mori, K., Tamura, N., Hosoda, K., Nakao, K. 1996 Molecular cloning of rat leptin isoform complementary DNAs- Identification of a missense mutation in Zucker fatty (fa/fa) rats. *Biochemical and Biophysical Research Communications* **225**: 75-83.
- 15 Takeuchi, T., Suzuki, H., Sakurai, S., Nogami, H., Okuma, S., and Ishikawa, H. (1990). Molecular mechanism of growth hormone (GH) deficiency in the spontaneous dwarf rat - detection of abnormal splicing of GH messenger ribonucleic acid by the polymerase chain reaction. *Endocrinology* **126**, 31-38.
- 20 Takiguchi S, Takata Y, Takahashi N, Kataoka K, Hirashima T, Kawano K, Miyasaka K, Funakoshi A, Kono A. 1998 A disrupted cholecystokinin A receptor gene induces diabetes in obese rats synergistically with ODB1 gene. *Am J Physiol* **274**:E265-E270
- 25 Tartaglia LA., Dembski, M., Weng, X., Deng, N., Culpepper, J., Devos, R., Richards, G.J., Campfield, L.A., Clark, F.T., Deeds, J., Muir, C., Sanker, S., Moriarty, A., Moore, E.A., Monroe, C.A., Tepper, R.L. 1995 Identification and expression cloning of a leptin receptor, OB-R. *Cell* **83**: 1263-1271.
- 30 Taylor, W.R., 1998 Dynamic databank searching with templates and multiple alignment. *J. Mol. Biol.* **280**: 375-406.

- Urban JH., Miller, M.A., Drake, C.T., Dorsa, D.M. 1990 Detection of vasopressin mRNA in cells of the medial amygdala but not the locus coeruleus by in situ hybridization. *Journal of Chemical Neuroanatomy* 3: 277-283.
- 5 Vandesande P. & Dierickx, D. 1975 Identification of the vasopressin producing and of the oxytocin producing neurons in the hypothalamic magnocellular neurosecretory system of the rat. *Cell and Tissue Research* 164: 153-162.
- 10 Van Tol HHM., Bolwerk, E.L.M., Lui, B., Burbach, J.P. 1988 Oxytocin and vasopressin gene expression in the hypothalamo-neurophyseal system of the rat during the estrous cycle, pregnancy and lactation. *Endocrinology* 122: 945-951.
- 15 Vidal-Puig, A., Solanes, G., Grujic, D., Flier, J. S & Lowell, B. B. 1997 UCP3: an uncoupling protein homologue expressed preferentially and abundantly in skeletal muscle and brown adipose tissue. *Biochem. Biophys. Res. Commun.* 235: 79-82.
- 20 Wahl GM., Lewis, K.A., Ruiz, J.C., Rothenberg, B., Zhao, J., Evans, G.A. 1987 Cosmid vectors for rapid genomic walking, restriction mapping, and gene transfer. *Proceeding of the National Academy of Science. USA* 84: 2160-2164.
- 25 Waller S., Fairhall, K. M., Xu, J., Robinson, I. C. A. F., Murphy, D. 1996 Neurohypophyseal and fluid homeostasis in transgenic rats expressing a tagged rat vasopressin prepropeptide in hypothalamic neurons. *Endocrinology* 137: 5068-5077.
- Whitaker, R. C., Wright, J. A., Pepe, M. S., Seidel, K. D., and Dietz, W. H. (1997). Predicting obesity in young adulthood from childhood and parental obesity. *N Engl J Med* 337, 869-73.
- 30 White, RB, Eisen, JA, Kasten, TL & Fernald, RD 1998 Second gene for gonadatropin-releasing hormone in humans *PNAS* 95, 305-309.

- Wu-Peng XS, Chua SC Jr, Okada N, Liu SM, Nicolson M, Leibel RL 1997 Phenotype of the obese Koletsy (f) rat due to Tyr763Stop mutation in the extracellular domain of the leptin receptor (Lepr): evidence for deficient plasma-to-CSF transport of leptin in both the Zucker and Koletsy obese rat. *Diabetes* **46**:513-518
- 5
- Young III WS., Reynolds,K, Shepard,E.A, Gainer,H, Castel,M, 1990 Cell-specific expression of the rat oxytocin gene in transgenic mice. *Journal of Neuroendocrinology* **2**: 917-925.
- 10
- Young III WS 1992 Expression of oxytocin and vasopressin genes. *Journal of Neuroendocrinology* **4**: 527-540.
- Yun JS., Li, Y.S., Wight, D.C., Portanova, R., Selden, R.F. 1989 The human growth hormone transgene : expression in hemizygous and homozygous mice. *Proceedings of the Society for Experimental Biology and Medicine* **194**: 308-313.
- 15
- Zeng Q., Carter, D.D., Murphy, D. 1994b Cell specific expression of a vasopressin transgene in rats. *Journal of Neuroendocrinology* **6**: 469-477.
- 20
- Zeng Q., Foo, N-C., Funkhouser, J. M., Carter, D. A., Murphy, D. 1994a Expression of a rat vasopressin transgene in rat testes. *Journal of Reproduction and Fertility* **102**: 471-481.
- 25
- Zhang Y., Proenca, R., Maffei, M., Barone, M., Leopold, L., Friedman, J.M. 1994 Positional cloning of the mouse obese gene and its human homologue. *Nature* **372**: 425-427.

Claims

1. 5'OT-EST polypeptide having a sequence selected from the group comprising the sequences set forth in any one of SEQ. ID. Nos. 2, 4 or 6, and sequences substantially homologous to any one of the polypeptides set forth in SEQ. ID. Nos. 2, 4 or 6.
2. A polypeptide according to claim 1 comprising an amino acid sequence encoded by at least one exon selected from the group consisting of exons w, x, y and z as set forth in SEQ. ID. No. 16, or equivalents thereof as set forth in any one of SEQ. ID. Nos. 3 or 5.
3. A polypeptide according to claim 2, which comprises an amino acid sequence encoded by at least part of exon w as set forth in SEQ. ID. No. 16, or equivalents thereof as set forth in any one of SEQ. ID. Nos. 3 or 5.
4. A mutant of a 5'OT-EST polypeptide according to any preceding claim which is capable, *in vivo*, of modulating the obesity of an animal expressing it.
5. A mutant according to claim 4, wherein the animal is a transgenic animal expressing the mutant as a result of transformation with a transgene.
6. A mutant according to claim 4 or claim 5, which comprises the sequence PRPRSFSAPFSSQDS, or a sequence substantially homologous thereto.
7. A mutant according to any one of claims 4 to 6 which comprises the sequence MLRALNRLAARPGGQPPTLLLLPVRGPRPRSFSAPFSSQDS, or a sequence substantially homologous thereto.
8. A nucleic acid encoding a 5'OT-EST polypeptide or mutant 5'OT-EST polypeptide according to any preceding claim.
9. A nucleic acid according to claim 8, having a sequence selected from the group consisting of any one of SEQ. ID. Nos. 1, 3, 5, 7, 16 or 17; sequences which are

hybridisable under stringent conditions with an oligonucleotide comprising 20 contiguous bases from any one of SEQ. ID. Nos. 1, 3, 5, 7, 16 or 17; sequences substantially homologous to any one of SEQ. ID. Nos. 1, 3, 5, 7, 16 or 17; and sequences complementary thereto.

5

10. A nucleic acid according to claim 9, comprising the sequence ATGTTGCGGGCTT TGAACCGCCTGGCCGCGCGGCCCGGGGGCCAGCCCCCAACCCTGCTCCTTCTGCCCCGTGC GCGGCCCACGGCCCCGCTCATTCTCGGCTCCTTTTTCTCGCAGGATAGC, or an equivalent sequence which encodes the same polypeptide having regard to the degeneracy of the nucleic acid code, or a sequence substantially homologous thereto.

10

11. A nucleic acid vector comprising a nucleic acid sequence according to any one of claims 8 to 11.

15

12. A vector according to claim 11 which is a cosmid vector.

13. A vector according to claim 11 or claim 12 further comprising the sequences of the oxytocin (OT) gene, the vasopressin (AVP) gene and/or the human growth hormone (hGH) gene.

20

14. A vector according to claim 12 having the structure of cVO14 as set forth in Figure 4 (SEQ. ID. No. 17).

15. A cell transformed with a vector according to any one of claims 11 to 13.

25

16. A method for producing a 5'OT-EST polypeptide or a mutant 5'OT-EST polypeptide according to any one of claims 1 to 7, comprising transforming a cell with a vector according to any one of claims 11 to 13 and culturing the cell to produce the polypeptide.

30

17. A transgenic non-human animal expressing, as a result of transgene expression, a 5'OT-EST polypeptide or mutant 5'OT-EST polypeptide according to any one of claim 1 to 7.
- 5 18. A transgenic animal according to claim 17, which has been transformed with a vector according to any one of claims 12 to 14.
19. A transgenic animal according to claim 17 or claim 18, comprising more than one copy of the transgene.
- 10 20. A transgenic animal according to any one of claims 17 to 19, which is a mammal.
21. A transgenic animal according to claim 20 which is a rat.
- 15 22. A transgenic rat comprising at least four concatameric copies of a transgene having the structure of cVO14 as set forth in Figure 4 (SEQ. ID. No. 17).
23. A non-human mammal possessing the following obese phenotype: (i) a very late onset of obesity, (ii) a highly selective visceral distribution of fat developing on a normal
20 rodent diet, without hyperphagia, (iii) an effect greatly preponderant in males, (iv) a predisposition to excessive dietary-fat induced obesity at an early age, before the phenotype becomes apparent on a normal diet, and (v) a dominant pattern of inheritance; the non-human mammal being obtainable by transformation with a vector according to any one of claims 11 to 14.
- 25 24. Use of an animal according to any one of claims 17 to 23 as a model for human late onset obesity, human dietary-fat associated juvenile obesity, human female post-menopausal obesity and/or human male infertility.
- 30 25. A method for identifying a compound or compounds capable of modulating obesity and/or infertility in a mammal, comprising the steps of:

a) exposing an animal according to any one of claims 17 to 24 to the compound or compounds to be tested;

b) determining the effect of the compound on the obesity and/or infertility phenotype; and

5 c) selecting the compound or compounds which are capable of modulating the obesity and/or infertility phenotype in the desired manner.

26. A method for producing a compound or compounds capable of modulating obesity and/or infertility in a mammal, comprising the steps of:

10 a) exposing an animal according to any one of claims 17 to 24 to the compound or compounds to be tested;

b) determining the effect of the compound on the obesity and/or infertility phenotype;

15 c) selecting the compound or compounds which are capable of modulating the obesity and/or infertility phenotype in the desired manner; and

d) producing the compound or compounds by conventional isolation or synthesis techniques.

27. A method for identifying a candidate compound capable of influencing lipid transport, comprising the steps of:

20 a) contacting 5'OT-EST polypeptide with a candidate compound or compounds and determining which candidate compound or compounds is capable of interacting with 5'OT-EST;

25 b) optionally, testing candidate compounds which interact with 5'OT-EST in a method according to claim 25.

28. A diagnostic reagent for the detection of mutations, polymorphisms or other changes in 5'OT-EST which may predispose an individual to obesity.

30 29. Use of a tissue derived from a transgenic animal according to any one of claims 17 to 24 in a screen to identify a genetic cause of obesity, comprising the steps of:

- a) isolating one or more gene products from tissue derived from a transgenic animal according to any one of claims 17 to 24; and
- b) determining whether the expression of a gene product is correlated with obesity.




FIG. 1




FIG. 2
2/14




FIG. 3
3/14

rat AVP/OXT gene locus




FIG. 4

4/14




FIG. 5

Figure 6 5'OT-EST PROTEIN OF DIFFERENT SPECIES

Mouse

MLRALNRLAQRPGDRPPTPLLLPVRGRKTRHDPPAKSKVGRVQTPPAVDPAEFFVLTERY
 GQYRETVRALRLEFTLDVRRKLHEARAGVLAERKAQQAITEHRELMAWNRDENRRMQELR
 IARLQLEAQAQEVQKAEARQRAQEEQAWVQLKEQEVCLKQEEAKNFITRENLEARIEEA
 LDSPKSYNWAVTKEGQVVRN

Rat

MLRALNRLAARPGGQPPTLLLLPVRGRKTRHDPPAKSKVGRVKMPPAVDPAELFVLTERY
 RQYRETVRALRREFTLEVRGKLHEARAGVLAERKAQEAIREHQELMAWNREENRRMQELR
 IARLQLEAQAQELRQAEVQAQRAQEEQAWVQLKEQEVCLKQEEAKNFITRENLEARIEEA
 LDSPKSYNWAVTKEGQVVRN

Human

MLRALSRLGAGTPCRPRAPLVLPARGRKTTRHDPLAKSKIERNMPPAVDPAEFFVLMERY
 QHYRQTVRALRMEFVSEVQRKVHEARAGVLAERKALKDAAEHRELMAWNQAENRRQLHEL
 IARLRQEEREQEQRQALEQARKAAEEVQAWAQRKEREVLQLQEEVKNFITRENLEARVEAA
 LDSRKNYNWAITREGLVVRPQRDS

Alignment

Mouse	MLRALNRLAQRPGDRPPTPLLLPVRGRKTRHDPPAKSKVGRVQTPPAVDPAEFFVLTERY
Rat	MLRALNRLAARPGGQPPTLLLLPVRGRKTRHDPPAKSKVGRVKMPPAVDPAELFVLTERY
Human	MLRALSRLGAGTPCRPRAPLVLPARGRKTTRHDPLAKSKIERNMPPAVDPAEFFVLMERY

Mouse	GQYRETVRALRLEFTLDVRRKLHEARAGVLAERKAQQAITEHRELMAWNRDENRRMQELR
Rat	RQYRETVRALRREFTLEVRGKLHEARAGVLAERKAQEAIREHQELMAWNREENRRMQELR
Human	QHYRQTVRALRMEFVSEVQRKVHEARAGVLAERKALKDAAEHRELMAWNQAENRRQLHEL

Mouse	IARLQLEAQAQEVQKAEARQRAQEEQAWVQLKEQEVCLKQEEAKNFITRENLEARIEEA
Rat	IARLQLEAQAQELRQAEVQAQRAQEEQAWVQLKEQEVCLKQEEAKNFITRENLEARIEEA
Human	IARLRQEEREQEQRQALEQARKAAEEVQAWAQRKEREVLQLQEEVKNFITRENLEARVEAA

Mouse	LDSPKSYNWAVTKEGQVVRN
Rat	LDSPKSYNWAVTKEGQVVRN
Human	LDSRKNYNWAITREGLVVRPQRDS

Predicted deleted form in JP17

MLRALNRLAARPGGQPPTLLLLPVRGprprsfssapfssqds

↑




FIG. 7

7/14





FIG. 8


20 weeks

	non-transgenic	JP17 transgenic
a	260.33 ± 0.28	243.34 ± 0.13 ***
b	92.67 ± 0.29	115.14 ± 0.24 ***

52 weeks

	non-transgenic	JP17 transgenic
a	273.83 ± 0.28	261.0 ± 0.45 ns
b	113.83 ± 0.10	157.83 ± 0.61 ***

FIG. 9**9/14**








FIG. 11

11/14

	Cholesterol mg/dl	Triglyceride mg/dl	Glucose mg/dl	Insulin ng/ml	Leplin ng/ml	Corticosterone ng/ml
MALE TRANSGENIC	122.3 +/- 6.4	*295.6 +/- 28.7	114.7 +/- 4.2	1.94 +/- 0.89	*24.4 +/- 1.49	168.9 +/- 23.5
MALE NON- TRANSGENIC	129.9 +/- 9.3	178.9 +/- 23.5	121.0 +/- 3.9	2.8 +/- 1.93	9.51 +/- 2.14	113.9 +/- 20.3
FEMALE TRANSGENIC	94.9 +/- 5.9	224.2 +/- 52.3	126.3 +/- 3.3	2.51 +/- 0.64	*14.74 +/- 1.38	256.3 +/- 104.1
FEMALE NON- TRANSGENIC	100.2 +/- 8.0	195.5 +/- 34.5	135.4 +/- 6.7	2.54 +/- 2.32	4.58 +/- 0.47	349.3 +/- 123.7

FIG. 12

**FIG. 13**

13/14




FIG 14

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT:

- (A) NAME: MEDICAL RESEARCH COUNCIL
- (B) STREET: 20 PARK CRESCENT
- (C) CITY: LONDON
- (E) COUNTRY: UK
- (F) POSTAL CODE (ZIP): W1N 4AL

(ii) TITLE OF INVENTION: GENE

(iii) NUMBER OF SEQUENCES: 16

(iv) COMPUTER READABLE FORM:

- (A) MEDIUM TYPE: Floppy disk
- (B) COMPUTER: IBM PC compatible
- (C) OPERATING SYSTEM: PC-DOS/MS-DOS
- (D) SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)

(2) INFORMATION FOR SEQ ID NO: 1:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 924 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 5..604

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

TGTC ATG TTG CGG GCT TTG AAC CGC CTG GCC GCG CGG CCC GGG GGC CAG	49
Met Leu Arg Ala Leu Asn Arg Leu Ala Ala Arg Pro Gly Gly Gln	15
1 5 10	
CCC CCA ACC CTG CTC CTT CTG CCC GTG CGC GGC CGC AAG ACC CGC CAC	97
Pro Pro Thr Leu Leu Leu Leu Pro Val Arg Gly Arg Lys Thr Arg His	30
20 25	
GAT CCG CCT GCC AAG TCC AAG GTC GGG CGC GTG AAA ATG CCT CCT GCA	145
Asp Pro Pro Ala Lys Ser Lys Val Gly Arg Val Lys Met Pro Pro Ala	45
35 40	
GTG GAC CCT GCG GAA TTG TTC GTG TTG ACC GAG CGC TAC CGA CAG TAC	193
Val Asp Pro Ala Glu Leu Phe Val Leu Thr Glu Arg Tyr Arg Gln Tyr	60
50 55	

CGG GAG ACG GTG CGC GCT CTC AGG CGA GAG TTC ACA TTG GAG GTG CGA 241
 Arg Glu Thr Val Arg Ala Leu Arg Arg Glu Phe Thr Leu Glu Val Arg
 65 70 75

GGG AAA TTG CAC GAG GCC CGA GCC GGG GTT CTG GCT GAG CGC AAG GCG 189
 Gly Lys Leu His Glu Ala Arg Ala Gly Val Leu Ala Glu Arg Lys Ala
 80 85 90 95

CAA GAG GCC ATC AGA GAG CAC CAG GAG CTG ATG GCC TGG AAC CGG GAG 337
 Gln Glu Ala Ile Arg Glu His Gln Glu Leu Met Ala Trp Asn Arg Glu
 100 105 110

GAG AAC CGG AGA CTG CAG GAA CTA CGG ATA GCT AGG TTG CAG CTC GAA 385
 Glu Asn Arg Arg Leu Gln Glu Leu Arg Ile Ala Arg Leu Gln Leu Glu
 115 120 125

GCA CAG GCC CAG GAG CTG CGG CAG GCT GAG GTC CAG GCC CAG AGG GCC 433
 Ala Gln Ala Gln Glu Leu Arg Gln Ala Glu Val Gln Ala Gln Arg Ala
 130 135 140

CAG GAG GAG CAG GCT TGG GTG CAA CTG AAA GAA CAA GAA GTT CTC AAA 481
 Gln Glu Glu Gln Ala Trp Val Gln Leu Lys Glu Gln Glu Val Leu Lys
 145 150 155

CTG CAG GAG GAG GCC AAA AAC TTC ATC ACT CGG GAG AAC CTG GAG GCA 529
 Leu Gln Glu Glu Ala Lys Asn Phe Ile Thr Arg Glu Asn Leu Glu Ala
 160 165 170 175

CGG ATA GAA GAG GCC TTG GAC TCT CCG AAG AGT TAT AAC TGG GCG GTC 577
 Arg Ile Glu Glu Ala Leu Asp Ser Pro Lys Ser Tyr Asn Trp Ala Val
 180 185 190

ACC AAA GAA GGG CAG GTG GTC AGG AAC TGAGAACAGA GGCCCTCTCAG 624
 Thr Lys Glu Gly Gln Val Val Arg Asn
 195 200

GCCCAAATAA GGACAGTGCT TGCCTAGGGA CTGGATATTG GGGTAGAAAT TGGTGCATCC 684

CAGGAGGGTG GCACAGCCTT GTCCAGAGCA GCCCCCATTC ATTCTAGATT TGGCACCAGG 744

TATAGTACCT GTTCTGACAC CACATACAAA CTCCGGACAG CATTAAACTC TGGGAAGTTC 804

CTATCACACA GAAGATCAGA CTGGACTGTC CCCTCTAGAA GCCAAGAGCT GTCTCCTGAG 864

TTTCTTGGA TAGTGTGAGC CCAATGTTTC CTGCTTTTAT AAATAAACTA TTGGAAAGCA 924

(2) INFORMATION FOR SEQ ID NO: 2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 200 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

Met Leu Arg Ala Leu Asn Arg Leu Ala Ala Arg Pro Gly Gly Gln Pro
 1 5 10 15

Pro	Thr	Leu	Leu	Leu	Leu	Pro	Val	Arg	Gly	Arg	Lys	Thr	Arg	His	Asp	
			20												30	
Pro	Pro	Ala	Lys	Ser	Lys	Val	Gly	Arg	Val	Lys	Met	Pro	Pro	Ala	Val	
		35					40					45				
Asp	Pro	Ala	Glu	Leu	Phe	Val	Leu	Thr	Glu	Arg	Tyr	Arg	Gln	Tyr	Arg	
	50					55					60					
Glu	Thr	Val	Arg	Ala	Leu	Arg	Arg	Glu	Phe	Thr	Leu	Glu	Val	Arg	Gly	
	65				70					75					80	
Lys	Leu	His	Glu	Ala	Arg	Ala	Gly	Val	Leu	Ala	Glu	Arg	Lys	Ala	Gln	
				85					90					95		
Glu	Ala	Ile	Arg	Glu	His	Gln	Glu	Leu	Met	Ala	Trp	Asn	Arg	Glu	Glu	
			100					105					110			
Asn	Arg	Arg	Leu	Gln	Glu	Leu	Arg	Ile	Ala	Arg	Leu	Gln	Leu	Glu	Ala	
		115					120					125				
Gln	Ala	Gln	Glu	Leu	Arg	Gln	Ala	Glu	Val	Gln	Ala	Gln	Arg	Ala	Gln	
		130				135					140					
Glu	Glu	Gln	Ala	Trp	Val	Gln	Leu	Lys	Glu	Gln	Glu	Val	Leu	Lys	Leu	
	145				150					155					160	
Gln	Glu	Glu	Ala	Lys	Asn	Phe	Ile	Thr	Arg	Glu	Asn	Leu	Glu	Ala	Arg	
				165					170					175		
Ile	Glu	Glu	Ala	Leu	Asp	Ser	Pro	Lys	Ser	Tyr	Asn	Trp	Ala	Val	Thr	
			180					185					190			
Lys	Glu	Gly	Gln	Val	Val	Arg	Asn									
		195					200									

(2) INFORMATION FOR SEQ ID NO: 3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 998 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(ix) FEATURE:

- (A) NAME/KEY: CDS
(B) LOCATION: 1..615

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

ATG	CTA	CGC	GCG	CTG	AGC	CGC	CTG	GGC	GCG	GGG	ACC	CCG	TGC	AGG	CCC
Met	Leu	Arg	Ala	Leu	Ser	Arg	Leu	Gly	Ala	Gly	Thr	Pro	Cys	Arg	Pro

96
44
92
40
88
36
84
32
80
528
576
525
585
745
305
365
925
985

TTGTTGGAAC ACA

998

(2) INFORMATION FOR SEQ ID NO: 4:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 205 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

```

Met Leu Arg Ala Leu Ser Arg Leu Gly Ala Gly Thr Pro Cys Arg Pro
 1           5           10           15
Arg Ala Pro Leu Val Leu Pro Ala Arg Gly Arg Lys Thr Arg His Asp
          20           25           30
Pro Leu Ala Lys Ser Lys Ile Glu Arg Val Asn Met Pro Pro Ala Val
          35           40           45
Asp Pro Ala Glu Phe Phe Val Leu Met Glu Arg Tyr Gln His Tyr Arg
          50           55           60
Gln Thr Val Arg Ala Leu Arg Met Glu Phe Val Ser Glu Val Gln Arg
          65           70           75           80
Lys Val His Glu Ala Arg Ala Gly Val Leu Ala Glu Arg Lys Ala Leu
          85           90           95
Lys Asp Ala Ala Glu His Arg Glu Leu Met Ala Trp Asn Gln Ala Glu
          100          105          110
Asn Arg Arg Leu His Glu Leu Arg Ile Ala Arg Leu Arg Gln Glu Glu
          115          120          125
Arg Glu Gln Glu Gln Arg Gln Ala Leu Glu Gln Ala Arg Lys Ala Glu
          130          135          140
Glu Val Gln Ala Trp Ala Gln Arg Lys Glu Arg Glu Val Leu Gln Leu
          145          150          155          160
Gln Glu Glu Val Lys Asn Phe Ile Thr Arg Glu Asn Leu Glu Ala Arg
          165          170          175
Val Glu Ala Ala Leu Asp Ser Arg Lys Asn Tyr Asn Trp Ala Ile Thr
          180          185          190
Arg Glu Gly Leu Val Val Arg Pro Gln Arg Arg Asp Ser
          195          200          205

```

(2) INFORMATION FOR SEQ ID NO: 5:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 943 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: 5..604

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

TGTC ATG TTG CGC GCT CTG AAC CGC CTG GCG CAG CGG CCG GGA GAC CGG	49
Met Leu Arg Ala Leu Asn Arg Leu Ala Gln Arg Pro Gly Asp Arg	
210 215 220	
CCC CCG ACC CCG CTG CTC CTG CCC GTG CGC GGC CGC AAG ACC CGC CAT	97
Pro Pro Thr Pro Leu Leu Leu Pro Val Arg Gly Arg Lys Thr Arg His	
225 230 235	
GAC CCG CCT GCC AAA TCC AAG GTC GGA CGG GTG CAG ACG CCT CCC GCC	145
Asp Pro Pro Ala Lys Ser Lys Val Gly Arg Val Gln Thr Pro Pro Ala	
240 245 250	
GTG GAC CCT GCG GAA TTC TTC GTG TTG ACC GAG CGC TAC GGA CAG TAC	193
Val Asp Pro Ala Glu Phe Phe Val Leu Thr Glu Arg Tyr Gly Gln Tyr	
255 260 265	
CGG GAG ACC GTG CGC GCT CTC AGG CTA GAG TTC ACG TTG GAT GTG CGA	241
Arg Glu Thr Val Arg Ala Leu Arg Leu Glu Phe Thr Leu Asp Val Arg	
270 275 280	
AGG AAA TTG CAC GAG GCC CGA GCC GGG GTT CTG GCC GAG CGC AAG GCG	289
Arg Lys Leu His Glu Ala Arg Ala Gly Val Leu Ala Glu Arg Lys Ala	
285 290 295 300	
CAG CAG GCC ATC ACG GAG CAC CGG GAG CTG ATG GCC TGG AAC CGG GAC	337
Gln Gln Ala Ile Thr Glu His Arg Glu Leu Met Ala Trp Asn Arg Asp	
305 310 315	
GAG AAC CGG CGA ATG CAG GAG CTA CGG ATA GCG AGG TTG CAG CTG GAA	385
Glu Asn Arg Arg Met Gln Glu Leu Arg Ile Ala Arg Leu Gln Leu Glu	
320 325 330	
GCA CAG GCC CAG GAG GTG CAG AAG GCT GAG GCC CAG CGC CAG AGG GCT	433
Ala Gln Ala Gln Glu Val Gln Lys Ala Glu Ala Gln Arg Gln Arg Ala	
335 340 345	
CAG GAG GAG CAG GCT TGG GTG CAA CTG AAA GAG CAA GAA GTG CTC AAG	481
Gln Glu Glu Gln Ala Trp Val Gln Leu Lys Glu Gln Glu Val Leu Lys	
350 355 360	
CTG CAG GAG GAG GCA AAA AAC TTC ATC ACT CGG GAG AAC CTG GAG GCA	529
Leu Gln Glu Glu Ala Lys Asn Phe Ile Thr Arg Glu Asn Leu Glu Ala	
365 370 375 380	
CGG ATA GAA GAA GCG TTG GAC TCT CCG AAG AGT TAC AAC TGG GCC GTC	577
Arg Ile Glu Glu Ala Leu Asp Ser Pro Lys Ser Tyr Asn Trp Ala Val	
385 390 395	

ACC AAA GAA GGG CAG GTG GTC AGG AAC TGAGCACAGA GACTTCTGGG 624
 Thr Lys Glu Gly Gln Val Val Arg Asn
 400 405

GGCCCAAATA AGCACAGTGC TTGCCTAGGG TCTGTGTACT GGGATAGGAA TTGGTACATC 684
 CCAGGAGGAT GGCTCAGCCG TTTCCAGAGC AACCTCAGTC ACTCCAGGCT CGGCACTCAC 744
 CACCTGACTG GGAAGTCCCA GATGTCCCTG TTCTGGCACC ACAGTCAAAC TGAGGGCAGC 804
 ATTAACTCT GGGAAGTTCC TATCGCACAG AGGATCGGAC TGGACTGTGT CCCTCTAGAA 864
 GCCAAGCTTG TCTTGTAAGT CTCTTGGAGT CCTGTGAGCC AAATGTTTCC TGCTTTTATA 924
 AATAAAGTAT TGGAGCCCA 943

(2) INFORMATION FOR SEQ ID NO: 6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 200 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

Met Leu Arg Ala Leu Asn Arg Leu Ala Gln Arg Pro Gly Asp Arg Pro
 1 5 10 15

Pro Thr Pro Leu Leu Leu Pro Val Arg Gly Arg Lys Thr Arg His Asp
 20 25 30

Pro Pro Ala Lys Ser Lys Val Gly Arg Val Gln Thr Pro Pro Ala Val
 35 40 45

Asp Pro Ala Glu Phe Phe Val Leu Thr Glu Arg Tyr Gly Gln Tyr Arg
 50 55 60

Glu Thr Val Arg Ala Leu Arg Leu Glu Phe Thr Leu Asp Val Arg Arg
 65 70 75 80

Lys Leu His Glu Ala Arg Ala Gly Val Leu Ala Glu Arg Lys Ala Gln
 85 90 95

Gln Ala Ile Thr Glu His Arg Glu Leu Met Ala Trp Asn Arg Asp Glu
 100 105 110

Asn Arg Arg Met Gln Glu Leu Arg Ile Ala Arg Leu Gln Leu Glu Ala
 115 120 125

Gln Ala Gln Glu Val Gln Lys Ala Glu Ala Gln Arg Gln Arg Ala Gln
 130 135 140

Glu Glu Gln Ala Trp Val Gln Leu Lys Glu Gln Glu Val Leu Lys Leu
 145 150 155 160

Gln Glu Glu Ala Lys Asn Phe Ile Thr Arg Glu Asn Leu Glu Ala Arg
 165 170 175

Ile Glu Glu Ala Leu Asp Ser Pro Lys Ser Tyr Asn Trp Ala Val Thr
 180 185 190

Lys Glu Gly Gln Val Val Arg Asn
 195 200

(2) INFORMATION FOR SEQ ID NO: 7:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 2852 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vii) IMMEDIATE SOURCE:

(B) CLONE: Rat 5'OT-EST-xdel

(ix) FEATURE:

- (A) NAME/KEY: exon
- (B) LOCATION: 1026..1270

(ix) FEATURE:

- (A) NAME/KEY: exon
- (B) LOCATION: 1799..2235

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 1030..1152

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

TGACCTCTGT GGATCTGATA TACATGTAAG TGACAGACCA TCCGAGCTAT ATAGTGAGAC	60
CTGTGCAAGG AAGGATGGAG TGCACGTTCC CTGATGTTCA GAGCAACCCT GTGTCACTCC	120
AGGTAGGTGA GATGAGAGGA AGAGGGTGGC CTTGGCCTGG GCCTCCTACG GGCCTGGAAG	180
TTGGGAGAAG GATGTAAGCA GACTCTGTTC TCTTCTGAGA AATATCAGGT ATTGCAGTCA	240
GCCCAGGCTC CTCAGACCCT CCTAAGTGCA GATTCTCTGC AGAATCTGGT GTTGACAACA	300
CTAATGAGTA GGATGAGACT TCAGTTCCCT AGCCCTCACC GTCAGCTTCT GATTACCAAC	360
AACTCTCCCA GAGGAGAGCC ATCTACCTTT GGGACAGATG CTCTCTGCCC TGCCTGCCT	420
CCTGTTTCTC TTCATTGTAG AGGAAGATAG TACTTTAAAA GCTTCATAAA TGGTCTCAAG	480
GTGGGAAGAC CCCGGCTCAG GTGAAAGAGG ACAAGCGTCA CCTCACACAG GCCACCCAGT	540
AGAAAACAAG TGATCACTGA TACTGAGAAC TCTGGCAATT GCAGAGCTGC CCAAGACCAC	600
AACAGGGCAG TGCAATGCAA GGAAAAGGTT TGTGCTCGA TTGCAAACCT AAAGTTTAAA	660

GTGCATCAGG AGAACGCTTA CTCAAAGAGG AAGTGTAAGC CTAAGTTAAG TAGCTAGAAG 720
 CTCAGAATTT CTTGCATCAG CCCTGGAAGG GTACACAGGC CACCGGTGGG CCAGAGAACC 780
 ACACGCTTTG GGGCGGTGTC CAAGCTTGTG AACAAGTAGG CAAGAGCGCC TGGTGTGTGA 840
 GCTGTCATTG GCGGGCAATA CAGCCCAGCG AACTGTGGTC TCCAAGGTGC CCCTCGACCC 900
 TCCCACTCTA CCCGAGACTC CAGGGACGCG ATGGGCCAGA CAGCAAGAGC TCCGCCTACG 960
 GGGGCGGGGA CAGGAGATTC CCGTGATGCT CCTCGACCAC TTCCGGACAG GGCGCAGGCG 1020
 CTAGCTGTC ATG TTG CGG GCT TTG AAC CGC CTG GCC GCG CGG CCC GGG 1068
 Met Leu Arg Ala Leu Asn Arg Leu Ala Ala Arg Pro Gly
 205 210
 GGC CAG CCC CCA ACC CTG CTC CTT CTG CCC GTG CGC GGC CCA CGG CCC 1116
 Gly Gln Pro Pro Thr Leu Leu Leu Leu Pro Val Arg Gly Pro Arg Pro
 215 220 225
 CGC TCA TTC TCG GCT CCT TTT TCC TCG CAG GAT AGC TAGGTTGCAG 1162
 Arg Ser Phe Ser Ala Pro Phe Ser Ser Gln Asp Ser
 230 235 240
 CTCGAAGCAC AGGCCCAGGA GCTGCGGCAG GCTGAGGTCC AGGCCCAGAG GGCCACAGGAG 1222
 GAGCAGGCTT GGGTGCAACT GAAAGAACAA GAAGTTCTCA AACTGCAGGT GGGCCGAGGT 1282
 CGTGAGGAAT GTGGGTATTG GAGATTCCGG TGAGGGAGGC TCTGGGGAGA GCAGCACAGG 1342
 GTGTCAAGTG ACCAGTCTTC AGGAGGCTTC TCTCTCTGCT CTGCACACAC AGAGTGCCTC 1402
 CCAGACAATG GTCAATGAAA GGTTACAGGC TAGTATTGCC GTGTGAACT TGAAGGTCAG 1462
 GGAAACCATA AATGAGAATG GAGCTGTTTT TATTGTGTAA GGGAGAGTGA CAAGGTTGAG 1522
 AGAGTCCACC ACCCCGCACC TCCCCCGCC CCAATCAGG TTGTCACGAT TCGATTTCGTT 1582
 CTTGGGTTGT GGCTGAGAGA TCTGATGGGT AATTGTCCGA GGAAGAGGGA TATAATGGTT 1642
 GAGGTCACCT AGTACAGTTG TGCTGGCCTA TTGGTGGGAC ACTCAAAGGG GCCCTGGGCT 1702
 CTTTGTACAC CCTTCTTAAG GTGGGCTAGA GACAGTAAGT TATGCAGGCA GCCAGCTCTG 1762
 AGAGATCCCA CGTAGCTAAC CTTTCTCTTC CCGTAGGAGG AGGCCAAAAA CTTTCATCACT 1822
 CGGGAGAACC TGGAGGCACG GATAGAAGAG GCCTTGGACT CTCCGAAGAG TTATAACTGG 1882
 GCGGTCACCA AAGAAGGGCA GGTGGTCAGG AACTGAGAAC AGAGGCCTCT CAGGCCCAAA 1942
 TAAGGACAGT GCTTGCCTAG GGAAGGATA TTGGGGTAGA AATTGGTGCA TCCCAGGAGG 2002
 GTGGCACAGC CTTGTCCAGA GCAGCCCCCA TTCATTCTAG ATTTGGCACC AGGTATAGTA 2062
 CCTGTTCTGA CACCACATAC AAACCTCCGA CAGCATTAAA CTCTGGGAAG TTCCTATCAC 2122
 ACAGAAGATC AGACTGGACT GTCCCCTCTA GAAGCCAAGA GCTGTCTCCT GAGTTTCTTG 2182
 GAATAGTGTG AGCCCAATGT TTCCTGCTTT TATAAATAAA CTATTGGAAA GCAAAGCCTT 2242
 TTGTTATGTG GCTTGCTTTT TCTGTGTGTA GAATAAGTTT ATTTGTCCCA GTTATTTGGG 2302

TCTTAAGGTT ATTAGCCAAA AGCCAGTTCA CCTAACTGAG CCAGGAGTTA GTTATCTGCT 2362
 TTGCTCAATC CTGGGCTTTG CTGGGTAGGG TCAGGTGTGT CCAAGGTCCA GAAAGCAAAA 2422
 AGGGTGCCCC GTTCTCTCTG GGAAGGCTTC CCCGTCAGTG ATTTCTGTAA CCGGACCCTG 2482
 CCCTGACACA GCGTCATTGG ACTACCCAGC AGACAGTAGA CTCCACTCTA AACCCGCTTC 2542
 TTGCGGTCAG TTGCTGTCCT TCAGTGTGTG TAAGCAGTGG CCAGACAGCA CCCTTGGGTG 2602
 TCATTTCAAG ACTCTCTCAC CTTGGTCTGC TTTACGTTTG GTTTGATTTG GTTTGTTCTG 2662
 GTTTTTGAGA CGAGGCCTTT CACTGGAACC TGGCACTCAG TATTTAGACT GCCCAGCCAG 2722
 CTAGCCTCAG AGAATGCATC TGCATATGCT TGCCTGGCGC TGAATTCGG TGCACATGGC 2782
 TTTGATGTGT ACCGGGGATC AGACACAGAT GTTTCATGAG TGCAGTGCAT GCCTGTTAGT 2842
 GGTAGAGCTC 2852

(2) INFORMATION FOR SEQ ID NO: 8:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 41 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

Met Leu Arg Ala Leu Asn Arg Leu Ala Ala Arg Pro Gly Gly Gln Pro
 1 5 10 15
 Pro Thr Leu Leu Leu Leu Pro Val Arg Gly Pro Arg Pro Arg Ser Phe
 20 25 30
 Ser Ala Pro Phe Ser Ser Gln Asp Ser
 35 40

(2) INFORMATION FOR SEQ ID NO: 9:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

- (A) DESCRIPTION: /desc = "Synthetic Primer"

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:

TTCACACCAC TCTGTGGAAC

20

(2) INFORMATION FOR SEQ ID NO: 10:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 20 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: other nucleic acid
 - (A) DESCRIPTION: /desc = "Synthetic Primer"
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:

AGGAGGAAGA CAGGTGAAAG

20

(2) INFORMATION FOR SEQ ID NO: 11:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 20 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: other nucleic acid
 - (A) DESCRIPTION: /desc = "Synthetic Primer"
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11:

TCATGTTGCG GGCTTTGAAC

20

(2) INFORMATION FOR SEQ ID NO: 12:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 20 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: other nucleic acid
 - (A) DESCRIPTION: /desc = "Synthetic Primer"
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: YES

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12:

TCTTTCAGTT GCACCCAAGC

20

(2) INFORMATION FOR SEQ ID NO: 13:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "Synthetic Primer"

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: YES

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13:

GTGATAGGAA CTTCCCAGAG

20

(2) INFORMATION FOR SEQ ID NO: 14:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 42 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "Synthetic Primer"

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: YES

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14:

GCCTCGTGCA ATTTCCCTCG CACCTCCAAT GTGAAGTCTC GC

42

(2) INFORMATION FOR SEQ ID NO: 15:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 42 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "Synthetic Primer"

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: YES

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15:

TCCTGCGAGG AAAAAGGAGC CGAGAATGAG CGGGGCCGTG GG

42

(2) INFORMATION FOR SEQ ID NO: 16:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 3264 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vii) IMMEDIATE SOURCE:

(B) CLONE: Rat 5'OT-EST

(ix) FEATURE:

- (A) NAME/KEY: exon w
- (B) LOCATION:1026..1241

(ix) FEATURE:

- (A) NAME/KEY: exon x
- (B) LOCATION:1332..1478

(ix) FEATURE:

- (A) NAME/KEY: exon y
- (B) LOCATION:1559..1682

(ix) FEATURE:

- (A) NAME/KEY: exon z
- (B) LOCATION:2211..2647

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16:

TGACCTCTGT GGATCTGATA TACATGTAAG TGACAGACCA TCCGAGCTAT ATAGTGAGAC	60
CTGTGCAAGG AAGGATGGAG TGCACGTTCC CTGATGTTCA GAGCAACCCT GTGTCACTCC	120
AGGTAGGTGA GATGAGAGGA AGAGGGTGGC CTTGGCCTGG GCCTCCTACG GGCCTGGAAG	180
TTGGGAGAAG GATGTAAGCA GACTCTGTTC TCTTCTGAGA AATATCAGGT ATTGCAGTCA	240
CCCCAGGCTC CTCAGACCCT CCTAAGTGCA GATTCTCTGC AGAATCTGGT GTTGACAACA	300
CTAATGAGTA GGATGAGACT TCAGTTCCCT AGCCCTCACC GTCAGCTTCT GATTACCAAC	360

AACTCTCCCA GAGGAGAGCC ATCTACCTTT GGGACAGATG CTCTCTGCCC TGCACTGCCT	420
CCTGTTTCTC TTCATTGTAG AGGAAGATAG TACTTTAAAA GCTTCATAAA TGGTCTCAAG	480
GTGGGAAGAC CCCGGCTCAG GTGAAAGAGG ACAAGCGTCA CCTCACACAG GCCACCCAGT	540
AGAAAACAAG TGATCACTGA TACTGAGAAC TCTGGCAATT GCAGAGCTGC CCAAGACCAC	600
AACAGGGCAG TGCAATGCAA GGAAAAGGTT TGTGTGCTCGA TTGCAAACCT AAAGTTTAAA	660
GTGCATCAGG AGAACGCTTA CTCAAAGAGG AAGTGTAAGC CTAACCTAAG TAGCTAGAAG	720
CTCAGAATTT CTTGCATCAG CCCTGGAAGG GTACACAGGC CACCGGTGGG CCAGAGAACC	780
ACACGCTTTG GGGCGGTGTC CAAGCTTGTG AACAAAGTAGG CAAGAGCGCC TGGTGTGTGA	840
GCTGTCAATTG GCGGGCAATA CAGCCCAGCG AACTGTGGTC TCCAAGGTGC CCCTCGACCC	900
TCCCCTCTA CCCGAGACTC CAGGGACGCG ATGGGCCAGA CAGCAAGAGC TCCGCTACG	960
GGGGCGGGGA CAGGAGATTC CCGTGATGCT CCTCGACCAC TTCCGACAG GGCGCAGGCG	1020
CTAGCTGTCA TGTTGCGGGC TTTGAACCGC CTGGCCGCGC GGCCCGGGGG CCAGCCCCCA	1080
ACCCTGCTCC TTCTGCCCCG GCGCGGCCGC AAGACCCGCC ACGATCCGCC TGCCAAGTCC	1140
AAGGTCGGGC GCGTGAAAAT GCCTCCTGCA GTGGACCCTG CGGAATTGTT CGTGTGACC	1200
GAGCGCTACC GACAGTACCG GGAGACGGTG CGCGCTCTCA GGTGTGTGTA AAGGGCAGGC	1260
GGCCTTCGGC GCCCCCTGGG AAGTGCTGGG GCTGGAGGAT GGGTGCTCAC TTGAAGCCCG	1320
TCCTCACCCA GGCGAGAGTT CACATTGGAG GTGCGAGGGA AATTGCACGA GGCCCGAGCC	1380
GGGGTTCTGG CTGAGCGCAA GGCGCAAGAG GCCATCAGAG AGCACCAGGA GCTGATGGCC	1440
TGGAACCGGG AGGAGAACCG GAGACTGCAG GAACTACGGT GCGAGAGGCG CGGGGCTGGG	1500
TGGGCTGGGC TAGGCTCACC CACGGCCCCG CTCATTCTCG GCTCCTTTT CCTCGCAGGA	1560
TAGCTAGGTT GCAGCTCGAA GCACAGGCCC AGGAGCTGCG GCAGGCTGAG GTCCAGGCCC	1620
AGAGGGCCCA GGAGGAGCAG GCTTGGGTGC AACTGAAAGA ACAAGAAGTT CTCAAAGTGC	1680
AGGTGGGCCG AGGTCGTGAG GAATGTGGGT ATTGGAGATT CCGGTGAGGG AGGCTCTGGG	1740
GAGAGCAGCA CAGGGTGTCA AGTGACCACT CTTAGGAGG CTTCTCTCTC TGCTCTGCAC	1800
ACACAGAGTG CCTCCCAGAC AATGGTCAAT GAAAGGTTAC AGGCTAGTAT TGCCGTGTGA	1860
AACTTGAAGG TCAGGGAAAC CATAAATGAG AATGGAGCTG TTTTATTGT GTAAGGGAGA	1920
GTGACAAGGT TGAGAGAGTC CACCACCCCG CACCTCCCCG CGCCCCCAAT CAGGTTGTCA	1980
CGATTGATT CGTTCTTGGG TTGTGGCTGA GAGATCTGAT GGGTAATTGT CCGAGGAAGA	2040
GGGATATAAT GGTGAGGTC ACCTAGTACA GTTGTGCTGG CCTATTGGTG GGACACTCAA	2100
AGGGGCCCTG GGCTCTTTTG ACACCCTTCT TAAGGTGGGC TAGAGACAGT AAGTTATGCA	2160
GGCAGCCAGC TCTGAGAGAT CCCACGTAGC TAACCTTTCT CTTCCCGTAG GAGGAGGCCA	2220

AAAACCTTCAT CACTCGGGAG AACCTGGAGG CACGGATAGA AGAGGCCTTG GACTCTCCGA	2280
AGAGTTATAA CTGGGCGGTC ACCAAAGAAG GGCAGGTGGT CAGGAACTGA GAACAGAGGC	2340
CTCTCAGGCC CAAATAAGGA CAGTGCTTGC CTAGGGACTG GATATTGGGG TAGAAATTGG	2400
TGCATCCCAG GAGGGTGGCA CAGCCTTGTC CAGAGCAGCC CCCATTTCATT CTAGATTTGG	2460
CACCAGGTAT AGTACCTGTT CTGACACCAC ATACAAACTC CGGACAGCAT TAAACTCTGG	2520
GAAGTTCCTA TCACACAGAA GATCAGACTG GACTGTCCCC TCTAGAAGCC AAGAGCTGTC	2580
TCCTGAGTTT CTTGGAATAG TGTGAGCCCA ATGTTTCCTG CTTTTATAAA TAAACTATTG	2640
GAAAGCAAAG CCTTTTGTTA TGTGGCTTGC TTTTCTTGT TGTAGAATAA GTTTATTTGT	2700
CCCAGTTATT TGGGTCTTAA GGTATTAGC CAAAAGCCAG TTCACCTAAC TGAGCCAGGA	2760
GTTAGTTATC TGCTTTGCTC AATCCTGGGC TTTGCTGGGT AGGGTCAGGT GTGTCCAAGG	2820
TCCAGAAAGC AAAAAGGGTG CCCCCTTCT CCTGGGAAGG CTTCCCCGTC AGTGATTTCT	2880
GTAACCGGAC CCTGCCCTGA CACAGCGTCA TTGGACTACC CAGCAGACAG TAGACTCCAC	2940
TCTAAACCCG CTTCTTGCGG TCAGTTGCTG TCCTTCAGTG TGTGTAAGCA GTGGCCAGAC	3000
AGCACCTTGG GGTGTCATTT CAAGACTCTC TCACCTTGGT CTGCTTTACG TTTGGTTTGA	3060
TTTGGTTTGT TCTGGTTTTT GAGACGAGGC CTTTCACTGG AACCTGGCAC TCAGTATTTA	3120
GACTGCCCAG CCAGCTAGCC TCAGAGAATG CATCTGCGTA TGCTTGCTG GCGCTGGAAT	3180
TCGGTGCACA TGGCTTTGAT GTGTACCGGG GATCAGACAC AGATGTTTCA TGAGTGCACT	3240
GCATGCCTGT TAGTGGTAGA GCTC	3264

(2) INFORMATION FOR SEQ ID NO: 17:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 44576 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: circular
- (ii) MOLECULE TYPE: other nucleic acid
 - (A) DESCRIPTION: /desc = "Cosmid DNA"
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17:

GCGGCCGCAT AATACGACTC ACTATAGGGA TCTGGTGGAG GACCTATGGC CCGCGAGCTA

GAGAAGTGGT	TCTCAACCTT	CCTAGTGTCTG	AGACCCTTTA	ACACAGTTCC	TCGTGTTGTG	120
GGGAAACCCC	CTCCTGCAAC	CATAAAATAA	TTTTTGTTAC	TACTTCATAA	CAAGTGTTGC	180
TACTCTATTG	CTATGAATTG	TAAATAAAAT	GTGTCTTCCA	ATGGTCTTAG	ATGACTCCCG	240
TGAAAGGGTC	ATTCTACCCC	TAAGAGGTCA	TGATCTACAG	GTTGAGAACC	ACTGATCTCC	300
AGTAACCTTC	ACTTGAGTCC	ATATCCTCCA	TGAAGGTATG	GAAGTCAATA	AAACTGAGCT	360
TCAAGCCTCA	TCAAAATGGG	TCCATCCCCT	GGTACAGTGT	GAGTGGAAGA	ATACCCACCA	420
TACGGTCACT	GGAAGGAGGA	TGTCTGAAGG	GTCTTAGATT	GTGTCAAGGG	GTCCTGGGTG	480
TCAGGATCTG	ACGAAGCAGG	CTCGTCATGT	TTCATGAAGA	CTACAGGTAT	GTGATAAAAC	540
TGCAAGCTGG	AAAAGTACCC	ACTGAGCCCG	TGTGGCTCTG	CTGGGATTTG	GAGGCATGAG	600
GAGCAGAGGG	TCTGGAGGAC	AGCAGTCCCA	GAAATAATCT	ATGACTAAGA	AGGCTGAACT	660
GGGGTGA CTC	TCTGGTGGA	AGAGTTGCCT	TTTAAGAAGG	AAGACATACC	AGGCATAGCA	720
ACAACTGCCT	TTAGTACTAG	CACTCTGAAG	GCAGAGGAAG	TCCGATTTCT	CTGAGTTCCA	780
AGCCAGCTTG	GTTTACACAG	CAAGTTCTAG	GCCAACTAGG	GTTACATAGT	GGACTCTCCT	840
CAAACGGGGT	TGAGAAAGGA	CTCAGCAGTT	AGCTCAGTTA	ACTCCAGTTC	TAGGAAATAT	900
GATCCCTTAG	TCTGACCTCT	TGGCATGTAA	GTGGTGCACA	TACATATATG	CACACAAAAT	960
ACATCAATCT	GCAAAGGGGG	AGGGAGGAAG	GGCTGGAGTC	TGAAGAAATA	GTTCAGTGGT	1020
TAAGAGAATT	CACTGCTCTT	CCCAATAGCC	AAATTCAGCT	CCTAGCATCC	ATGTCAGATG	1080
GCCCACGAAC	ACCTGTAATT	CTAGCCCCTA	AACTCAGTGC	CCCTTCACAA	GACGGGGACA	1140
CACGTACACA	TATACCTAAA	AAATTAGGTG	GTTTTTTTTT	ATTTATAAGG	TCAAATGCAG	1200
AATATCAAAT	GGGTTAGACA	GCAGCTCCAA	GCTGGCCTCT	TCCTCCCAGG	GCTCTTCTTG	1260
ACTCTTGGCA	CCCTCTTTGG	GTCCAGAACC	CAGACATTAG	CCATGACTCA	GCTGATAAAA	1320
TGCAACCCAT	GGCTCATTAA	TTAGGAAGTC	TGTAATTAGC	CTGTCTGGTA	GCCTCCAGAG	1380
AGAACCCTTT	TCACCTGTCT	TCCTCCTCTC	ACCCAGGGGA	AGAGCTCAGT	TTTGGCCCTG	1440
AGACAGAAGA	AGGGAACGAG	ACCATGAGCA	ACGGGAAATG	AGATGCTGGC	GCACACACAC	1500
TTTATGTGTG	TGAAGTCTCA	GAGAGGTCAC	CAATAATGAG	GCAATGGAAA	TGAGCTGAGC	1560
TGCCTGAACC	TCCAAGTTTC	CTCCAAGAAA	ACCCACAGG	GGAGATGGGG	CATGGCCCAG	1620
GCCAGCTGCC	CCAGCCTCTG	CTGGCAGAAA	GTGAGCCCGC	TGCCATTTTA	ATTTTTGATA	1680
CAGGGTCTCA	CTCTACAGCT	CTGGGGGCCT	AAAAC TCACT	ATGTAGACTT	CAAAC TCAAC	1740
CAAACCAACA	ACAAAAACAA	ACAAAACCCC	TGCACTGACT	GGAGAGATGG	CTCGGTTGAG	1800
AACAATGGCT	GCTAGGAGTC	AAACCCAGGT	CCTGTGGAAG	AGCATGCTGG	TAAC T GCTGG	1860

GTCATCGCTG	GGTCACTCTC	TTCACACACA	CACACACACA	CACACACACA	CACGGCAATG	1920
AACTCTTCAG	TGTCTTGATT	TACGGTTTCT	TCCGATAAAT	CCTCAGGAGG	GCAGTCAAGT	1980
GGCTCATTTG	GCAAATGCTT	GCCTGAGACC	TGAGTTTGGT	TCCCAGAACC	CATGGAGGCA	2040
GAAGGAAAGG	GCTCCACAAA	GCTCTCTTCT	GAACTCCATA	TGTGCACACA	CACCCACTTC	2100
GCACACATTC	ATAATAGTGA	TGAATGAAAA	TGAAGACAGA	TAAAAAAAAC	CAATTTTCGTG	2160
AAACTGTTAG	CACGTTCACT	CAATGGCTTT	GGGGGTAACC	TGTTTCAGAG	CCATGGTACT	2220
CAGTCACTAG	GCTCATACTG	GTCAGACGCT	GAGGTCAGCA	ATGGAGAGCT	GCTACACCTA	2280
AAGGTAGCAG	AGGTCAATTTG	GCTCTGACTC	AGAATATTCC	AGCTCTCCAC	ATTCACAGAA	2340
GTTCTACTTG	GTCGTAGAAA	AAAGCTGAGC	CTTTTTTTTT	TTTTGGAAC	TTATTTTTTT	2400
AAAGATATAT	TTATTTTATG	TATATGAGTG	CACTGTAGCT	GTCTTCAGAC	ACACCAGAAG	2460
GGGGCATCGG	ATCCCATTAC	AGATGGCTGT	GAGCCAACAT	GTGGTCGCTG	GGGATTGAAC	2520
TTAGGACCTC	TGGAAGAGCA	GTCAGTGCTC	TTAACCGCTG	AGCCATCTCT	CCAGCCCTGG	2580
AACTTTATTT	TGAACATGCA	ACCCACCTA	CCACTATGGG	TTCAGTCACC	AGCGCCTTAG	2640
GAATAAAATT	GGAGAAAATA	AGCTTTATGG	TTAGTCAGCT	GTCAGCTGTG	GGGTTGGGGA	2700
CAGAAGAATG	GTTATGTTTT	GTTTTCCCAT	CAAGGCCTCA	CTCTGTGACC	TGGTTGGTCT	2760
GCCACTTGCT	CTGTAGATCA	GGTTTCAATT	ACAGAGATCC	ACCTGCTCCG	TGTCGCTATG	2820
CTGGGATAAG	AACTAAGTCA	CCCTGCCTAC	CTTATTACTT	TGTATTCTTG	GGCATGGAAC	2880
TCAATTCCTT	GTCAGCGAGA	GAATAACTTC	CTCGATCGGA	GTGTTTTTAT	GTGAATTGGG	2940
CCAAAAAGAC	TGCGATGCTC	TGAGACCTAT	TTGTGAAGCC	AAGAGTAGTG	GGTAGCACAA	3000
GTCAGAAATC	CAAGGACTTG	GTAAGCTGAG	ACAGTAGGAT	GTGTGCGCTC	ATGCACACAC	3060
ACACACACAG	ACACACACAC	AGACACATAC	ATGCATGGAC	GCACAGAGGC	ACCCACGCAC	3120
ATGTGCCTGG	ATGAGGCTTC	AGTTCTTCAT	AAAGCTGCCT	TTGAGTTTGT	GCCCTCCCAC	3180
TCTTCCTGAG	GACTGGAGTC	CTCACACCTT	GGGCTGATAG	TGCACCACTA	CCTTTTTTTAG	3240
TGACCTCCTC	TTTGCACTCA	CAGGCTGAAG	GTACAGGGAG	GACTCTAGCG	GCCGTCTGCC	3300
TCTGTTTAAC	ATGAACCTGC	AAGGCAGTGG	GCAGCCTCAC	CCCTAGCGAT	GGCACTGAGT	3360
GATGCCAGGA	ACGCTGTCCT	CATGTGCCCT	TGGCTGTTGG	GGCACAGTGT	GCCTCTGCAG	3420
GGCCAGCCTG	ACCGTGTGTG	CCAGCCAGAA	TGCACAATTT	CTGCCCAGCC	TTGGAAGCTT	3480
TTTGTCTTTC	CTTGTGAGTT	TCTTGTCACC	CAGCAGTGTT	TCTTGCCTCT	TTGCTTGACG	3540
CCTCTATGGG	AAGATGGACA	AGACTTTTTT	TTTTCTACAT	CCCCTGCAAA	CAGGTTTGTC	3600
ATACCTCTCA	GGGGCAGGGG	TCTTGTCCTT	GTCAAGCGCA	GCAGGCCACC	AGACCCAGAA	3660
CTATGAAATC	TACCCAACCT	GTCTCTGTAC	AAAGTTAAAC	AACAAAAAGA	AACCTTGGTTT	3720

TGT TTTTGTGTT TTTT TTTTGTGTTG TTTTGTGTTT TGAGACAGGG TTTCTCTATG 3780
 TAGTCCTGGC TATTCTGGAA CTTGTTCTAT AGACCAGGCT ATCCTGGAAC TCAAAGAACG 3840
 GCCTGACTCT GTCTCCCGGG TGCTGGTCAC TCTGAAGATC TGTGCCACCA TCATCAGGCT 3900
 GGGTTTTAAA AGATTATGGT TTATATTTAA TGTGTATGAG TGT TTTTGTGTT GCATGTATAT 3960
 CTGTACATGA CAGGTGTGCC TGGTGT TTTAC AGAGGCCAGA AGAACATACC AGATCCCCCT 4020
 GGAAGTGAAG TTACAGACAG TCGTGAGCCA TCTCGGGGTT GCTGGGGACA GAATCCGAGG 4080
 GCTCTTCTTG AGTAGCAAGT GCTTCTAACC GCTTAGGCCT CTCTGCAGCC CCCACTTACA 4140
 GGATTTAAAG GTAGAACAAG GTTTGTCAAC TGTCCTGGAG ACCCTGGCCT TTAATTCAG 4200
 AACTCTGGAG GTAGAGACAG ATGATTCTCT ATGAAGTTCA GGCGAGCCTG GTCTACACAG 4260
 AGTGCCGCAT GATAGCAAGA AGAAGATCCT GTCTTTAAAA GAGACGAGAG GGGTTGGGGA 4320
 TTTAGCTCAG TGGTAGAGCG CTTGCCTAGC AAGCACAAGG CCCTGGGTTC GGTCCCCAGC 4380
 TCCGAAGAAA AAAAAGAGAC GAGAGCCAGT GGTGGTGCA CGTCTTTGAT CCCAGTACTC 4440
 TGGAGGCAGA GGTAGTGGAT CTCTCTTGAG TTCAAGGACA GCGTGGTCTA CAAAGTGAGT 4500
 TTTAGGACAT CCAGGATTAC ACGCACAGAA ACCTTGCTCTC ATAAAAACAAC AAACAAGACA 4560
 AGACAGAAAC TCTCCTAACG TAGACCGCCA CACCTGATTT TTTAAAGCTC TCAGTGAAAC 4620
 TGAGCATGGT AGCACATGTT TGTAATCCCA GCAGACATGT GGGGAGACAA AGGAATGGAC 4680
 TCAGACTCAG CCGGAGAGCA AGTTCACGGC TAGACTGGAC CATTCCTACA ATGAGGTAGG 4740
 AATTGGGGTT AGCACATCAA GTAAGTAACC CTGGAAACAA GTTTGACTTG TCCAAGGTCA 4800
 CACAGCAATG TCTGGAAAGC TAAGTCTGGT TCCAAGGCCC CCCCTTCCTC CCTCTCTCCC 4860
 TCTCTATAAT TGAAAAGTCC ACTGCTTGGC AAAAAGTCCC AGGACTATAT TAAACACAAA 4920
 TGCTGGTGTT CTCCATGTCT TAGGGCTTTT ATCCTAGAAG GAATTCAAAC ACACAACACG 4980
 AATACCCAC AGAAAGGAGG GCAGGGTGGG GGGGTAAGGG AGAGAGGAGG AACTTCAGGC 5040
 TACTGGGGGT ATTAACCAGC TCTGTACCCC ATCCACACAG ACCCAAGTTA GAAAAGAGCA 5100
 GGAGAGGGGG TCTGGAGAGG TTGT TAACTG GCCCAGCAGT TTGGCCTGCT CTTGCAGGGG 5160
 CCCAGCTCTG TTCCCAGCAC CCATTTAGT GGCTCACAAC TTTTAACTCC AGCCCCAAGG 5220
 ACTCTGCTTC CCTCTGAGAG CTCTGTACTT AACAGGGACA CACAGACACA TACAATTTAA 5280
 AAAATGTTTT AAAGTGAGAG ACGCTCTAGA CAGGCTAGCA AGTATTGAGT TGTGGCAGGT 5340
 ACAGCTATTT TAATAGTGAT TTCAGGTTAG AACCTGGGG AGGGGAACC AGGAGTTAAA 5400
 CTATGTTAAA TCAGAAAGAC CCAAAGCCAA TCTGGTGGAA GCTGCCATTG GAGGTTCTAA 5460
 CAAGTCTGGC TTGTCAGGGA AAGGCTCAGA ATGAAGGTTT GAGCTGGGGC ATCATTAGTG 5520

TATAAAAAGT	ATGAAAACAC	TCTAGGAAGA	AGACAAGAGG	AGGAACACCA	CGGAGAGCGA	5580
GCCTTACGAT	GTTCCAGCAC	GTAGACGCCA	AAGTGAAGCC	AGGAAACCAA	GCACAGGGAC	5640
CAGGAAAGCC	CAAAGTTCAT	TGTGAAAAGG	ACAAAGGCTT	CATCCTGGGA	AACTAGGCTG	5700
GGAGAGGCCG	TGTTAAATAA	AGACAGACAC	ACCCATCAAA	ATGACCCACA	GAGGGCTTCA	5760
TGATTACAAT	AGTATTTTCAT	AGGCGGATTT	GGGCAGAAAT	CTGAATGCAG	GGGATTACAG	5820
AGTAAATGCT	GACTTTTGGG	TAAGAATGGC	AGATCACAGG	ACAGGTGTGT	GACTCACATC	5880
TTTAAAGCAC	ACTCCCAGGG	CAGAGGTAGT	GAGTTTGAGT	TTAGGGGGCTA	GTCTGGTCTG	5940
GACTGGAAAT	TCTATGAGAC	CCTGTTCTCA	AAAATAAAG	TATTTGGGAA	AAAAGAACTT	6000
CTGAGGGAAA	TGGAGGCCGT	GTAGGTCTCT	CTGGGAGCCC	GTGCGGCAGG	TGGCGAGGGA	6060
GGATCTGAAA	TGGGGAGAGT	CAGCAGACTG	CTGGACCTTT	CCTAGCCAGC	AGAGATGCTA	6120
AGGCAGGTGA	AGATTAGGTC	TCATGGACCT	GACACCCGTG	CACACAGGCA	GCATGGCGCC	6180
TTCAAAGCTC	TAGTGGATGT	GATTGCCCCA	GACAAGTCTG	CCCCAAAGCT	CATCTTCGTC	6240
CATTAATAGA	AAAAAGGTTT	CTTCTGACCA	AGGAAGCTGT	TCTCTCTGGA	AAACAATCAC	6300
TTAACAAGGA	CATTACTAAC	ACGAAGCTGC	TGTCCGATCA	CATCACCATG	ACGCAAGCAC	6360
TTCCCTTGGG	GTTCATACGC	AGTGACTCAG	TGCTCACGAC	CCTGTGCTAG	GCTTGGCCCT	6420
CACTCCTTTT	CCGCTGGAAT	TAAGTGGGGA	GTCAGACACC	CCAGAGGACC	TGCCCAAGCC	6480
AGAAAGCTTC	AAGCCACAGG	AGCCAGTGTG	TCCTTGGCTT	CCCTACACAT	GAGCTGTCTC	6540
TTATCCTCGA	TCGAGGGCCT	CACAGTCATT	CCTGAAAAGA	TCTGGCCCCC	AGCCCTGAGT	6600
ATGGAAGGCT	AACTTGGCTA	CCAGTCCCCA	CTGTCTTAT	TAGGAAGAGG	CAAAACCGTC	6660
CTCTGGCACT	CTCTTGAAGC	ATACTGGTAT	ATCCGAGAGA	GGTAACAGGA	GCCGATGGGA	6720
GCTGGGAGGG	TCCTGGCCTA	GGCATAGTCT	AGAAGACTTG	GGCTAAGTAG	TCTGGGTCCC	6780
CAAACCATAA	CATTTTTCTG	GTGACTAAAG	AAAAGGAGTC	TGTAAGCCTA	AAGCAGAATG	6840
TGGTGATACA	CGCCTACAGT	CCTAGCACTG	GAGAGGTGGA	GATAGAAAGA	TCAAGAGTTC	6900
AATGCCAGCT	TTCTGCTATG	TAGTAAGGTC	AAGGTCAGCC	TGGAATAAAC	GACTGCCTTA	6960
GAAACAACCA	AATGACTTAC	CGTCTAAAGT	CAGGAACTAC	ACTTGCTTTC	TCAGACTGTG	7020
TCTGTCTGTC	TGGGGCTCCT	CCCATTTCCT	CTCCTAACAA	CATCCACTTC	CACTCCTGCC	7080
TTAGATCTGA	GATAGTACCA	GCCTCAGGGC	ATGGGGTCTC	CCCATAGCTT	TTCTCTGCA	7140
GTACTGTGGG	CTCACCTAGG	ACTGTTTCTG	AACTATATCC	TACCCTAGCT	CTCTACCCTA	7200
GAAGGCCTGA	AACTCACAGA	AATTCTCCTG	CCTCTGCTTT	CCAATGGCTG	GGGTAAAAAG	7260
CATGTGTCAC	AACTGTCCTT	TTTATTCTTT	TAATATCGAG	ACAGGGTCTC	ACCAAGTTGC	7320
CCCAAGACGC	CAGCCACACC	TGGGACAGGG	CAGGCCTTTG	GCTCTATGTT	CAGTCTTGAC	7380

TCCATGACTG TGGCCGCTAG CCCATGAGGC TGCGCGTGGG AATTTCTTC TGAAAGCTCA 7440
 CCTGGTATCG ATGCTTCCTC TTATCCTACA CCACAACTAA CAAACCTGCC CCACCTCCTG 7500
 GTCCTGACCC TGCTGCAGAC CTGCTAGTCC TTGGTGAATG AGACCTGGGG ACCCCTCTAG 7560
 TCTGTTGAGA GCTGCTGAAA TGCTCAACTA TGATTTCCAG GTGACCCTCA AGTCGGCTCA 7620
 CCTCCCTGAT TGCACAGCAC CAATCACTGT GCGGGTGGCT CCCGTCACAC GGTGGCCAGT 7680
 GACAGCCTGA TGGCTGGCTC CCCTCCTCCA CCACCCTCTG CATTGACAGG CCCACGTGTG 7740
 TCCCCAGATG CCTGAATCAC TGCTGACAGC TTGGGACCTG TCAGCTGTGG GCTCCTGGGG 7800
 AGCCACTGGG GAGGGGGTTA GCAGCCACGC TGTCGCTCTC TAGCCAACAC CTGCAGACAT 7860
 AAATAGACAG CCCAGCCCGC TCAGGCAGCA GAGCAGAGCT GCACGACGCG TCGATCCCAA 7920
 GGCCCAACTC CCCGAACCAC TCAGGGTCTT GTGGACAGCT CACCTAGCTG CAATGGCTAC 7980
 AGGTAAGCGC CCCTAAAATC CCTTTGGCAC AATGTGTCCT GAGGGGAGAG GCAGCGACCT 8040
 GTAGATGGGA CGGGGGCACT AACCCTCAGG GTTTGGGGTT CTGAATGTGA GTATCGCCAT 8100
 CTAAGCCCAG TATTTGGCCA ATCTCAGAAA GCTCCTGGCT CCCTGGAGGA TGGAGAGAGA 8160
 AAAACAAACA GCTCCTGGAG CAGGGAGAGT GTTGGCCTCT TGCTCTCCGG CTCCCTCTGT 8220
 TGCCCTCTGG TTTCTCCCA GGCTCCCGGA CGTCCCTGCT CCTGGCTTTT GGCCTGCTCT 8280
 GCCTGCCCTG GCTTCAAGAG GGCAGTGCCT TCCCAACCAT TCCCTTATCC AGGCTTTTTG 8340
 ACAACGCTAT GCTCCGCGCC CATCGTCTGC ACCAGCTGGC CTTTGACACC TACCAGGAGT 8400
 TTGTAAGCTC TTGGGGAATG GGTGCGCATC AGGGGTGGCA GGAAGGGGTG ACTTTCCCCC 8460
 GCTGGAAATA AGAGGAGGAG ACTAAGGAGC TCAGGGTTTT TCCCGACCGC GAAAATGCAG 8520
 GCAGATGAGC ACACGCTGAG CTAGGTTCCC AGAAAAGTAA AATGGGAGCA GGTCTCAGCT 8580
 CAGACCTTGG TGGGCGGTCC TTCTCCTAGG AAGAAGCCTA TATCCCAAAG GAACAGAAGT 8640
 ATTCATTCTT GCAGAACCCC CAGACCTCCC TCTGTTTCTC AGAGTCTATT CCGACACCCT 8700
 CCAACAGGGA GGAAACACAA CAGAAATCCG TGAGTGGATG CTTTCTCCCC AGGCGGGGAT 8760
 GGGGGAGACC TGTAGTCAGA GCCCCGGGC AGCACAGCCA ATGCCCGTCC TTGCCCCCTGC 8820
 AGAACCTAGA GCTGCTCCGC ATCTCCCTGC TGCTCATCCA GTCGTGGCTG GAGCCCGTGC 8880
 AGTTCCTCAG GAGTGTCTTC GCCAACAGCC TGGTGTACGG CGCCTCTGAC AGCAACGTCT 8940
 ATGACCTCCT AAAGGACCTA GAGGAAGGCA TCCAAACGCT GATGGGGGTG AGGGTGGCGC 9000
 CAGGGGTCCC CAATCCTGGA GCCCCACTGA CTTTGAGAGA CTGTGTTAGA GAAACACTGG 9060
 CTGCCCTCTT TTTAGCAGTC AGGCCCTGAC CCAAGAGAAC TCACCTTATT CTCATTTCC 9120
 CCTCGTGAAT CCTCCAGGCC TTTCTCTACA CTGAAGGGGA GGGAGGAAAA TGAATGAATG 9180

AGAAAGGGAG	GGAACAGTAC	CCAAGCGCTT	GGCCTCTCCT	TCTCTTCCTT	CACTTTGCAG	9240
AGGCTGGAAG	ATGGCAGCCC	CCGGACTGGG	CAGATCTTCA	AGCAGACCTA	CAGCAAGTTC	9300
GACACAAACT	CACACAACGA	TGACGCACTA	CTCAAGAACT	ACGGGCTGCT	CTACTGCTTC	9360
AGGAAGGACA	TGGACAAGGT	CGAGACATTC	CTGCGCATCG	TGCAGTGCCG	CTCTGTGGAG	9420
GGCAGCTGTG	GCTTCTAGCT	GCCCGGGTGG	CATCCCTGTG	ACCCCTCCCC	AGTGCCTCTC	9480
CTGGCCCTGG	AAGTTGCCAC	TCCAGTGCCC	ACCAGCCTTG	TCCTAATAAA	ATTAAGTTGC	9540
ATCATTTTGT	CTGACTAGGT	GTCCCTTCTAT	AATGACGCGT	CGTGCCCACC	TATGCTCGCC	9600
ATGATGCTCA	ACACTACGCT	CTCTGCTTGC	TTCCTGAGCC	TGCTGGCCCT	CACCTCTGCC	9660
TGCTACTTCC	AGAACTGCCC	AAGAGGAGGC	AAGAGGGCCA	CATCCGACAT	GGAGCTGAGA	9720
CAGGTACCAC	TGTGGTCCGT	TCAGGGCTGC	TGACAGTGCC	GTAGGAAGGG	TCATGGGCTA	9780
GGAGAGAGGG	AAACCTTGTC	TGAGCAGTCA	GACTTTAGGG	GAGGTTCTTG	GAAGGAAGCA	9840
GTTATCTTAT	ATGGAGTAGA	TGGGTTTCCC	AGAACGGTAA	GAGGGGACCA	GGTGCCAGAG	9900
AAGCCACATA	AAGGACAGTG	TCCCCAGGCA	GGGGATATGC	CAGAAAATGA	GAGATACTTA	9960
TCACTGGGCT	TGGGATGAGA	ACGGGTAAAA	CTGGGTACCC	TGGCCTCCTC	TGCACAGCTG	10020
GAGGTGGCCG	GTGGTATGTT	GGCTCACCAG	GACTGGGTAG	ATGGTACGAA	ACTGTTCTCG	10080
CCTGAGTACA	AAGCCTTTCC	CACCCAGCTC	AAACTCTCTT	AGCTCCTTTT	TTAGCCAGCT	10140
GCACCGGTTT	CTTCCTGTCC	ACGGAAGACG	GCCATTGCCC	TGTGTCTGAG	CGGAGTATGT	10200
CCCACATCTA	GCCTCAGCCT	CGTGCCCAGA	TCTGCTGTAC	TGTATGTTCA	GCTCTGAGTC	10260
TGCCCTTCCG	GCAGGGCTGA	AGGGAATCCA	GTCACTAGGC	TCAAATCTGG	TCAGGTCACA	10320
GGTGGCTCAG	TTTTGAACAA	GCTCGATGGG	CAGTAGGCAG	TTACCCGAGT	CTGCCTTCCG	10380
TTTGCTGAGT	TCCTTTGGAG	ACTTCCGAGG	CACTAGGTGT	GTCTTGCAAC	CATCAGCCTA	10440
ATTCGGTCCT	TGCCACCTTC	CTACTAGGGC	ATAATAGGTT	GGCGGGAGGT	AAAAGCCCAC	10500
CAGCGTGGGG	CAGGGGTAAG	AGTGAGCGAG	CCGTAGGTAC	AGGAAAGAGG	ATCTTGGAAT	10560
GTGTAGGGCC	ATCTGAATGT	CGGAGAGGTA	AGTCTCTGAG	AGACTGCTGC	ACACCGGTGA	10620
CACATCAGAG	CTGAGGAGGT	CCCCCAAGTG	TTGTCTCCCC	CGCCCCCGGC	CCCATACGAC	10680
TCTGTCAAAG	CAGGAGAGGG	TTTTGAGACC	TCATGAGAAC	TGATCCTCCT	GATAACCTAG	10740
CCGGTTAGAT	TTCCACTCTC	GCCCTTTACG	GCTGCTTCGT	CCTAGATAGA	GCCAGAGCAT	10800
CTGGCCGGTG	AAGCTGGGAT	AGCAGCAGGG	TGACCTTAGG	TTCCCAACGC	CCCTCTTGGC	10860
CTGGCTCCAG	CTGACCCGCG	TCCTTCCCCG	CAGTGTCTCC	CCTGCGGCCC	TGGCGGCAAA	10920
GGGCGCTGCT	TCGGGCCGAG	CATCTGCTGC	GCGGACGAGC	TGGGCTGCTT	CCTGGGCACC	10980
GCCGAGGCGC	TGCGCTGCCA	GGAGGAGAAC	TACCTGCCCT	CGCCCTGCCA	GTCTGGCCAG	11040

AAGCCTTGCG GAAGCGGAGG CCGCTGCGCT GCCGCGGGCA TCTGCTGCAG CGATGGTGCG	11100
CACAAAGCCA GCGGGGCTGA GCATGGGGAA TGGATGGGGT GGGTGGGAGG TAAAGGGGGG	11160
CTAAGTGGGG GACTGAGGAA TCAGGACCGG AGATGGAGGG TGAGTAGTAT GAAGGGGGTC	11220
GAGAGTTGGA ACGTAGCAGG GTAGGATAAA GGGGATTGTG GGGATGGCGC CCCTATAGGT	11280
GCGCCCACCC CAGGACGCCT GACCTCACAC AGCCCTTCCT TCAGAGAGCT GCGTGGCCGA	11340
GCCCCAGTGT CGAGAGGGTT TTTTCCGCCT CACCCGCGCT CGGGAGCAGA GCAACGCCAC	11400
GCAGCTGGAC GGGCCAGCCC GGGAGCTGCT GCTTAGGCTG GTACAGCTGG CTGGGACACA	11460
AGAGTCCGTG GATTCTGCCA AGCCCCGGGT CTA CTGAGCC ATCGCCCCC ACGCCTCCCC	11520
CCTACAGCAT GGAAAATAAA CTTTAAAAA ATGCACCCTG GTGTCTGTCT CTCTTCTGG	11580
GGTGGGGAGA AAAGGGGGGA GAGGAATTGG AGTGGGA ACT TTCTACTCTG CTCTGACTGA	11640
TCCCCACATC CAAAGTCGTG CATAAGATAC GCCCCACCG CCAGAAGGGG CAGAACCTAT	11700
AAGTCTTAGA GTATAAAGGA AGCTTCTGCT GCTCCTGGAT ACCCACATAA TACTCAGAAA	11760
AAAAGGCAAG TCAGAAGAAG GGAAAGATCT GAGATCCAGA GGAGCCTGAA GGGTCAGGGT	11820
GACTTAGCAA GTTCTATCT GAGACCGAAA TAAAAGGACA TTGTGGACAA GAGAAACAGA	11880
GCAGGACATG AGGAGAGACA GGATCAGCAA GAGTGACAGA GAAAGAGGGG ACAGGCCAGG	11940
GGTGGCCATC TCAGCCCTGA TTTCACCCAG ACTAAGGCAA AAACAACGTG AAGGACTCTT	12000
AACCAAGGCT GTGCTTGGAT GGGAGGAGAA GGTACAGAGA CATTACCCCA GACCTAAAGA	12060
AGACAATGCC ACCCGCCTTC TCTCCAGGTG CTCCACCATC AAGACCCAGC CACTGAGAGG	12120
CAGACTCCAG TAAGAGTCCA GCTACAAGTC CTCTACAGGC ACATGTTCAA ACCGTCACAC	12180
CCCACTCAG GCAGGGAAAT AGACAAGATA GGCTGGAGTT GTGGCTCAGG AGCAGAAGTC	12240
TTCCCTAGCT ATGGTTCCAG CACCATGGAG ACGGAAGGGG GACTGAGCGG GGGGGGGGGC	12300
GGGGGGGAGG AAAAAGTAGC AGCTACTAGG GGCATTTCTA TGACCCTTGT CCTCAACCAT	12360
AGCTAGAGAC CCAGAGGAAC ACAGAAGTCC AGCAGCAAGG CGCACATGCT TGCAATAGCT	12420
CCCAGACGTA AATACTTCAT TCCGTTCCGC ACATCCGGGT CATCAGCACT TGA CTCCCC	12480
CCCCACACTT CTTATTACCT CCTCTTTTT CTAAAATTTT AGATTTATTC ACTTATGTAG	12540
ATGGGTGTTT TTGGTTTTGT ATGAATGTCT GAGCACCATG TGTGTGCCTG GCGCCTCAGA	12600
GGTCAGGAGA GGGCATCGGG TCCCCTGGAA CTAGTTACAG GTGGTTACAG CCTACCGTGT	12660
GGGCACTAGG AACTGAATCC CAGTCCTCTT AACTGACCCG CACATCCAAA CCCAGGCTTC	12720
AGCCCCTCAT CAGCCTGTCC CTCCTCCAGG CCCTCAGGTG TCTCCCGTCT CCGGCTGCTC	12780
TCCCAGACAT CCTTCCATCC TCTGGTCTCC CTGCTCCTCG CCCTCCTGTT AACATCCTTT	12840

CTCTCTGCCC	CATCTGTCCCT	GGGCATCCTC	TCTTGCGAGC	TGCAGCAAGG	TCAGGATGGT	12900
TTACCTCATT	TGGGATGGCC	TGCAGGTTCT	GAGGTCAGGG	GCAACTACAG	AGAAGAGAGA	12960
GATTAGTCTG	ATTGACTTAA	GGTGGTTCAG	CAAGGTCAGC	TCTGCCCAGA	CTCACGGTCT	13020
TTTACCCAGA	TGCCAGCTCT	CTTCCCATCT	CCTCGGTGCC	TATACACCTC	TCTGCATGCC	13080
CCGGTTTAGA	CAGGTAGCAC	AGGGGCCAGG	CAGACTCCTA	TCCCAGCCTC	CTCCTTCTGT	13140
GGCCCTCTTA	GGGTCTGACC	TCCAATAGGG	CAGGGCCAGG	GAAGGGCCAG	ACCAAAAAGG	13200
GACAGAAAGA	AGCGTGGCAG	GCGGCATGGG	CACACTTGAT	TCAACCCCTA	CGGCTGGTGT	13260
ATGGGCAGCT	TTAGAATGAA	GGTCAGATTC	TCACTTCGAG	CCTCTGCGCA	GGTGGAGTGT	13320
TGTAAGCGTC	TCGCTTTCCT	CCACCTGTTT	CTGGAAGAAT	CAGGCTCCTC	TTCCTCGAGG	13380
AGAGAATTAT	ACCTGCTCAC	CCTACTTCTG	CCTACTGGAC	ATAATATATA	TTTTTTTCCT	13440
TTCAGGGAGT	CCTTTCCTCA	GCTACAGAGC	CATTTAAGGG	CACTCCCAGA	G TTCACAGCA	13500
GATGCTTGCC	TCCTCTCTTC	AGCCTCCAGA	AGCAGAGAGG	CTTGTGAGCA	AATGCCAGGA	13560
CCTCTGACCT	CCACAÇAGAC	GCTGTGCTGT	GTGCACAGCC	CTCAAGCACA	CAGCGAAGCA	13620
ATAGTGAAAA	GTAACCTAGA	CCATTTTCAG	GCTGGGGAGA	TGGCTCAGGA	GATAAGAGAT	13680
CACTGCTCAA	CTTGAGCCTC	GGGACCACAG	GTAAGACCAA	CTTGTCTGCT	GCAAGAGAGC	13740
TGCCTGGTGA	GATTGGGACA	CACAGAGGCA	GAGTTCATCT	AGGACCGGGC	ACGTCTCTGTG	13800
TTTGCCGAGG	TCCCACACCC	GCGGATCCCG	GCCCCGAGCA	GCTCTCTGCT	CCCAGAACCC	13860
GTGAGAAAGA	GACCTCACCG	CCTGGTCAGG	TGGGCACTCC	TGAGGCTGCA	GAGCGGAAGA	13920
GACCACCAAC	ACTGCCCACC	CCTGCCCACA	TCCCTGGCCC	AAGAGGAAAC	TGTATAAGGC	13980
CTCTGGGTTC	CGTGGGGGAG	GGCCCAGGAG	CGTCAGGACC	CCTGCCTGAG	ACACCGCCGG	14040
AACCTGAGGG	AAACAGACCG	GATAAACAGT	TCTCTGCACC	CAAATCCCAT	GGGAGGGAGA	14100
GCTGAACCTT	CAGAGAGGCA	CACAAGCCTT	GGAAACCAGA	AGAGACTGCT	CTCTGTACAT	14160
ACATCTCGGA	CGCCAGAGGA	AAACACCAAA	GGCCATCTGG	AACCCTGGTG	CACTGAAGCT	14220
CCTGGAAGGG	GCGGCACAGG	TCTTCCTGGT	TGCTGCCGCC	ACAGAGAGCC	CTTGGGCAGC	14280
ACCCCGCCTG	GTGAACTCAA	GACACAGGCC	CACAGGAACA	GCTGAAGACC	TGCAGAGAGG	14340
AAAAACTACA	CGCCCGAAAG	CAGAACACTC	TGTCCCCATA	ACGGA CTGAA	AGAGAGGAAA	14400
ACAGGTCTAC	AGCACTCCTG	ACACACAGGC	TTATAGGACA	GTCTAACCAC	TGTCAGAAAT	14460
AGCAGAACAA	AGTAACACTA	GAGATAATCT	GATGGTGAGA	GGCAAGCGCA	GGAACCCAAG	14520
CAACAGAAAC	CAAGACTACA	TGGCATCATC	GGAGCCCAAT	TCTCCCACCA	AAACAAACAT	14580
GGAATATCCA	AACACACCAG	AAAAGCAAGA	TCTAGTTTCA	AAATCATATT	TGATCATGAT	14640
GCTGCAGGAC	TTCAAGAAAG	ACGTGAAGAA	CTCCCTTAGA	GAACAAGTAG	AAGCCTACAG	14700

AGAGGAATCG CAAAAATCCC TGAAAGAATT CCAGGAAAAC ACAATCAAAC AGTTGAAGGA 14760
 ATTAAAAATG GAAATAGAAG CAATCAAGAA AGAACACATG GAAACAACCC TGGATATAGA 14820
 AAACCAAAGG AAGAGACAAG GAGCCGTAGA TACAAGCATC ACCAACAGAA TACAAGAGAT 14880
 GGAAGAGAGA ATCTCAAGAG CAGAAGATTC CATAGAAATC ATTGACTCAA CTGTCAAAGA 14940
 TAATGTAAAG CGGAAAAAGC TACTGGTCCA AAACATACAG GAAATCCAGG ACTCAATGAG 15000
 AAGATCAAAC CTAAGGATAA TAGGTATAGA AGAGAGTGAA GACTCCCAGC TCAAAGGACC 15060
 AGTAAATGTC TTCAACAAAA TCATAGAAGA AAAGTCCCT AACCTAAAAA AAGAGATACC 15120
 CATAGGCATA CAAGAAGCCT ACAGAACTCC AAATAGATTG GACCAGAAAA GAAACACCTC 15180
 CCGTCACATA ATAGTCAAAA CACCAAACGC ACAAATAAAA GAAAGAATAT TAAAGCAGT 15240
 AAGGGAAAAA GGTCAAGTAA CATATAAAGG CAGACCTATC AGAATCACAC CAGACTTCTC 15300
 GCCAGAAACT ATGAAGGCCA GAAGATCCTG GACAGATGTC ATACAGACCC TAAGAGAACA 15360
 CAAATGCCAG CCCAGGTTAC TGTATCCTGC AAAACTCTCA ATTAACATAG ATGGAGAAAC 15420
 CAAGATATTC CATGACAAAA CCAAATTTAC ACAATATCTT TCTACAAATC CAGCACTACA 15480
 AAGGATAATA AATGGTAAAG CCCAACATAA GGAGGCAAGC TATACCCTAG AAGAAGCAAG 15540
 AAATAATCG TCTTGGCAAC AAAACAAAGC GAATGAAAGC ACACAAACAT AACCTCACAT 15600
 CCAAATATGA ATATAACGGG AAGCAATAAT CACTATTCCT TAATATCTCT CAACATAAAT 15660
 GGCTTAACT CCCCAATAAA AAGACATAGA TTAACAACT GGATACGCAA CGAGGACCCT 15720
 GCATTCTGCT GCCTACAGGA AACACACCTC AGAGACAAAG ACAGACATTA CCTCAGAGTG 15780
 AAAGGCTGGA AAACAATTTT CCAAGCAAAT GGTCAGAAGA AGCAAGCTGG AGTAGCCATT 15840
 CTAATATCAA ATAAAATCAA TTTTAACTA AAAGTCATCA AAAAAGATAA GGAAGGACAC 15900
 TTCATATTCA TCAAAGGAAA AATCCACCAA GATGAACTCT CAATCCTAAA TATCTATGCC 15960
 CCAAATACAA GGGCACCTAC ATATGTAAAA GAAACCTTAC TAAAGCTCAA AACACACATT 16020
 GCACCTCACA CAATAATAGT GGGAGATTTC AACACCCAC TCTCATCAAT GGACAGATCA 16080
 TGGAAACAGA AATTAAACAG AGATGTAGAC AGACTAAGAG AAGTCATGAG CCAAAGGGAC 16140
 TTAACGGATA TTTATAGAAC ATTCTATCCT AAAGCAAAAG GATATACCTT CTTCTCAGCT 16200
 CCTCATGGTA CTTTCTCCAA AATTGACCAT ATAATTGGTC AAAAAACGGG CCTCAACAGG 16260
 TACAGAAAGA TAGAAATAAT CCCATGCATG CTATCGGACC ACCACGGCCT AAAACTGGTC 16320
 TTCAATAACA ATCAAGGAAG AATGCCATA TATACTTGGA AACTGAACAA TGCTCTACTC 16380
 AATGATAACC TGGTCAAGGA AGAAATAAAG AAAGAAATTA AAAACTTTTT AGAATTTAAT 16440
 GAAATGAAG GTACAACATA CCCAACTTA TGGGACACAA TGAAAGCTGT GCTAAGAGGA 16500

AAACTCATAG CGCTGAGTGC CTGCAGAAAG AAACAGGAAA GAGCATATGT CAGCAGCTTG	16560
ACAGCACACC TAAAGCTCT AGAACAAAA GAAGCAAATA CACCCAGGAG GAGTAGAAGG	16620
CAGGAAATAA TCAAACTCAG AGCTGAAATC AACCAAGTAG AAACAAAAGG ACCATAGAAA	16680
GAATCAACAG AACCAAAAGT TGGTTCTTTG AGAAAATCAA CAAGATAGAT AAACCCTTAG	16740
CCAGACTAAT GAGAGGACAC AGAGAGTGTG TCCAAATTAA CAAAATCAGA AATGAAAAGG	16800
GAGACATAAC AACAGATTCA GAGGAAATTC AAAAAATCAT CAGATCTTAC TATAAAAACC	16860
TATATTCAAC AAAACTTGAA AATCTTCAGG AAATGGACAA TTTTCTAGAC AGATACCAGG	16920
TACCGAAGTT AAATCAGGAA CAGATAAACC AGTTAAACAA CCCCATAACT CCTAAGGAAA	16980
TAGAAGCAGT CATTAAAGGT CTCCCAACCA AAAAGAGCCC AGGTCCAGAC GGGTTTAGTG	17040
CAGAATTCTA TCAAACCTTC ATAGAAGACC TCATACCAAT ATTATCCAAA CTATTCCACA	17100
AAATTGAAAC AGATGGATCA CTACCGAATA CCTTCTACGA AGCCACAATT ACTCTTATAC	17160
CTAAAAACA CAAAGACACA ACAAAGAAAG AGAACTTCAG ACCAATTTCC CTTATGAATA	17220
TCGACGCAAA AATACTCAAC AAAATTCTGG CAAACCGAAT CCAAGAGCAC ATCAAAACAA	17280
TCATCCACCA TGACCAAGTA GGCTTCATCC CAGGCATGCA GGGATGGTTT AATATACGGA	17340
AAACCATCAA CGTGATCCAT TATATAAACA AACTGAAAGA ACAAACCAC ATGATCATTT	17400
CATTAGACGC TGAGAAAGCA TTTGACAAAA TTCAACACCC CTTCATGATA AAAGTCCTGG	17460
AAAGAATTGG AATTCAAGGC CCATACCTGA ACATAGTAAA AGCCATATAC AGCAAACCAG	17520
TTGCTAACAT TAACTAAAT GGAGAGAAAC TTGAAGCAAT CCCACTAAAA TCAGGGACTA	17580
GACAAGGCTG CCCACTCTCT CCCTACTTAT TCAATATAGT TCTTGAAGTT CTGGCCAGAG	17640
CAATCAGACA ACAAAGGAG GTCAAGGGGA TACAGATCGG AAAAGAAGAA GTCAAAATAT	17700
CACTATTTGC AGATGATATG ATAGTATATT TAAGTGATCC CAAACATTCC ACCAGAGAAC	17760
TACTAAAGCT GATAGACAAC TTCAGCAAAG TGGCTAGGTA TAAAATTAAC TCAAATAAAT	17820
CAGTTGCCTT CCTCTATACA AAAGAGAAAC AAGCCGAGAA AGAAATTAGG GAAACGACAC	17880
CCTTCATAAT AGACCCAAAT AATATAAAGT ACCTCGGTGT GACTTTAACA AAGCAAGTAA	17940
AAGATCTGTA CAATAAGAAC TTCAAGACAC TGAAGAAGGA AATTGAAGAA GACCTCAGAA	18000
GATGGAAAGA TCTCCCGTGC TCATGGATTG GCAGGATTAA TATAGTAAAA ATGGCCATTT	18060
TACCAAAGC AATCTACAGA TTCAATGCAA TCCCCATCAA AATACCAATC CAATTCTTCA	18120
AAGAGTTAGA CAGAACAATT TGCAAATTCA TCTGGAATAA CAAAAACCC AGGATAGCTA	18180
AAGCTATCCT CAACAATAAA AGGACTTCAG GGGGAATCAC TATCCCTGAA CTCAAGCATG	18240
ATTACAGAGC AATAGTGATA AAAACTGCAT GGTATTGGTA CAGAGACAGA CAGATAGACC	18300
AATGGAATAG AATTGAAGAC CCAGAAATGA ACCCACACAC CTATGGTCAC TTGATTTTTG	18360

ACAAAGGAGC	CAAAACCATC	AAATGGAAAA	AAGATAGCAT	TTTCAGCAAA	TGGTGCTAGT	18420
TCAACTGGAG	GTCAACATGT	AGAAGAATGA	AGATCGATCC	ATGCTTGTCA	CCCTGTACAA	18480
GCTTAAGTCC	AAGTGGATCA	AGGACCTCCA	CATCAAACCA	GACACACTCA	AACTAATAGA	18540
AGAAAACTA	GGGAAGCATC	TGGAACACAT	GGGCACTGGA	AAAAATTTCC	TAAACAAAAC	18600
ACCATGGCTT	ACGCTCTAAG	ATCAAGAATC	GACAAATGGG	ATCTCATAAA	ACTGCAAAGC	18660
AACTGTAAGG	CAAAGGACAC	TGTGGTTAGG	ACAAAACGGC	AACCAACAGA	TTGGGAAAAT	18720
ATCTTTACCA	ATCCTACAAC	AGATAGAGGC	CTTATATCCA	AAATATACAA	AGAACTCAAG	18780
AAGTTAGACC	GCAGGGAAAC	AAATAACCCT	ATTAAAAAAT	GGGGTTCAGA	GCTAAACAAA	18840
GAATTCACAG	CTGAGGAATG	CCAAATGGCT	GAGAAACACC	TAAAGAAATG	TTCAACATCT	18900
TTAGTCATAA	GGGAAATGCA	AATCAAAACA	ACCGTGAGAT	TTCACCTCAC	ACCAGTGAGA	18960
ATGGCTATGA	TCAAAAACCTC	AGGGGACAAC	AGATGCTGGC	GAGGATGTGG	AGAAAGAGGA	19020
ACACTCCTCC	ATTGTTGGTG	GGATTGCAAA	CTGGTACAAC	CATTCTGGAA	ATCAGTCTGG	19080
AGGTCCTCA	GAAAATTGGA	CATTGAACTG	CCTGAGGATC	CAGCTATACC	TCTCTTGGGC	19140
ATATACCCAA	AAGATGCCCC	AACATATAAA	AAAGACACGT	GCTCCACTAT	GTTCAATTGCA	19200
GCCTTATTTA	TAATAGCCAG	AAGCTGGAAA	GAACCCAGAT	GCCCTTCAAC	AGAGGAATGG	19260
ATACAGAAAA	TGTGGTACAT	GTACACAATG	GAATATTACT	CAGCTATCAA	AAACAACGAG	19320
TTTATGAAAT	TCGTAGGCAA	ATGGTTGGAA	CTGGAAAATA	TCATCCTGAG	TAAGCTAACC	19380
CAATCACAGA	AAGACATACA	TGGTATGCAC	TCATTGATAA	GTGGCTATTA	GCCCCAATGC	19440
TTGAATTACC	CTAGATACCT	AGAACAAATG	AAACTCAAGA	CGGATGATCA	AAATGTGAAT	19500
GCTTCACTCC	TTCTTTAAAA	GGGGAACAAG	AATACCCTTC	GCAGGGAAGA	GAGAGGCAAA	19560
GATTAAAACA	GAGAATGAAG	GAACACCCAT	TCAGAGCCTG	CCCCACATGT	GGCCCATACA	19620
TATACAGCCA	CCCAATTAGA	CAAGATGGAT	GAAGCAAAGA	AGTGCAGACC	GACAGGAGCC	19680
GGATGTAGAT	CGCTCCTGAG	AGACACAGCC	AGAATACAGC	AAATACAGAG	GCGAATGCCA	19740
GCAGCAAACC	ACTGAACTGA	GAATAGGACC	CCCGTTGAAG	GAATCAGAGA	AAGAACTGGA	19800
AGATCTTGAA	GGGGCTCGAG	ACCCCATATG	TACAACAATG	CTAAGCAACC	AGAGCTTCCA	19860
GGGACTAAGC	CACTACCTAA	AGACTATACA	TGGACTGACC	CTGGACTCTG	ACCTCATAGG	19920
TAGCAATGAA	TATCCTAGTA	AGAGCACCAG	TGGAAGGAGA	AGCCCTGGGT	CCTGCTAAGA	19980
CTGAACCCCC	AGTGAAGTAG	ACTGGTGGGG	GGAGGGCGGC	AATGGGGGGA	GGGTGGGGAG	20040
GGGAACACCA	TAAGGAAGGG	GAGGGGGGAG	GGGGATGTTT	GCCCGGATAC	CGAAAGGGAA	20100
TAACATCGAA	ATGTATATAA	GAATACTCAA	GTTAATAAAA	AAAAAAAAAA	AAAAAGAGAT	20160

CACTGCTCTT GCAGAGGCC	CCAGTTCTGT TCCCCACAAC	CTCTTAGGAT GACTCACAAC	20220
CACCTGTAAC CCCATTTT	CAG GGGATCTGAT GCCCTCTTCT	GGTCCCCATG GGCCTGCAC	20280
TCATTTACAA ATACTTTT	CAC ACAGAGACAC ATGCACAGAA	ATGGAAATTT AACAGAATAA	20340
ACATCGGAAC ATTAATAA	ACA AACAAAAACA AAACAAAAAA	CAAAAAAAC CCCATAGGAC	20400
TGGAGAGATG ACTCAGTGG	T TAAGAGCACT GACTGCTCTT	CCAGAGGTCC TGAGTTTAAA	20460
TCCCAGCAAC TACATGGT	G CTCACAACCA TCTGTAATGG	TCTCTTCTGG TGTGCCTGAA	20520
GACAGTGACA GTGTACCC	CAC ATACATGAAA TAAATAAATC	TTTAAAAAAA AAAAGCCCAG	20580
AAAGTGATGA ACTCTATT	AC CACCAAAAAG AAAAAAAGA	AAAAGAAAAA CTCAAATCAA	20640
TCTTGAAGTC TCTTTCGC	AT ATCTCTTTGG CCTCCACCCT	GTCTGTGGAT CCCACATGTG	20700
GGGGCGGTGG GGCATCTG	TG TTCATTTGCT GAGTGTGAGA	GCCACATAAA GTGCTGGTTT	20760
ACGTGTTTAC TTGTTTTCT	TA GATGGGATGG AGCCCAGGAC	CTTAACCTTG TGGGGCAAGA	20820
CTTGCTCTCC TGAGCTCT	AC CCAAGCAGTC TGGATTGCGG	GTTTCCTGTT TGTCTGTGAG	20880
CTCTCTGCTT TGTGGTCAT	T TGTGCCCCACT GGCTCTTAGA	TCCCATGACT TCCCAGAGAA	20940
CGCTGTCCTG CAGAGGCAG	A CACAGGGCCC CTGAGCTCAG	GCCCGGCCCT GGAGACAGAA	21000
ACGGAGAGGC CAGTTGATT	C TTGATATTTT CCGTTGTGGC	TTCTTGGGG CCTGTGTGAG	21060
AATTCAGCTC TGTAGAAAC	C TTATGGTTCT GCAACTACCC	TCCCCTGGCC AAGACCCTTT	21120
CTTCTAGCCC GGGATTACC	C CCTCAACCTC TGAGGTCGCC	GCCAAGGTCT CCTTCCAGAT	21180
ATGGAAGTGA CTGGATGAG	T CCCTTGCGGC CTGCGCTGCC	TTCCCATCAC CCAGGCCCT	21240
GTTTGGCTTT GCCCTTTCC	C ACAGAAAGTC ACCATTGCTG	TTTGGACTTC CAAATGGTGC	21300
TCCTAAGTCT GTCTGCCG	CA GGCCTTACCC CAGTCGGGAG	TGGGAAACGG GCCTAACTGG	21360
AGATGACAAC CTGTAGAG	A C C C C TCGGTCC TCCTAGCAGC	CTGCTGGGCT GTTCTCCCTC	21420
TGAATTGCCA ATGTCCAT	G GCGTTCCCGGT GCCTTTCTCTC	CCTCCCGTTT CTGACAATTA	21480
GACGCCAGTC AAGTTTGAA	A AGGAAATCTG CTTTATTTAT	TTATTTATGT TTTTTTTTTTA	21540
ATTTTTTTCT GGTAGTGG	C ATGGGGAACG AAGGAAGCGC	CCTAAAGGTA TCATCACAAA	21600
GCAGGGCTCA GCGGCCGG	T TCAGTGCTGG GAGAAGGCGG	CCTCAGGGTC GCAGGCGGGG	21660
TCCTCGTGGC AGCCGTCT	G CACAGAGAGAC GCCGAGTCAG	GGCCGCCCTG GCCCAGCCCG	21720
CCTGGTCCTG GAGCCCCG	G T CCCGTCTCGA CCCCTGCCCG	ACTCACCCGG GCTGCAGCAG	21780
ATGCCGGCGG CGGCGCAG	C G C C C C G C T C CCGCAGGGCT	TCTGGCCGGA CTGGCAGGGC	21840
GACGGCAGGT AGTTCTCT	C C T T T T G C A G C C CCGTGCCAC	GAAGCAGCCC	21900
AGCTCGTCCC CGCAGCAG	A T G C T G G G C C G A A G C A G C G G C	CTTTGCCCCC GGGGCCGAG	21960
GGGAGACACT GGTGGGAG	G G A A G G A T G A G C C G G G G G C G G	GAGGGGAGCG GCCGGGGAGG	22020

GAGACCCTGT GGGGCGGGGG GCTGAGCCGG GCGGGCGAGG GCGGCCGGAG GAGCGCGGGA 22080
 GGTGGCGGGT CTCCCTGGCT CTCTCTTTGG GCTCAAAGC GGTCTGAAGGA GGGCAGTCAA 22140
 AAGCTCCTCC GCTCCCTCGA TTCCCAGGCT AGGTGGGGCC GGTACGCGGT CAGCGCGGGA 22200
 AAGGGGGCGG CGGGGGCGAC CCTGTGGCAG CGGGCCGGGC AGCCCGGAGA GCCACGGGTC 22260
 GAGGGCGGGG CTCTCACCGT GCGCACGTGG AGGTCCAGCA CCGCGCGTTT GCCGCCAGG 22320
 GGGCAGTTCT GAATGTAGCA GGCGGAGGTC AACGCCAGGA GGCCGAGCAG GCAGCAGGCG 22380
 AGGCTGGAAC CTGCCATGGC GTTGGTGTTC AGTCCGAGAT CGGTCTGACCG ATCCACCGTC 22440
 GGTGATGGTT TCTCCAGCCC AGACCGACCT TTTTATGCCT TGTCCACTGC CATGGTGGGG 22500
 CCCAGTCTAA GAGGGTGA CTGACTGG TCACAGCCAG GTCTCTTGGG TCAAAGTGT 22560
 CCACACTGTT TAGAAGCAGG CCCTTCATTT GCAGGGTCTG GGCTGGGGTC AAGGTCACCG 22620
 CCTCAGCTAA TGACCTGAGC TCAAAAGGGA CACAGCCTAG AAGGGGAGGC CTAAGCTACA 22680
 AGAGGATAAA GAGACTTGGA GGGGGTAGAG GTGCAGCCTA GCCAAGAGCT GTTTTTTCAT 22740
 AGAAATCCAA TACCTCAGAA TGAGGTTGGA TAGCGCAAGT GGGTGAGGAA GCCCTTACGT 22800
 GGATCTAAAG CTTAGATGGG GAAAAGGATC TTGTTCAATC TCTGAGTGCA GCTCAGCCCT 22860
 TCTTCTAACT AGCCCGTAAA ACAAATATC AGTAGAAATC AAACCCAAAA ACACAACAAA 22920
 CAGACCAAAA TAAAGTAAAA AGAAAGAAAA ATCACAATAA AAGGAAAAAT CACTTTGCA 22980
 CTTACAAC TC TGTATTAGGG CTGGAGAGAT GGCTCAGTGG TTAGGAGCAC TGA CTGCTCT 23040
 ACCAAAGGCC CTGAGTTCAA ATCCCAGCAA CCATATGGTG GCTCACAACC ATCTGTAATG 23100
 GGATCTGATG CCCTCTTCTG GTGTGTCTGA AGAGAGCTAC AATGTGCTTA TATATAATAA 23160
 ATAAC TTAA AACTCTTTAA AACTCTGTAT TAGAACTTGC TATGAGGACC AGGCTGGCCT 23220
 TGA ACTCACA GTGATCTATT TGCTTCTGCC TCCCAAATGC TAGGTACCTA CACTCCCGTT 23280
 TGAGAAAACA CAGGCCATCA GCTGCTTGAG CGTGGCCAAC AGGCGGCCTC AGCTACAGAG 23340
 AGCCATTTGT CCTAAGGCCA TACCCTTCCT GGTGGCCACA TGTAATGGTG GCCCATTTTA 23400
 GTACATACAA CTAGGCATCT CGTGTTGCAT TTCAGGGTTG GGCTGCAGGC CTGCATAGGT 23460
 CTGCATGGGA AGAATGCTAC ATGCAGCTCA GTAGCAGACT GCCTGCCTAG TGTGTGAGAG 23520
 ACCTTGGGTC CAGTCCCCAG CATGGTGGTA GCAAGACATT TTGGGAACAG TTTTGTCTTT 23580
 AAATTTTAAC TTTTATTTGT GTGTATGTTT GTGTACACAG GTTTCCTTGG CAACCAGAAG 23640
 AGGATGTTGT ATCCCCAGGA CGTGTCATTA AAGGGGATCA TGAGTAGGCC TATGTGGGTG 23700
 CTGGGAACAA AATTCAGAAT TCTGCAAGAG CAGTGTGCAG ACTTAACCAT TAAGCCATCT 23760
 CCCCAGCTCC TTGATTTTGC ATTTGAATAC AGTTTAAAT GAAATGCACA TTAAGCCACG 23820

GTGACAGTGA	TGCAAACCTTT	TAATCCCAGA	ACTCAGGAGG	CAGAGGCAGG	AGAATGTCTG	23880
TGAGTTCCAG	GCCAGCCTGG	TCTACAGACC	TAGTTCCAGG	CCAGCCTGGG	CTACACAAAA	23940
AAACAAAAGC	AAAACCAAAA	CAAAATAAAG	ACACAGACAA	ACCATGGCAG	GAAGACATGG	24000
GAGCCTCAAC	CTCTTCATTT	GACGGCTGAG	AAATCGAAAA	CAGATGACCA	GGAGAGACCA	24060
AGGTCTCACT	GCTGCCTTCA	AGGCTTGCCC	TCAGTGACTG	GAAGATGTTT	CACTGGGCCG	24120
CATCTTAATA	TCTTACCATC	TCAGGGCTGG	AGAACTGGCT	GAGTGGTTGA	GTTGCTCTTG	24180
CAGAAGTCCT	AGGTTTGATT	CCGAGGACCC	ACAGGGTGCC	TGAGATCACT	TATCCCAGTT	24240
CCAGTGAGC	CAGTACCCAA	ATAGTGCACT	ACACACTTGC	AGGCAGAACG	TTCAGACACA	24300
TAAAATAAAA	TAAATAGACC	TAAAAACATT	TAAAAGAAAG	GAGAAGCATT	ATCCAGAGTC	24360
GTTTTATTTT	GTTTTGAGAT	AGACTCTTAG	TTGACCTGGG	ACTGTCTGTG	TAGACTAGGC	24420
TGGGCTTGAA	CTCACAGCGA	TCCCCCTGCC	TCCCAAAGTG	CTGGGTGTAC	CACCGTGCCA	24480
GGTACCTAGG	CCCCTGTTTA	AGAAAGACACT	TGCCATCAGT	GGCTGGGTGT	GGTCTTAGCT	24540
GCAGAAAGCC	ACCTGGCCCT	TCCCAGGTGT	CCACATATAA	TGGTTGGTCC	ACTTTGGTAC	24600
GAATGCTGGG	CACCCCAACT	GCATGTCAGC	TTTGGGCTTT	GGGTTAGCTG	AGGTCTGCAT	24660
ACTGGTTCTA	GTTGCCACCC	CCTTCTCTTC	CATAGAGGTG	GGGCCTAAGC	CCGTGTTCTA	24720
AACTCCATCT	CAGGCTCTCT	TAAGAAGTGA	CCTGCGACAT	CCAGGAAGAA	GTAACAGCCA	24780
GTGCCCCCGA	GACCCACTCA	CTACATGCAG	TCTCAGCCCC	TAGAGAGGAT	GGAAAAGCCT	24840
CCGGTCTCCT	TGTTCTTATG	ATCAGCCTTC	TCCTCAAGGA	GCTGGGGCCA	GTGGGGCAAA	24900
GCACATTCTC	TTCTGACCCT	GAATCACAGA	TCCTGAGTCA	CTGGTGCAAA	CTATCAAGCG	24960
CTAAGTTGGT	GGTGAGGTTG	ACCTGTACTA	CAAATCACTT	CATTTCTCAC	CCAGACTAGC	25020
TTATTGGCAT	TCCAGGCATA	GAAAGCCAAG	AGCTTGACCC	CCACTATAGC	CCCAGAGAGA	25080
CAGCCCACAT	AGTCTGTGGG	CATAGTGATC	TCATCTTAGG	TAATCCATGC	ACATAAATTA	25140
GCATGTCTTG	ATAATACATA	CCTAATGCTC	CTGTTAGGCC	AGCATGCCTA	ACATGCTCAC	25200
CAACCCAATC	TGTGTTTGGG	AAAGGCCAAT	ATTCCGCAAG	GCAGAATGCT	AGTCCTTCAG	25260
GAATGGGGCT	GCAGCTGGAC	TGGGGAGAAC	ACACTGAGGT	TATAAGAGGA	CCATTGAGGC	25320
CTAATAGCCA	AGGTAGAGTA	GGCGGAGCCT	TGGGTTACAG	TGTTCAGCAC	CAGGAGGAAA	25380
GAGTCACTAT	CACCATGGGG	TTCATCTGTC	ACTGGAGGAA	GCAGAAATATG	AACTAAGAGG	25440
CATATTATGT	TGGGTTACGA	CTTTAGTTAA	GATCTGAGTG	TATCCCATGT	GATACATTGT	25500
CAGTCCTTAG	GAAGATGTCT	TGGGAGATGG	TGAGATCTTT	AAGATAGAGA	CCCAGTGTCA	25560
GGTTCTTTAT	GTCTCTGACA	GCATGCCCAT	GAAGGAAGTG	GTCTCTCCTG	GATCTCTTTT	25620
TCAGTTTTGC	AGGCATGGGA	TGAAGGGGTG	TATCCTTCCG	TGTGCTTCTG	CCATGATGTG	25680

STA A000000000 05

TACTTCAACA	TAGACCTGTA	AGGAACAGTG	GCTACAGATT	GTGGACTGAA	GTCTCTGAGA	25740
CTGTGAGTCC	AAATAACCCT	TTCTTTCTAG	GCATGGCGGC	ACACACCTGT	AATCTCAGCA	25800
TGCTGGAAAT	GTGCAGCAGG	ATCAGGAGTT	AAAGACCAGT	CTCAGATAAA	TGACAGTTCA	25860
AAGCCATCAA	GGGGATAATG	AGATACTTCC	TCAAAAACCA	TCAAATTAAA	ACTTTTGT TT	25920
TTATACATTA	CAACTTGTC	GGGGTTTTGC	TATAGTAATT	AAAAGTCACC	ACAGGAAACA	25980
AAGGCACGTA	AACATAGCAA	CATGTGCTAT	GTTTAAGGCA	ACATGTGCTA	GGAAGGTAGA	26040
TATCACCATG	CTGGGTGCTT	AGACCAGGGC	TATGTCGAGG	TCCCGGAGGA	GAGCTGAGGA	26100
AGCCCTGGGT	GAATGTATAA	TGTATCACGG	GCCTCAGACC	TGTGAGATCT	GGCAAAGCTT	26160
CCCCCTGCAC	GCTGTGGGTG	AGGTGAATGG	GGATTCGGCA	GAGCCTTTGT	CTGGTCTGAG	26220
TGCAAATGCT	GACGGTATGT	TCTAGTGGAG	GTGTTTACAA	AGGACGGGCC	AGTGTGCGCT	26280
TTAGCCATAG	AAGTGGTGGC	TCCCTGATGA	ATGTCCACAA	CCTGGGATTG	CTGCCCACAA	26340
GATCAGCCAG	GCCCTCTCCT	GCGCTGTGCA	GAGTGAACAC	ACGGAGGTTC	TGGGCTGCTC	26400
CAGTGGCTGC	TACCATTCTG	CCAGAGAGTG	CACAGGCCAC	CTGACCCCAG	CCTTTCTGTC	26460
CATGTGTCTG	TCCTTTCTTC	ACTCTCTCAC	CACCCTTGTT	AGGGTCCCAG	ATCCAAGTTA	26520
TGTAGGGGGT	GGATTAGGAA	ATGCTATGGG	ATGAGAGGCA	GTGTTGGTTG	TCATTCTCCT	26580
TAGGGTAACC	TGTGAGTATC	AAGGAAAGAA	AGTGTACACG	CAGAAGGCTC	ACCGTGCTGC	26640
TGCTATGTAC	AAGTGAGCAC	AAATGTAACC	TCTGGAAATA	CCCATTTATC	ATGTCTGTTT	26700
TGGGGGCAGA	GCCCAGGCAG	GCGTTTCTAC	TCATGGTCCT	AGGAGCAGCC	TCTCCTCATC	26760
TGGTATGCAG	CCCTTCCTTA	TCCGAGACGG	AGCCTGGTGC	CGGGACACAG	GTCATTTCCC	26820
TGCAGTTGTA	TATTATTTGG	GCAGCTCACT	TCTTTAAAT	ATTTTGGAAA	AAATTATGTG	26880
TATGAGCCTG	CATGTATGTC	TGTGCAAAAT	GTCCACAGAG	GCCAGAAGAA	GGTGTGAGAC	26940
CCCCTGGAAC	TGGGAGTTCC	GGGTGGTCGT	GTTTGGCATA	TGGGGCCTGG	AAAATGAACC	27000
CTGGTCTCCT	AGAAGAGCAA	CCAGTGCGCT	CAGCTGCTGA	GCACCTCTCC	AATCCTGCT	27060
TCTCTGGACT	GGGAGACAAA	GGAAAAGTGA	GAGACTGATT	CTGTTCTGTC	AAGTCTCTGA	27120
GCATAGGGAA	GACCTAGGTT	CATTCTATGT	CATCTGTCTG	TCTGTCTGTC	TGTCTGTCTA	27180
TCTATCTATC	TATCTATCTA	TCTATCTATC	TATCTATCTA	TCTGAGACAG	GATTTCACTA	27240
TGTTAGCCTT	GGCTGTCTTG	GAACCTATG	TAGACAAGGC	AGGTCTTAAA	CTCGCAGAAG	27300
ATCCTGGTGG	TCTCTCCCCA	CTTTGCCTGA	TTAGGCTCAC	TTTTAAAGGG	AATGAAATGG	27360
GCTGGGTGTG	GCAGTACACA	CCTTGCTCTC	AGCACTCCGA	GGCACAGAAA	GGCAGATCTC	27420
TGAGTTTGGG	GCCAGCCTGG	TCTATGCAGT	GAGCTATAGG	CAAGCCAGGG	CTACATGGTA	27480

GGACCTTGTC	TTAAAAAGAG	CCCCAAACAA	ATAGCTCACT	TGCCCAGGTG	AGGTCCACCA	27540
GCATCTCTAC	ATTTTGACCG	GAAGCTAAGA	GGAATCTTTA	TTACATCACG	CCTGCCACAG	27600
TCTCCATCTT	TGTTGCAGCT	GGAGTGCTCC	CACAGGGCTT	CCACTGCACG	CACTGCACCC	27660
GAAGGGGCTT	CCACTTCACG	CACTTCACCC	GAAGGGGCTT	CCACTTCACG	CACTTCACCC	27720
GAAGGGGCTT	ACACTTGATT	CACTTGACCC	GAAGGGGCTG	ACACTGCTTG	CACTGCACCT	27780
TAAGGGGCTG	ACACTGACCC	AATGGCACCC	GAAGGGGCTG	ACACTGACCG	CACTGCACCG	27840
AAGGGGCTGA	CATTGCACAC	GCTGCACCCA	AAGGGGCTGA	CACTTGCTGC	ACTGCACCCC	27900
AAGGGGCTGA	CACTTGACAG	CACTGCACCT	ACCAAGGGTG	ACACTGCACC	TGCTGCACCC	27960
AAGGGGCTG	ACACTGCATG	CACTGCACCT	ACCGGGGCTG	ATACTGCACC	CACTGCACCC	28020
AGGGGGGCTG	ACACTGCACC	CACTGCACCC	AGGGGGGCTG	ACATTGCACA	TGCTGCACCC	28080
AAAGGGGCTG	ACACAGCACC	CACTGCACCC	GAGGGAGCTG	ACACTGCACG	CACTGCACCT	28140
ACCGGGGCTG	ACACTGCACC	GCTTGTAATG	TACATTACTG	TTTTTTTTTT	TTCTTTTCTT	28200
TTTTTCAGAG	CTGAGGACCG	AACCCAGGGC	CTTGCCCTTG	CTAGGCAAGT	GCTCTACCGC	28260
TGAGCTAAAT	CCCCTACCCC	TACATTACTG	TTTAGAAACA	AATTTATGGT	CCTTCTCACA	28320
TGCTGCAGGA	GATTACACAA	AGTTGGGGGT	TATCAAGAAT	GTGGATCACG	GTGGATCATT	28380
TTAGCACTGT	CCCCCCCACA	GAAAGGGTCA	TTTCTAGACA	GAAGAAAATA	GTTTATATGG	28440
AACACTTCTG	GGCTGGGCAG	TGGTAGCACA	TGCCTTAAAT	CCCAGCGCTT	GGGAGGCAGA	28500
AGCAGGCGGA	AGCACGCGGA	TGCACGCGGA	CGCACGCATA	TCTGTGAGGT	TTAGGCCAAC	28560
TCGGTCTATG	CAGCAGCTTC	CAAGACAGCC	AAGGCTGTAT	GGAGACCCTG	TCTCGGGGTT	28620
GGTGGGGAAT	CTCTTCACCG	TCTTGCTCAC	TTCTTTATGT	GTGAGACACA	TAGACGTTTT	28680
TCTTCTGAAT	ATTTTATTGC	TGCTTGTGGC	ATTCACAAC	TAGGGAAAAA	TTGTTAATG	28740
CTGCATTCCC	AGCACTTGAG	CCAGTGAAGT	TCAGGCCTCC	GCTCGTCTTG	TAATGGTATT	28800
TGCACAGGGG	ATGCCTTGGC	TGAGTGAGTT	CTTCCAGAAA	ACTCCTGGGC	CCTTAACACC	28860
TATTTCCAGC	ATTTGGAAAT	CCGAGGCAGG	AGGATTGACA	TGAGTTGCAG	ACATAGTCAG	28920
CTAGAAGTGC	AGCATTAAT	CCTATCTTAA	AATAATTATT	AGAATAATTT	AGGGGGAAAA	28980
GCCTCTAATA	GAGATGGGAG	AGTGTGCGCA	TGACTGCCCT	ACTGTGTGCT	TCTAGAAATC	29040
AATATGAATG	GGCCAGAACT	AGAGAAAAGG	CTGTGAGAGG	CTGTACCCTA	CTGTGTGCAA	29100
CCCACTTCCC	TCCTACTATG	TGGGTGCTGG	GCATGACACG	AGGTTATCAG	GCTGGGTGAC	29160
AAGCACCTT	ACCTGTGGGC	AGTCTTGCTG	GTCCAACCTA	TTTGCAATTT	AATCCCAGCT	29220
ACTTCAAACC	CCATGGGTGC	ATATTTACCC	ACTTTTGTTT	TTGGAAACAG	GATCTTAAAA	29280
TAAACAGGTC	TCACTCTGTA	ACCCATGCTG	GCCTGAATTC	AGCATCTTCA	GCCTCAGTCT	29340

CCCAAGCGCT ACGATTTCCCT ATGTGCCATA TGTCACAATA CATGCACTTC AGTTTTGTCA 29400

AAAGAAGTGA ACCAGGAATA ACTGGTACCT ACCTATAAGA CTGCTGTGAT GAAGGAGGAC 29460

ATTGTGTAAA ACGAAACTCA GGATATAGTA AGTGCTCAAC ACGTGTTAGA CATGTTGGTC 29520

TCCATGAGGG CACAAACCCA GGGCCTCATG CATGCCAAGA ATTGGCCCTA TCACTGAGCT 29580

ATACAATTAG TCCCTATGAC CTACTGTGAC CTCAGACGCA CACCATGGAT CTGACATTGC 29640

ATCAAATCAG AAATGAATTT CTGAAAGACT TGCTCATAGC ATGCCCTCCC ACACCCCCGT 29700

CCCAGCCCCC CCTCTCACTG GCAAGGACAT CTCACTGTGG TGGTGGCAGG GCCTCTAAAA 29760

CATCATAGGA TAGCTGAGCA GCAGTGGCAC ATGGCCTCTC AGTCCCAGCA CAGGGGAGGC 29820

AGTCAGCCTG GTCTATAGTG TAAGCTCCGG GACAGCCAGG GCTACATAGA GAAACCCTGT 29880

CAAACCTACC CTACTTAAAA ACAGAAGTAG AGCAGTAGTT TGGATTACAC TGCTTTGACA 29940

CTTGGTGGGT AGCATGTGTG CACCTGCCCC GGAGCTATCT GGATTCTCAA ATGGAAGACA 30000

CAGACACAGA CACAAACACA AACACACACA CACACACACA CACACACACA CACACACACA 30060

CACACACACA CACACCAGTT AACTTTTGAC ACGCCATGAC TAGCTCAAAG GCTAGGGACT 30120

CCCAAACCTT CCCCTGTCAG CAAATGCTCC CCTCTGGTAC TCCTGAGACT AAGCTAAGCC 30180

TTCCCCTGCT GTCCCAGGCC CAACGGAGGA AGTGAGCATG GTCACCTACC TGATTCTTTT 30240

TTTTCTTTTT TTCGGAGCTG GGGACCAAAC CCAGGGCTTG CGCTTGCTAG GCAAGCGTTC 30300

TACCATGAGC CAAATCCCCA ACCCCACATA TTCTGATTCT TACATGGCTG ATTGGCTTTC 30360

TGTCCCTGCA GTTCTTACAT CCTGTCTTTC TTCCCTGAAT CATGAGGACC CTCTCTCTC 30420

TCTCTCTCTC TCTCTCTCTC TCTCTCTCTC TCTCTCTCTC TCTCTCCCTT CTCTCTGTGT 30480

CTCTGTGTCT CTGTCTGTCT GTCTGTCACA CACACACACA CACACACACA CACACACACA 30540

CACACTAGCC CATGCAAATC TAAGGGCCCC TTCCCGTCTC CCTTTGCCTG ACCATTGGCT 30600

CCTGGCATCT TTATTGATCA ATCAAAAACC AATTGGGGAT AAGGACCTAC AGTGTTTGGA 30660

CATGAAGATT CCTAATTTGG GGGCTGCATT AATTCAAAAC ATTGGAACCA ATTCCCAACA 30720

ACAACAACAA CAACAAATAA AGCAAAGAAA AAAGTTTACA ACGCTGCCTT CATTATTTGA 30780

GAAACAAATG TAAGGAAAAC CATCAGGTAT CTGGACTTTT AAACGGCCGG GATTTAGAGA 30840

CTCTGGGATG TTTTCTGTGT TGGGGATTGA AGCCAGGGCC CTGGGACATG GTAAGGAAGC 30900

ACTGTACCAT GAAACTACAC CCCAGAGTCT GATAAGGCTA CTGAATGACA ATTAAGATT 30960

CATAATTGCT GAAATTCTGG AAAACTCTAA GCTACCAATT TTGTATATGC TCAACTTGGT 31020

TTCTTGAAAA CATCTGAGGT TCTTGACGT AACTTTTCCT CAGAGCAAGT ACAACTAAAT 31080

TCTGACTTTG TGACAATAAA GATTGTCAGG AAAGGCTTTG TGAAAATGTT CAGTCCCCAG 31140

GAGACGTGCC CTCCTGCAGC CTGTGAATGG CGGCCAGGTC ACAAGTCAGC AGATGCAGTG	31200
GAACGGAGTG TGGTACTTCT GTGAGACACT GCAGGACTGG ATGGATGGCT TAGTAGTTAA	31260
GAACATGGGC TGCTCTCCCA GAGGACCTGG TTTCAATTCC AAGCCTTGGG CCCTGCAAGA	31320
ACCTTATATA GACTGGCTTC AAGTTCTCCA TGTAGCTGAA TATGACATTA AACTCCAGAT	31380
ACTCCTGAGT CCTAGGTTTA CAGCTGTGTA CAGCTATGTT TCTTCCCTGA CGACCCCGCA	31440
GCCCCCATTT TGAGATAGGG ATTTAGGTAG CCCAGGCTGG CCTCACACTG ACTAAGTGAG	31500
ACTGGCTTTA AACTCCTCAT CCTTTAAGGT ACCACCATGA ATTTGCTGTA TAGCTCTGGC	31560
TGGCCTTATA TAATGTAGAC TAGACTGGCC TTAACTTTA AAATTGTGCA CTTTATTTTT	31620
TTTTAAATTA TGTATTTTAT GTATATGAGT AACTGTAGC TGTCTTCAGA CACAGGGCAC	31680
CAGACCTCAT TACAGATGGT TGTGAGCCAC CATGTGGTTG CTGGGAGCTC AACTCAGGAC	31740
GTCTGGAAGA GCAGTCAGTG TTCTTAACCT CTGAGCCATC TCTCCAGCTC TCTGCTTAAT	31800
AAGTGCTGGG ATGACTAGCA TGTGTCACCC TCCTGGCCAC TTCTGGTGTC TCCTTTCCAG	31860
GCTTTTAAAA ATTATCTGTT GGCATGTCCA CACAGGGTTA TATGCATATG AACGCAGGTG	31920
CCTGTGGGCT GTCCTGTCCT GGAAGTGGAC TTACAGATGG CTGTGAGCCA CTTGATGTGG	31980
GTGCCTGGAA ACTAACTGGG GGTCTGAAAA AGCGGGAAGA ACTCACATGA CTGTGGAGTC	32040
TGCTACCCCT TTTATTATAA AAGAAAAGAA GATATTTTAA CAGCACGTAT GAGACACAAG	32100
TGAAAGCTGT GGCCATGGTC TTCAGGGATG GTTAGGTCCT GCAAACTGA AGGAGGTGGG	32160
CTCTGGGTGT TGGTCACATG GTAGATTGAT AGGCCCTGGG TTCAATCCCC ACCTCTGCAT	32220
AAAGCAGGCA TGGTGGTTCA CTGCCTGCTT TTAGAGGAAG AGGCAAGAGG ATTGGTAGAA	32280
TCTCAAGGTC ATTTTCAGCT ACATAGCACC AGTCAAATCT TTGAGTCCAA GACCAGCCTG	32340
ATCTGTGTAC TGAGTTCCAG GGCAGCTACA TAGTTGAGAC CCTACTTAAA ATTTCAAACA	32400
ACAAAACCCA CAAGGTTTAA AACTCTATC ACTTTTAGTT ATGTTTGTGT GTAAGTGTTT	32460
GTGCCCACGG AGGTTAGAGC ACTGTATCCC CCGGAGTGGT GAGCGGGCTG GCATGAGTGC	32520
TGAGGGCTGA ATTCAGCATC TGTGTTCAAC ATATTTGTTA AAGCACACGA AGAGGAAATG	32580
GCCAGTGTCA ACAGGAGCCC AGCCAGGCTT GGGGTGGGAA AATGCTTTGA CTTCTATCTG	32640
GCAAGAAAAA AACAAATCCA AGTTTGATCC TTGCCAGACT CTTTGGCCTT TACCAGGCTT	32700
CCTCACAGAG TCTGCTGTAA CTGTTTCTGC AAATTCGCAG AGGAACCTGA GATCTCAGGG	32760
CACGTTGGAT ACCCACGTGC TGGAGAACT GAACAATGAC TTTAGGTTTC ATCGTGCCTG	32820
GATGAAACAT GAAAATACCC CACACCGCTG AGCTGACAAA TGTGCCTCTC TCTCTGTAGC	32880
CCTTCAGTCA GCTGAGCAGT TTGCCCTCGC TCGGCTGCAG TACCAGCACA GGCACCCAG	32940
TCTCCCCGAT GAGCGGTCTC ATGAGGATTC AGGTTGGTCT CGAACTCCCT ATGTAGCTGA	33000

AAATGACCTT GAGATTCTAC CAATCCTCTT GCCTCTTCCT CTAAAAGCAG GCAGTGAACC 33060
 ACCATGCCTG CTTTATGCAG AGGTGGGGAT TGAACCCAGG GCCTATCAAT CTACCAAGTG 33120
 AACAAACCCC AGAGCCCACC TCCTTCAGTT TTGTAGGACC TAACCTAGCC CTGAAGGCCA 33180
 TGGCCATGGC TTTCCCTCA GCACCCACTT ATCATGAAGG GGCAAGGGTC CAGTTTCTTG 33240
 GTTAAGTATC TACGCTTGTG ACTAGGGAGA TACATCCTGG GCAGGAGTGA AGGGTTACCC 33300
 ATTCAGCAGC AGAGTTCCTA GGTTTACTGT GACAACAAAG ATCTAGGAAT GGCCTAGGTT 33360
 GTCCTGACAT GATCCCATTA GCCTACCTCA GATATCTGAA TGCAGGGGCT CACTGTGTGT 33420
 CCCAGTCAGG GACAGTATTT ACTACCCTAA AGTGGGTTAC AGCTCTCGGG GGGGGGGGGC 33480
 TCGGTGCAGG ACGACACCTG CACCTTCACA CTTGCTTCTT CAATGGAGTA AGAGGCTGCT 33540
 AACATCCCCA AGGTTTCCAT TTCAGCTAGG ATGAGAGTCT GGAGTTCATG TCCCTGGTAT 33600
 TCAAGTATAT GACACTGAAG AGCAAAGAGG CAGAGAGCTC ATCCACTAAC AGGCATGCAC 33660
 TGCACTCATG AACATCTGTG TCTGATCCCC GGTACACATC AAAGCCATGT GCACCGAATT 33720
 CCAGCGCCAG GCAAGCATA CAGATGCAT TCTCTGAGGC TAGCTGGCTG GGCAGTCTAA 33780
 ATACTGAGTG CCAGGTTCCA GTGAAAGGCC TCGTCTCAA AACCAGAACA AACCAAATCA 33840
 AACCAAACGT AAAGCAGACC AAGGTGAGAG AGTCTTGAAA TGACACCCAA GGGTGCTGTC 33900
 TGGCCACTGC TTACACACAC TGAAGGACAG CAACTGACCG CAAGAAGCGG GTTTAGAGTG 33960
 GAGTCTACTG TCTGCTGGGT AGTCCAATGA CGCTGTGTCA GGGCAGGGTC CGGTTACAGA 34020
 AATCACTGAC GGGGAAGCCT TCCCAGGAGA AACGGGGCAC CCTTTTGGCT TTCTGGACCT 34080
 TGGACACACC TGACCCTACC CAGCAAAGCC CAGGATTGAG CAAAGCAGAT AACTAACTCC 34140
 TGGCTCAGTT AGGTGAACTG GCTTTTGGCT AATAACCTTA AGACCCAAAT AACTGGGACA 34200
 AATAAACTTA TTCTACAACA AGAAAAAGCA AGCCACATAA CAAAAGGCTT TGCTTTCCAA 34260
 TAGTTTATTT ATAAAAGCAG GAAACATTGG GCTCACACTA TTCCAAGAAA CTCAGGAGAC 34320
 AGCTCTTGGC TTCTAGAGGG GACAGTCCAG TCTGATCTTC TGTGTGATAG GAACTTCCCA 34380
 GAGTTTAATG CTGTCCGGAG TTTGTATGTG GTGTCAGAAC AGGTACTATA CCTGGTGCCA 34440
 AATCTAGAAT GAATGGGGGC TGCTCTGGAC AAGGCTGTGC CACCCTCCTG GGATGCACCA 34500
 ATTTCTACCC CAATATCCAG TCCCTAGGCA AGCACTGTCC TTATTTGGGC CTGAGAGGCC 34560
 TCTGTTCTCA GTTCCTGACC ACCTGCCCTT CTTTGGTGAC CGCCCAGTTA TAACTCTTCG 34620
 GAGAGTCCAA GGCCTCTTCT ATCCGTGCCT CCAGGTTCTC CCGAGTGATG AAGTTTTTGG 34680
 CCTCCTCCTA CGGGAAGAGA AAGGTTAGCT ACGTGGGATC TCTCAGAGCT GGCTGCCTGC 34740
 ATAACCTACT GTCTCTAGCC CACCTTAAGA AGGGTGTCAA AAGAGCCCAG GGCCCTTTG 34800

AGTGTCCCAC CAATAGGCCA GCACAACTGT ACTAGGTGAC CTCAACCATT ATATCCCTCT	34860
TCCTCGGACA ATTACCCATC AGATCTCTCA GCCACAACCC AAGAACGAAT CGAATCGTGA	34920
CAACCTGATT GGGGGCGGGG GGAGGTGCGG GGTGGTGGAC TCTCTCAACC TTGTCACTCT	34980
CCCTTACACA ATAAAAACAG CTCCATTCTC ATTTATGGTT TCCCTGACCT TCAAGTTTCA	35040
CACGGCAATA CTAGCCTGTA ACCTTTCATT GACCATTGTC TGGGAGGCAC TCTGTGTGTG	35100
CAGAGCAGAG AGAGAAGCCT CCTGAAGACT GGTCACTTGA CACCCTGTGC TGCTCTCCCC	35160
AGAGCCTCCC TCACCGGAAT CTCCAATACC CACATTCTCT ACGACCTCGG CCCACCTGCA	35220
GTTTGAGAAC TTCTTGTTCT TTCAGTTGCA CCCAAGCCTG CTCCTCCTGG GCCCTCTGGG	35280
CCTGGACCTC AGCCTGCCGC AGCTCCTGGG CCTGTGCTTC GAGCTGCAAC CTAGCTATCC	35340
TGCGAGGAAA AAGGAGCCGA GAATGAGCGG GGCCGTGGGC CGCGCACGGG CAGAAGGAGC	35400
AGGGTTGGGG GCTGGCCCCC GGGCCGCGCG GCCAGGCGGT TCAAAGCCCG CAACATGACA	35460
GCTAGCGCCT GCGCCCTGTC CGGAAGTGGT CGAGGAGCAT CACGGGAATC TCCTGTCCCC	35520
GCCCCGTAG GCGGAGCTCT TGCTGTCTGG CCCATCGCGT CCCTGGAGTC TCGGGTAGAG	35580
TGGGAGGGTC GAGGGGCACC TTGGAGACCA CAGTTCGCTG GGCTGTATTG CCCGCCAATG	35640
ACAGCTACAA CACCAGGCGC TCTTGCTTAC TTGTTACAA GCTTGGACAC CGCCCCAAG	35700
CGTGTGGTTC TCTGGCCAC CGGTGGCCTG TGTACCCTTC CAGGGCTGAT GCAAGAAATT	35760
CTGAGCTTCT AGCTACTTAA GTTAGGCTTA CACTTCCTCT TTGAGTAAGC GTTCTCCTGA	35820
TGCACTTTAA ACTTTAGGTT TGCAATCGAG CAACAAACCT TTCCTTGCA TTGCACTGCC	35880
CTGTTGTGGT CTTGGGCAGC TCTGCAATTA ATTGCCAGAG TTCTCAGTAT CAGTGATCAC	35940
TTGTTTTCTA CTGGGTGGCC TGTGTGAGGT GACGCTTGTC CTCTTTCACC TGAGCCGGGG	36000
TCTTCCCACC TTGAGACCAT TTATGAAGCT TTTAAAGTAC TATCTTCCTC TACAATGAAG	36060
AGAAACAGGA GGCAGTGCAG GGCAGAGAGC ATCTGTCCCA AAGGTAGATG GCTCTCCTCT	36120
GGGAGAGTTG TTGGTAATCA GAAGCTGACG GTGAGGGCTA GGGAAGTAA GTCTCATCCT	36180
ACTCATTAGT GTTGTCACAA CCAGATTCTG CAGAGAATCT GCACTTAGGA GGGTCTGAGG	36240
AGCCTGGGCT GACTGCAATA CCTGATATTT CTCAGAAGAG AACAGAGTCT GCTTACATCC	36300
TTCTCCCAAC TTCCAGGCCC GTAGGAGGCC CAGCCAGCAC CCTCTTCCTC TCATCTCACC	36360
CTACCCTGGA GTGACACAGG GTTGCTCTGA ACATCAGGGA ACGTGGCACT CCCATCCTTT	36420
CTTGCAACAG GTCTCACTAT ATAGCTCCGG ATGGTCTGTC ACTTACAATG TATATCAGAC	36480
TCACAAGAGG TCCATCTGCC ATTGCCTCCT AAATGCTGGG GTTAAAGGCA CATAACACCA	36540
CACCTGTCCT AAACCTTTCT TCTTCGGGGT CATCCTAGAT AACCAGTATC TCATTTTACA	36600
TAACTTCAGT GTCTGGGCAA AGAGAATATT TCTATGGTGT GGGTCATTCC TAGAGGCTTC	36660

CTAACCTTGC	TGGCTCTGAC	GTTCTCTCGG	CTGGTCAGGT	CTACTCATCC	TTCTTTCAGA	36720
GGGTTTCATA	AGTTGTAAGA	GATTTAGGCC	TACGGTGGAT	GAAAGATGTG	GAGTCATTTT	36780
GAGTAGCTAA	TGCTACAGAA	CTAGAAGGCA	GGTTCTCTGC	CCCCTTCTCT	GACCTGTTGG	36840
GGAAGTGGAA	GTAACCTTCC	ATTTGTGACC	TTCCCCACTA	GGTGGCGAGA	TAGAATTGTC	36900
AAAGCTGGGA	AAGGAGGCTT	TTCTGGGCAG	TTCATGGGTA	GAAGGACAGA	CAGACAGAGT	36960
TGGAGGAATG	GAAGCCTCCT	CATTTACCAA	GGGGTAAACT	ATGGATGAGG	TGACTTCAGG	37020
TGCCTGCAGG	ACCCTATGCA	GACGGTCCCA	GGATTTAATG	ATCAGGCCAT	TCTATTTCTT	37080
CTGGTGTCAA	ATCCAGTGAT	ATCATTAAAA	CAAAAACAAA	AAAGCCCCAA	TCAGGGTCTT	37140
ACTTGATGGC	CTTATATTTT	CAACAAAGCC	CAGGCTGGCC	TTGAACTTGA	AGCAATATCC	37200
CTGCATCTGT	CTCCAGAGTG	CTAAGATTGT	GTGTGTCACC	ATACCAAGGT	ACAGTGATCT	37260
CTTGAAACAG	GGAGGTGCAA	GTCATTACTC	AAACCCCTCC	TCACAATGTT	CTATGAGCAA	37320
ATCCGAAGTT	GATGTTGGCT	TTTAAAGTCA	CCAGACAAGT	GTCCTTCTGC	TTAGATCTTC	37380
CTAGGAACTG	AGGTTTGAAA	CAAAAAGCAT	AACATGGTTG	GAGAGATGGC	TCAGTAGTGA	37440
AATTCTGAAT	GTGGTTCCCA	GCATCCACAT	TGGGCACCTC	AGAATGGCCT	ATAACTTCAA	37500
TTCTAGGGAC	CAAGTAATCT	CTTCTGGCTT	ATGGGTGTCA	CTCACATGCA	TGTGTGCATA	37560
TGGTGCCTAA	GTAAAAAAAT	AATCTTTTAA	AAGCAGATTT	TAAAAAAAT	TTCAACGATT	37620
TTTTTTTAAAT	GTTCAATTGGT	GTTTTGCCTG	CATGTATATC	TGTGTGAGGG	TGTCAGGTTT	37680
CCAGGAACTG	GAGTTACAGA	CAGATGTGAG	CTACCTGTTG	GTGCTAGGAA	TTGAACCCAG	37740
GTCCTCTGGA	AGAATAATCA	GTGCTCTTAC	CCACTGAGCC	ATCTCTCCAA	CCCAAATACA	37800
TCTTAAAAAA	AATTAAAACA	GTGGACCTGC	CTTCTAGTTC	TGTAGCATTG	GCTACTCAAA	37860
ATGACCCACA	TCTTTCATCC	ACCGTAGGCC	TAAATCTCTT	ACACTTATGA	AACCCTCTGA	37920
AAGAGGATGA	GTAGACCTGA	CCAGCCGAGA	GACATCAGAG	CCAGCAAGGT	TAGGAAGCCT	37980
CTAGGAATGA	CCCACACCAT	AGAAATATTC	TCTTTGCCCA	GACACTGAAG	TTATCTGAAA	38040
TGAGATACTG	GTTATCTAGG	ATGAACCCCG	AGAGAAGAAA	GGTTTAGGAC	AGGTGTGGTG	38100
GTATGTGCCT	TTAACCCAG	CATTTAGGAG	GCAATGGCAG	ATGGACCTCT	TGTGAGTCTG	38160
ATATACATTG	TAAAGGGGAG	AACTCCCGGA	ATTTGTTCTC	TGACCTACAC	ATGTGACATG	38220
CATGTGTTTC	TGCACACACA	CATACACACA	CACACACTGT	AAAAATGCAA	AATGGCTACC	38280
AAGTGGTCAT	TGAGCTTCTC	AACCTCACTG	ACAGCTACAT	TATTATATAG	ACTTACTGGG	38340
AACAGATCCG	CAGGAAATTA	TTTGGAATCT	TTTTCTTTTC	TCTAACGGGG	GCTGATCTGG	38400
AACTTCTGAG	CCTTTTTGTT	CCCTATCATG	AATGCTGGGA	TGGCAGGCGT	TTCCACATGA	38460

CTCGTTTCGAT	GTAGTATTGC	AGACTGAACG	CAGGACTTTC	CACACACTAA	GCAGGCATTC	33520
TGTGAACTGT	TACGTCTCCA	GCCCCATTTT	TAAATTCTAA	CACCAAAGTG	CTAGTTTTGT	33580
CCCTTGACCT	GGACACTGCA	GTGAGTTTAC	AGAAGTTATA	ATCACCCCTGT	TTAGTGTAGA	33640
AGCTACCTCA	ATCACCATGA	CATTTTTTCA	AAATGTGTTC	ACTTTCCTCT	TTAGAGTCCA	33700
AGCACACCAA	GCTTGGCGGA	ACAATGATAC	AGTCTAACTG	GATCTGTTTC	AAAATTGCAA	33760
CTTGACTCTA	CATCTAAATA	GGTATGTGTT	GTGACAAGTT	TATTATGTTG	TGTGTGTGTG	33820
TACACATGTG	CCACAGGAAG	CCAAAGGACA	ACTTGCTAGA	GTGCATTTTC	TTTCCTGGGA	33880
ATTGGCCTCT	GGTGTTCAGG	CTTGGTAGCA	CGCACTTTGA	CCCTCTAAGC	CATCTTGATG	33940
GCCCAGAGAG	TGAACCACGC	TGTTTTCACT	TTCCTACTTC	TTGGGCTGAA	TTCTCAAGTA	39000
CCTGCCCTTG	CAGCTTTGCA	CCCTTCCTAA	CTTCAAAAGG	AAACTGACAT	GGAGAAGGGT	39060
GATACTTGAG	GATTTCTCTG	CTCACTTAGC	TCAGGACTCT	GGCCTAAGAA	CAGGGAACCC	39120
AGCAGTGTGA	ACAGGGGTCC	AAGAGAGTTC	ATTTGTACTT	ACCGGCAAAA	CAGTGTGGCA	39180
GGCTTCACAC	AAATACATAC	TCGGCACCAG	GACAGGGCCA	CTCTGGATGG	AGGTGGGCTT	39240
AGGTGGGGTA	CTGCCCACCC	AGGGTTGTCC	TCTCTGTAA	GCAGACTCAT	GGGGACAGCC	39300
CAGAAGTGAT	CCCACAGTCT	CTCTGAAGCT	GACAATAGGG	GATAATTCTA	AGTCCTCATC	39360
CTGTGCTCAT	CCACAGTCCT	TTGTCGATCT	GGACACTACT	ATCATGGGCT	GCTGGAAACA	39420
GGTCTTTGCA	GCCCAAGTCT	GAGCCACTAG	CTCTGCTTTC	ACTGCCAGCC	ATTAACCTCC	39480
GGGAGTGGGC	GTGGGATAAG	AAGAAACATT	TATAGAGTCA	ACGGCCAATC	TGTATTTGGG	39540
CTGAAAACCA	TATTAAGGAA	GGGCCAAGCC	TGGCATAATG	GTGACCAGAG	CCACTAGGGG	39600
ACCAACTGCA	CCCAGCTTTA	GCAAAGTGAC	AGGCAGCATG	AGGTACCATT	ATGTGTGCTG	39660
GGCATGCGGC	TTCAGGATGG	CTCTGTGACC	TCCTAGAGGT	TGTCTTATTG	GCAGGCATAG	39720
GAAACAAAGG	CAGAGAATGA	ATGCTACAGC	CAGAGAGACC	CAGATCTGCT	AAGTGGATGA	39780
CTCTTGATCA	TATGTGTGTA	TGTTGTTTTT	GAGGCAGGGT	CTCACTGTGT	AGCTCTGACT	39840
GTCCTGGAAT	TGGATCTGTT	GGTCTCAAGT	TCAGATCCTA	GTGGTTTATT	TTTCCTGTGT	39900
ATGTGTGCTT	GTCATGCACA	AGCATGTGTT	AAGGTGAGTA	GATATGTAGG	CACATGGAGA	39960
TCAGAACAAT	GGTGTCACTC	CAAACCTTTA	TAGACCTATA	TCCATCTTGA	CATTAGGGTT	40020
ACAGGTGTGT	TCAACATAGA	TATGGCCAAA	ATTTAATGTG	GGTTCTGAAG	ATCTAAATAT	40080
GTCTTGCTGT	GGCTAGTTCT	ACGTCAACCT	GACACAAGCT	AGAGTTATCT	GAAGGAAGGG	40140
AACCTTAGTA	GAGAACTGT	CTCCATGAGA	TCCAGCTGTA	TAGCATTTTC	TTAATTCTTA	40200
GTTAGAGACT	AATGGGGGAG	GGCCCAGTCC	ATTGTGGGTG	ATGCAACCTT	AGACAGGTGA	40260
ACCTGGGTTT	TGTAAGAAAG	CAGGCTGAGC	AAGCCATGAG	GAAGCAAGCC	AGTAAGCAGC	40320

ACTGACCATG GCCTCTGCAT CAGCTCCTGC CTCCAGGTTC CTGCCCTGTT TGAGTTCTTG 40380
 TCCTGACCTC CTTCCGTGAT GAACAGTGAT ATGGAAGTAT AACCAAATAA ACCCTCTCCT 40440
 CCCAAGTTGC TTTGGTCATG GTGTTTCATC ACAGCAACAG AAAGCCCAAC TGAGGCAGGT 40500
 TTTTCATGCTG TATAACAAGC TGAACCATCT TACCAGCTCC ATAGTGTTTA TTTTAAAAGA 40560
 TGAGTGTGTA ACTTTCCTTT TTTTCCTTTT AAAAATCCAA AGAACCACGT TCCTCAGGAA 40620
 AAGCTCTGGG CCAGTTCTCC TGGTAACTTT GAAGTCTTTT TAAAGGCAGA GTCTATGTTA 40680
 GACAAGCTGG CCTCAACCTC ACAGAGATCA CCTCCCTCTG CCCGTTAACT GCCTGGTGAG 40740
 CTACAATGTG TTTTAAAGA TGTCCCTGTT CCCTCTTAAA CAACTCCAAT TTCACCCATG 40800
 TGTTCCTCATT TGGTAGGACA GGAAGCCATT TGTTTCATCAT GAAGCTTCTG CTGATGTCAG 40860
 GACAGGCGCG CGCGCGCACA CACACACACA CACACACAGC AGCTTTAGTC ATTTGTGGTC 40920
 AGCTGGGAAA ATGGGAAAAC ACGGTTGGAG CTGAGTTGAA CTGAAGAGTT GGTGGAGACA 40980
 CATGGTGCAA ATCCTGAGCA GTAGCTGAAG GAAAGGTACA AGTTTGGCAG TAGATTGGCC 41040
 AATGAGGTGC AGAGATAAAG CAGAAGGGCT GCCCCGAGAG CTGCAGCATG GTGCGTGGA 41100
 CCCTTCAGGA GGTAGAAAGG TAGAAAGGGC TGCTTGGA CTAGTGTGT AGATTACTGT 41160
 CTTTCAGCAG GTGAAAGACA AGGCTAGAGC CTGTGATTGG ACAGTAGAAA AGGAGGGCGG 41220
 GCTGAGAGTT TGAGAGTCTG GAGGGATAGG AGGAAAGAAG GAAGATGGAG GAAGAGAAGG 41280
 ATGACCCAGA GCTGTGTGGC TTAAATAGC CACAGGTAGC TATGAATATC ATATAAGGGG 41340
 TGGATTATGA CAGGACAATT TGTCCACTCA AGGTGGGCAG CTTATATCAT ATTAATTGGC 41400
 TCTGAGTTCT TTGTCTTGGG CATTTTGTGA GCTGAGAATT TACTGATATA AATCTGACTG 41460
 ATAAATTACA AGCCTCTAGA GTTTTGATTT TACTGGGTTA CAGGGATTTG TGACAGTTAA 41520
 CTGCGAGATG CTACAGCCAG AGAGACACGG ATTCTGCTAA GTAGATGACT CTTGTACATA 41580
 TGTGTGTATG GGGGCTAGCT GTGAAGGCAG TGAACTGCT GCCAGGGCCA GAGAGTAGTT 41640
 GGCCTACTG TGGGATGGTG CATCCATTTT TTTAAAAATT ATTTAATGCA AACTAGTGA 41700
 GTCATCCAGT AGGAAATGCT GGGGTCTGGG GAGCTGGGGG TGGAGGAAAG CCACAAGCCC 41760
 ACGGAGCCCC AGATCCCCCA CCTCTTTGGA GAATAACACT GATATCAGTG ACTCAGACAC 41820
 AATAGATCTT GGGGTTTCTG ACCCAAGCTC CTCTAGTAAG CATGGGTGCA AAAGGTGTGG 41880
 AATGGAGAGT GAAGGAAGAC TTTTTCATAA GCCTGTCACA AATGAGGAGG AAGCTAAGCT 41940
 TGGGAAATGC AGGCCTTCAG TGGCAGACCA AGTGGAGTCA ATGAAGTAAG GTCTGAGTAG 42000
 AAGGGCTCTG GGTGTGCGCT TCAGGCTGGG TGCACACTTC TTTCTGAGGA AATGCTCACT 42060
 TCCACTTTGA CCATTCCCTG ACCCAGGTCA TAGCTGATGT GCCAGAGTGT CATGGGTGAA 42120

GTGGTCACTT TCGCTCTTTC CACACAAGTG TGCTGTGTAA GACACCCTTT CTCTGGTCAT	42180
ACAGGAGTCC CCTGTGGGGT TTGAGCCCTG ACTTAAAAAG AAAGGATGAG GGCTACTTCT	42240
GTGGAAGGGA GCAAAGAGCA GAGGTCATTC CTGCTGGAGG AGATCTGCTA ACAAGCATGT	42300
GATGTTTAAC ATTAAGGGCT GCTCATCAAG TCAGCACTGA CTCCAGCAGA GTCCTGTCGA	42360
GGCTACTCCA GTATGCCCTG GTCAAGACTA GCCTTGGCAA GGGAGCAGCC TGGGCTGTTG	42420
CTAGGTGGAT AGAAGCACAC ACAGAGGATT TTCTTAGTGG TGTATGTAAT CACTGAGGTC	42480
TTGCTGACCC AGTAGGCATA CTCCTCCATT GCTAGACTCA GTCACACAAA GTGTACAAGA	42540
ACAGGGCATT CTTTCATGGAA AATTCCTGAC TGGGTCTTTT AGAGCTCCAG TTCCTAGAGG	42600
GGCAGATGAT CCCAGTGACT TATGCTCAGT GTAAAGCTGG TCTGCTGTCA CATCTTTGCT	42660
CCCCAAGGTT TCTGGGATTC CTCCTGTACT TTCTTCTATT TTTATTTTCA AGACAGGGCT	42720
TCTCTGTGTA GTCCTGGCTG CTCTGGAAGT TGCTCTGCAG ACCAGGTTGG CCTCAAATTT	42780
ATAGAGATCC ACTTGCCTCT GCCGTCCAAG TACAGGGATT AAAGTTGCAT GCCACCACTG	42840
CCCAGCCTCT CTAAATTTTT CTTAATTAAT TTATTTTCA AGACAGAGTC TCACTATGTA	42900
GTCCTGGATA TGCTGGAAGT CAGTAATGTA GAACAGGCTG TCCTTGAACA TACAGAGTTC	42960
CACCAACCTC TGCTTCCAAG TGCTGGGATT GAAGTGTGTG CCACTATGCC CAGCTAAAAC	43020
CTGTTTTATT TTCTGTGCAT GGGTGTGTC CTGCATGTAT GTCTGTGCAT CATTTGCCTG	43080
ACTGGTGCCC ACGGAAGTCA GAGGAGGACA CTGGATCCCC TGAGGTGCCC ACGGAAGTCA	43140
GAGGAGGACA CCGGATCCCC TGCAGTGCCC ATGGAAGTCA GAGGAGGACA CCGGATCTCC	43200
TGGATCTGGA TGAAGTGAAG ATCACATGGG TCTTGGGAAA AGATCCCGGG TTTGCTCTAA	43260
GAACAAGTGC TCTTAATGAT TGAGATGTCT CTCTATCCCA TGTTTCTTTG TACACAAACA	43320
CCATGGACAC GTGGCATACT CTGGGCTTCC TTTTCACACC ACTCTGTCGA ACTTAAATTC	43380
TGCTGGCGGC TCCAAGTAC CTTTCCTTTC TATTCCTAAA TTCTCGGCAT GGCTTGGGTC	43440
TGGTTAAGTC CCCCCTTTTC CAAGCAGCCG GAAGCACTTA TCTCTGAATG TGCCTCTGTG	43500
GGACACACCG GGGGACCTGC TGAAGCCTCT GAAGAGCAGA GGTGATGTCT GCCTCCCCAT	43560
CTTTGCCCTC TTGTGCTAAG AAGCTACTTG TGATGCTGGA GGTGGTGGGG AAAACCCACC	43620
AGCCTTGCCA CCTGAAGTGA AGGGCAGCCA CGGCCTGTGT CCTAGCCAGT GGGGATTAGT	43680
GAAAATGGTA AAGTGGGCAA CGAGGCTGCT TGCTTTCTGA GCTTCCTCCT ATTTTGGGTT	43740
GGTAGCAGCA GCGGCCAGT TCCTTCCCAC TGTGGGGATG AGGAGTACGC CCTCAGGATG	43800
CCGGCATCAG AGAAGGCAAG AACAGACGCA GTGTCGCACG TCTTCAATTA CAGCACTTGG	43860
GAGGCAGAGA CAGGCAGATC TCTGCGAGTT CAAGGCCAGT CTGGTCTACA CAGTGAGTTC	43920
TAGGTTGCTC TGTGTTACAC AGGGAGAAGT GTCTGAAGAA ACAAACAAAG AGAAAATTAA	43980

AGTTAGATGT AGTGGCACGG TCATAATCTA AAATGTGGCC TAGCTGTTCT CTGTTCTCTG 44040
 TTTCTCTTTC TTCCTCCCTC CCTCTCTCTT CTTCAATTGTC TGTCTGTCTG GTGCTTGTAT 44100
 ATCAAAATGT AAGTTCTAAG ATATGCTTCA GCACCGTGCC TGCCTGCCTG CCGCCATGCT 44160
 CCACCATGAT AGTCATAGAC CCACCCTCTC GAACTGTGAA TCCCAAATTT ACTTTCTTCT 44220
 ATGAGTTGCC CTGGTTATGG TGCCTTATCA CAGCAACAGA GCAGTGAGTA ATATACCCAC 44280
 CCTCAAAGAC AAGCTGAAAG AGAGACCCAT GTGCTGTGGC ATGCGTGTGC CTACACTTAA 44340
 CACACATAAA TAAATACATC TCCTGAAGAA AATTTAAAAG TTATTCTGGA CAGAAACTAG 44400
 AGAGGCCAGA CTGGCCTCAG CTCAAGCCCA CAGCAGCTCC TCTGTCCTGC TGTCCCTTCC 44460
 TGTAGAGAAA TTCAGTGAGA CCCAAGCTGT CTGTCCTAGG GCTATAAGCT GGGTGGGTGG 44520
 CTGGGATGAC CACACTTGAT AGAAAAGAGG AAAAGGAACT GGGAGTTGCG GCCGCC 44576

(2) INFORMATION FOR SEQ ID NO: 18:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 23 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: other nucleic acid
 - (A) DESCRIPTION: /desc = "Synthetic Primer"
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18:

GGACAGCCCG AAGGACTACA GGT

23

(2) INFORMATION FOR SEQ ID NO: 19:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 20 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: other nucleic acid
 - (A) DESCRIPTION: /desc = "Synthetic Primer"
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19:

CGAAGAACTC CGCAGGGTCC

20

(2) INFORMATION FOR SEQ ID NO: 20:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 18 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "Synthetic Primer"

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 20:

AAGACCCGCC ACGACCCG

18

(2) INFORMATION FOR SEQ ID NO: 21:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "Synthetic Primer"

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 21:

GAATCAGCAC CCTCTCCGCC

20

(2) INFORMATION FOR SEQ ID NO: 22:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 25 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "Synthetic Primer"

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 22:

TGCGGAGTTC TTCGTGCTGA TGGAG

25

(2) INFORMATION FOR SEQ ID NO: 23:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "Synthetic Primer"

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 23:

GGTGCTCGGC GGCGTCCTTC

20

(2) INFORMATION FOR SEQ ID NO: 24:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "Synthetic Primer"

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 24:

GAGTGGCGGA GAGGGTGCTG A

21

(2) INFORMATION FOR SEQ ID NO: 25:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 18 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: other nucleic acid
 - (A) DESCRIPTION: /desc = "Synthetic Primer"
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 25:

GGCCGAGGCT GAGCGGGG

18

(2) INFORMATION FOR SEQ ID NO: 26:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 20 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: other nucleic acid
 - (A) DESCRIPTION: /desc = "Synthetic Primer"
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 26:

CTGAAGGACG CCGCCGAGCA

20

(2)- INFORMATION FOR SEQ ID NO: 27:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 19 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: other nucleic acid
 - (A) DESCRIPTION: /desc = "Synthetic Primer"
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 27:

CTCCAACGCC TGCCGCTGC

19

(2) INFORMATION FOR SEQ ID NO: 28:

- (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "Synthetic Primer"

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 28:

GCAGGAGGAG CGGGAGCAGG A

21

(2) INFORMATION FOR SEQ ID NO: 29:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 19 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "Synthetic Primer"

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 29:

TCCAGTGCCC CGCAAGCCG

19

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/12 C12N5/10 C07K14/47 A01K67/027 G01N33/50
C12Q1/68

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C07K A01K G01N C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE EMBL SEQUENCES 'Online! Accession No. AI011995, 17 June 1998 (1998-06-17) LEE N.H.: "EST; rat cDNA clone RPLAR4" XP002127678 corresponds to nt 86-614 if seq. ID 1	9
P,X	DATABASE EMBL SEQUENCES 'Online! Accession No. AI180224, 12 October 1998 (1998-10-12) LEE N.H.O: "EST; rat cDNA clone EST223967" XP002127679 complementary to nt 1798-2234 of seq. ID 4 — -/-	9,10



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"8" document member of the same patent family

Date of the actual completion of the international search

14 January 2000

Date of mailing of the international search report

28/01/2000

Name and mailing address of the ISA

European Patent Office, P.B. 6818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Galli, I

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO 99 04265 A (SAHIN UGUR ;TURECI OZLEM (DE); PFREUNDSCHUH MICHAEL (DE); GOUT IVA) 28 January 1999 (1999-01-28) seq. ID 361	9
A	MOHR E. ET AL.: "A single rat genomic DNA fragment encodes both the oxytocin and vasopressin genes separated by 11 kilobases and oriented in opposite transcriptional directions." BIOCHIMIE, vol. 70, no. 5, May 1988 (1988-05), pages 649-654, XP000867203 cited in the application the whole document	1-29
A	HO M.-Y. ET AL.: "Bovine oxytocin transgenes in mice" J. BIOL. CHEM., vol. 270, no. 45, 10 November 1995 (1995-11-10), pages 27199-27205, XP002127677 the whole document	1-29
A	WALLER S.J. ET AL.: "Transgenic and transcriptional studies on neurosecretory cell gene expression." CELL. MOL. NEUROBIOL., vol. 18, no. 2, April 1998 (1998-04), pages 149-171, XP000867082 the whole document	1-29
A	KLEBIG M L ET AL: "ECTOPIC EXPRESSION OF THE AGOUTI GENE IN TRANSGENIC MICE CAUSES OBESITY, FEATURES OF TYPE II DIABETES, AND YELLOW FUR" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA,US,NATIONAL ACADEMY OF SCIENCE. WASHINGTON, vol. 92, May 1995 (1995-05), page 4728-4732 XP002037980 ISSN: 0027-8424 cited in the application the whole document	1-29
A	US 5 789 651 A (WOYCHIK RICHARD P) 4 August 1998 (1998-08-04) abstract	1-29
A	WO 96 05309 A (UNIV ROCKEFELLER ;FRIEDMAN JEFFREY M (US); ZHANG YIYING (US); PROE) 22 February 1996 (1996-02-22) abstract claim 1	1-29
	— —/— —	

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 844 253 A (SMITHKLINE BEECHAM PLC) 27 May 1998 (1998-05-27) abstract	1-29
A	KLEYN P W ET AL: "IDENTIFICATION AND CHARACTERIZATION OF THE MOUSE OBESITY GENE TUBBY: A MEMBER OF A NOVEL GENE FAMILY" CELL,US,CELL PRESS, CAMBRIDGE, NA, vol. 85, 19 April 1996 (1996-04-19), page 281-290 XP002057713 ISSN: 0092-8674 cited in the application the whole document	1-29
A	WEIGLE D S ET AL: "OBESITY GENES AND THE REGULATION OF BODY FAT CONTENT" BIOESSAYS,GB,CAMBRIDGE, vol. 18, no. 11, 1996, page 867-874 XP002057714 ISSN: 0265-9247 the whole document	1-29

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9904265	A	28-01-1999	AU 8571598 A	10-02-1999
US 5789651	A	04-08-1998	US 5843652 A	01-12-1998
WO 9605309	A	22-02-1996	US 5935810 A	10-08-1999
			AU 3329895 A	07-03-1996
			BG 101228 A	30-09-1997
			BR 9508596 A	21-10-1997
			CA 2195955 A	22-02-1996
			CZ 9700460 A	12-11-1997
			DE 19531931 A	07-03-1996
			DE 29522109 U	02-12-1999
			DE 777732 T	29-01-1998
			EP 0777732 A	11-06-1997
			ES 2108663 T	01-01-1998
			FI 970656 A	17-02-1997
			GB 2292382 A, B	21-02-1996
			GR 97300021 T	30-07-1997
			HK 1001495 A	19-06-1998
			HU 78052 A	28-07-1999
			JP 10262688 A	06-10-1998
			JP 9506264 T	24-06-1997
			JP 9502729 T	18-03-1997
			LV 11868 A	20-10-1997
			LV 11868 B	20-01-1998
			MD 970100 A	30-04-1998
			NO 970683 A	16-04-1997
			PL 319021 A	21-07-1997
			SI 9520090 A	31-08-1998
			SK 22197 A	04-02-1998
			TR 960148 A	21-06-1996
			LT 97020 A, B	25-09-1999
			ZA 9506868 A	09-04-1996
EP 0844253	A	27-05-1998	CA 2216622 A	25-05-1998
			JP 10304883 A	17-11-1998